University of Alabama at Birmingham


Report on Federal Awards In Accordance With OMB Circular A-133 For the Year Ended September 30, 2013

EIN: 63-6005396

University of Alabama at Birmingham Report on Federal Awards in Accordance with OMB Circular A-133 September 30, 2013

Table of Contents

| | | Page |
|----------|--|-------|
| Part I | Federal Award Programs | |
| | Independent Auditor's Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards | 1–2 |
| | Independent Auditor's Report on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and On Internal Control over Compliance in Accordance With OMB Circular A-133 | 3–6 |
| | Schedule of Expenditures of Federal Awards Year Ended September 30, 2013 | 7–41 |
| | Notes to Schedules of Expenditures of Federal Awards | 42–44 |
| Part II | Schedule of Findings and Questioned Costs | |
| | Schedule of Findings and Questioned Costs Year Ended September 30, 2013 | 45-47 |
| Part III | Summary Schedule of Prior Audit Findings | |
| | Summary Schedule of Prior Audit Findings Year Ended September 30, 2012 | 48 |
| Part IV | 2013 Financial Report | |





Independent Auditor's Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards

To the Board of Trustees of The University of Alabama:

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of The University of Alabama at Birmingham ("UAB"), a campus of The University of Alabama System, which is a component unit of the State of Alabama, and of Southern Research Institute ("SRI"), its discretely presented component unit, as of and for the year ended September 30, 2013, and the related notes to the financial statements, which collectively comprise UAB's basic financial statements, and have issued our report thereon dated January 27, 2014. The financial statements of Triton Health Systems, L.L.C. and UAB Research Foundation were not audited in accordance with *Government Auditing Standards* and accordingly, this report does not include reporting on internal control over financial reporting or instances of reportable noncompliance associated with Triton Health Systems, L.L.C. or UAB Research Foundation. Our report includes an emphasis of a matter regarding the presentation of the financial statements as discussed in Note 1 and an emphasis of a matter regarding the retrospective application of new accounting standards adopted during 2013 as discussed in Note 3 to the financial statements.

Our report includes a reference to other auditors who audited the financial statements of SRI, as described in our report on UAB's financial statements. This report does not include the results of the other auditors' testing of internal control over financial reporting or compliance and other matters that are reported on separately by those auditors.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered UAB's internal control over financial reporting ("internal control") to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of UAB's internal control. Accordingly, we do not express an opinion on the effectiveness of UAB's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.



Compliance and Other Matters

As part of obtaining reasonable assurance about whether UAB's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Pricewatechouse Cooperes LLP

January 27, 2014



Independent Auditor's Report on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over Compliance in Accordance with OMB Circular A-133

To the Board of Trustees of The University of Alabama:

Report on Compliance for Each Major Federal Program

We have audited the compliance of the University of Alabama at Birmingham ("UAB"), a campus of The University of Alabama System, which is a component unit of the State of Alabama, with the types of compliance requirements described in the *OMB Circular A-133 Compliance Supplement* that could have a direct and material effect on each of UAB's major federal programs for the year ended September 30, 2013. UAB's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

We did not audit Southern Research Institute's ("SRI"), a discretely presented component unit of UAB, compliance with the terms and conditions of its federal grants, contracts, and agreements with the federal government; and its subgrants received from UAB. Compliance with these requirements was audited by other auditors whose report thereon has been furnished to us, and our opinion, insofar as it relates to SRI's compliance with those requirements, is based solely on the report of the other auditors.

The University's basic financial statements include the operations of Triton Health Systems, L.L.C. and UAB Research Foundation, which did not receive federal awards during the year ended September 30, 2013. Accordingly, our audit, described below, did not include the operations of these component units.

Management's Responsibility

Management is responsible for compliance with the requirements of laws, regulations, contracts, and grants applicable to its federal programs.

Auditor's Responsibility

Our responsibility is to express an opinion on compliance for each of UAB's major federal programs based on our audit of the types of compliance requirements referred to above. We did not audit UAB's compliance with the requirements governing maintaining repayment records, monitoring the timing and amount of collections and the performance of due diligence related to campus-based student loans, compliance requirements specified by the Federal Perkins Loan, Health Professional Student Loan, Nurse Faculty Loan Program, and Loans for Disadvantaged Students Programs and described in the OMB *Circular A-133 Compliance Supplement*. Compliance with these requirements was audited by other auditors whose report thereon has been furnished to us, and our opinion, insofar as it relates to UAB's compliance with those requirements, is based solely on the report of the other auditors. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and OMB Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations*. Those standards and OMB Circular A-133 require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal



program occurred. An audit includes examining, on a test basis, evidence about UAB's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of UAB's compliance.

Opinion on Each Major Federal Program

In our opinion, based on our audit and the report of other auditors, UAB complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended September 30, 2013.

Other Matters

The results of our auditing procedures disclosed instances of noncompliance, which are required to be reported in accordance with OMB Circular A-133 and which are described in the accompanying schedule of findings and questioned costs as items 2013-001. Our opinion on each major federal program is not modified with respect to these matters.

UAB's response to the noncompliance findings identified in our audit is described in the accompanying Management Views and Corrective Action Plan. UAB's response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

Management of UAB is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, except as noted in the following paragraphs, we considered UAB's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with OMB Circular A-133, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly we do not express an opinion on the effectiveness of UAB's internal control over compliance.

We did not consider internal control over compliance with the requirements of laws, regulations, contracts and grants applicable to the federal programs of SRI. Internal control over these compliance requirements was considered by other auditors; and our report, insofar as it relates to UAB's internal control over those compliance requirements, does not include SRI.

The University's basic financial statements include the operations of Triton Health Systems, L.L.C. and UAB Research Foundation, which did not receive federal awards during the year ended September 30, 2013. Accordingly, we did not consider internal control over compliance with requirements of laws, regulations, contracts, and grants applicable to federal programs for these component units.



We did not consider internal control over compliance with the requirements governing maintaining repayment records, monitoring the timing and amount of collections and the performance of due diligence related to campus-based student loans, which are specified by the Federal Perkins Loan, Health Professional Student Loan, Nurse Faculty Loan Program, and Loans for Disadvantaged Students Programs and described in the OMB *Circular A-133 Compliance Supplement*. Internal control over these compliance requirements was considered by the other auditors referred to above; and our report, insofar as it relates to UAB's internal control over those compliance requirements, is based solely upon the report of the other auditors.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration and the other auditor's consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. Also, the report of other auditors associated with student loans referred to above did not identify and deficiencies in internal control over compliance that they consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Report on Schedule of Expenditures of Federal Awards Required by OMB Circular A-133

We have audited the financial statements that collectively comprise UAB's basic financial statements as of and for the year ended September 30, 2013, and have issued our report thereon dated January 27, 2014, which contained an unmodified opinion on those financial statements. Our audit was conducted for the purpose of forming opinions on the financial statements that collectively comprise the basic financial statements. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by OMB Circular A-133 and is not a required part of the basic financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the basic financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the basic financial statements or to the basic financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the basic financial statements as a whole.



The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of OMB Circular A-133. Accordingly, this report is not suitable for any other purpose.

Pricewaterhaus Coopers LLP

June 27, 2014, except for our report on the Schedule of Expenditures of Federal Awards, for which the date is January 27, 2014.

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|---|-------------------------------------|----------------|-----------------------|
| RESEARCH AND DEVELOPMENT CLUSTER | | | | |
| Department of Agriculture | | | | |
| Direct | | | | |
| Agricultural Research_Basic and Applied Research | | | 10.001 | \$ 6,796 |
| Total Direct | | | | 6,796 |
| Total Department of Agriculture | | | | 6,796 |
| Department of Defense | | | | |
| Direct | | | | |
| Basic and Applied Scientific Research | | | 12.300 | 305,207 |
| Military Medical Research and Development | | | 12.420 | 3,976,857 |
| Basic Scientific Research | | | 12.431 | 404,691 |
| Basic, Applied, and Advanced Research in Science and Engineering | | | 12.630 | 77,483 |
| Uniformed Services University Medical Research Projects | | | 12.750 | 186,018 |
| Research and Technology Development | | | 12.910 | 388,587 |
| Contract #FA8650-13-C-7339 | | | 12. | 372,723 |
| Contract #FA9201-09-C-0207 | | | 12. | 299,335 |
| Contract #DOD - IPA - Meakin | | | 12. | 236,335 |
| Contract #DOD - IPA - Ward | | | 12. | 229,215 |
| Contract #FA8651-11-C-0291 | | | 12. | 66,276 |
| Contract #W91CRB-11-C-0023 | | | 12. | 42,449 |
| Contract #FA4819-09-C-0038 | | | 12. | 32,353 |
| Contract #FA9451-10-C-0254 | | | 12. | 28,944 |
| Contract #W912HZ10C0106 | | | 12. | 9,935 |
| Total Direct | | | | 6,656,408 |
| Pass-Through | | | | |
| Basic and Applied Scientific Research | North Carolina A&T State University | N00014-09-1-0842 | 12.300 | 20,002 |
| Basic and Applied Scientific Research | MEDICAL UNIVERSITY OF SOUTH CAROLINA | N00014-08-1-0341 | 12.300 | 5,786 |
| | | | | 25,788 |
| Military Medical Research and Development | THE CURATORS OF THE UNVERSITY OF MISSOURI | W81XWH-11-2-0155 | 12.420 | 422,673 |
| Military Medical Research and Development | HENRY M JACKSON FOUNDATION | W81XWH-08-2-0700 | 12.420 | 153,303 |
| Military Medical Research and Development | NATIONAL TRAUMA INSTITUTE | W81XWH-11-1-0841 | 12.420 | 32,572 |
| Military Medical Research and Development | University of Texas Health Science Ctr at Houston | W81XWH-11-1-0240 | 12.420 | 12,881 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|---|-------------------------------------|----------------|-----------------------|
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED | | | | |
| Department of Defense, continued | | | | |
| Military Medical Research and Development | HENRY FORD HEALTH SYSTEM | W81XWH-11-1-0671 | 12.420 | 2,368 |
| Military Medical Research and Development | University of California in San Francisco | W81XWH-10-1-0509 | 12.420 | 19 |
| | | | | 623,816 |
| Basic Scientific Research | Texas A&M University | W911NF-07-1-0197 | 12.431 | 91,030 |
| Basic, Applied, and Advanced Research in Science and Engineering | Alabama State University | 5-522776-12 | 12.630 | 52,055 |
| Air Force Defense Research Sciences Program | REGENTS OF THE UNIVERSITY OF MINNESOTA | FA9550-12-1-0319 | 12.800 | 105,895 |
| Research and Technology Development | Northern Illinois University | W15QKN-12-1-0001 | 12.910 | 258,394 |
| Contract | CHENEGA FEDERAL SYSTEMS LLC | GST0407DB0305 | 12. | 399,149 |
| Contract | High Performance Technologies Inc | GS04T09DBC0017 | 12. | 364,163 |
| Contract | CHENEGA FEDERAL SYSTEMS LLC | GS04T13DBC0006 | 12. | 363,597 |
| Contract | low a State University | HR0011-12-C-0075 | 12. | 185,158 |
| Contract | Advanced Technology Institute | 2004-611 | 12. | 136,373 |
| Contract | POLARIS GROUP | W9113M-10-C-0054 | 12. | 130,074 |
| Contract | Sentar | FA8750-11-C-0250 | 12. | 109,302 |
| Contract | C LOGIC DEFENSE | W15QKN-09-9-1001 BRG-057 | 12. | 83,567 |
| Contract | High Performance Technologies Inc | GS01T09DBC0017 | 12. | 37,944 |
| Contract | SCIENTIFIC SYSTEMS CO | N00014-11-M-0300 | 12. | 19,988 |
| Contract | The Geneva Foundation | HU001-10-1TS05 | 12. | 9,745 |
| Contract | High Performance Technologies Inc | PP-CFD-KY03-018-P3 | 12. | 5,072 |
| Contract | Advanced Technology Institute | W15QKN-07-C-0066 | 12. | 1,396 |
| Contract | AMERICAN FOUNDRY SOCIETY | W15QKN-11-2-0001 | 12. | 714 |
| Contract | SARC/SARCOMA ALLIANCE FOR RESEARCH | SARC 006 | 12. | 354 |
| Contract | High Performance Technologies Inc | HPTI-PETTT-UAB | 12. | 247 |
| Contract | Advanced Technology Institute | W15QKN-10-2-0001 | 12. | (1,571) |
| Total Pass-Through | J, | | | 3,002,250 |
| Total Department of Defense | | | | 9,658,658 |
| rotal Department of Deletibe | | | | 3,030,030 |
| Department of Interior | | | | |
| Direct | | | | |
| Conservation Grants Private Stewardship for Imperiled Species | | | 15.632 | 38,402 |
| Marine Turtle Conservation Fund | | | 15.645 | 8,562 |
| Total Direct | | | | 46,964 |

| Federal Grantor | Pass-Through Grantor | Contract/Award or Pass-Through Num | CFDA Number | Total Expenditures |
|---|-------------------------------------|------------------------------------|----------------|-----------------------|
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED Department of Interior, continued | | | | |
| Pass-Through | | | | |
| Assistance to State Water Resources Research Institutes | Auburn University | G11AP20063 | 15.805 | 11,540 |
| Total Pass-Through | | | | 11,540 |
| Total Department of Interior | | | | 58,504 |
| Department of Transportation | | | | |
| Direct | | | | |
| University Transportation Centers Program | | | 20.701 | 75,559 |
| Contract #DTFT60-04-Z-7001 | | | 20. | 137,853 |
| Total Direct | | | | 213,412 |
| Pass-Through | | | | |
| University Transportation Centers Program | GEORGIA INSTITUTE OF TECHNOLOGY | DTRT12-G-UTC12 | 20.701 | 327,507 |
| University Transportation Centers Program | University of Florida | TASK ORDER # 2 | 20.701 | 41,210 |
| University Transportation Centers Program | University of Florida | TASK ORDER #1 | 20.701 | 20,512 |
| University Transportation Centers Program | University of Florida | TASK ORDER # 005 | 20.701 | 20,248 |
| University Transportation Centers Program | University of Alabama in Tuscaloosa | DTRT06-G-0047 | 20.701 | 11,622 |
| | | | | 421,099 |
| Contract | University of Florida | DTRT12-G-UTC04 | 20. | 58,984 |
| Contract | Alabama Dept of Transportation | 930-607B | 20. | 22,557 |
| Contract | University of Florida | UF-EIES-1200009-UAB | 20. | 2,249 |
| Unknow n | Alabama Dept of Transportation | 930-842 | 20. | 164,797 |
| Unknow n | Alabama Dept of Transportation | 930-843 | 20. | 120,593 |
| Total Pass-Through | | | | 790,279 |
| Total Department of Transportation | | | | 1,003,691 |
| National Aeronautics and Space Administration | | | | |
| Direct | | | | |
| Science | | | 43.001 | 2,156,221 |
| Contract #NNJ10HB16B | | | 43. | 7,162,468 |
| Contract #NNM07AA05A | | | 43. | 41,501 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|---|--------------------------------------|----------------|-----------------------|
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED | | | | |
| National Aeronautics and Space Administration, continued | | | | |
| Contract #NNX09AV81G | | | 43. | 35,488 |
| Unknown #NNX11AC61G | | | 43. | 264,197 |
| Unknown #NNX09A128G | | | 43. | 55,072 |
| Total Direct | | | 40. | 9,714,947 |
| Daga Through | | | | |
| Pass-Through Contract | University of Alabama in Huntsville | NNX10AJ80H | 43. | 70,555 |
| Contract | NATIONAL INSTITUTE OF AEROSPACE ASSOCIATES INC | NNL09AA00A | 43. 43. | 66,458 |
| Contract | NATIONAL INSTITUTE OF AEROSPACE ASSOCIATES INC | T12-6300-UAB | 43. 43. | 13,696 |
| Unknow n | The Center for the Advancement of Science in Space, Inc | NNH11CD70A | 43. 43. | 206,458 |
| Total Pass-Through | The Center for the Advancement of Science in Space, inc | NINTI ICD/OA | 43. | 357,167 |
| Total Fass-Tillough | | | | 337,107 |
| Total National Aeronautics and Space Administration | | | | 10,072,114 |
| | | | | |
| National Science Foundation | | | | |
| Direct | | | | |
| Engineering Grants | | | 47.041 | 711,438 |
| Mathematical and Physical Sciences | | | 47.049 | 793,730 |
| Computer and Information Science and Engineering | | | 47.070 | 425,305 |
| Biological Sciences | | | 47.074 | 883,904 |
| Social, Behavioral, and Economic Sciences | | | 47.075 | 363,010 |
| Education and Human Resources | | | 47.076 | 2,226,141 |
| Polar Programs | | | 47.078 | 92,218 |
| International Science and Engineering (OISE) | | | 47.079 | 12,212 |
| Office of Cyberinfrastructure | | | 47.080 | 250 |
| Contract #PLR-1342923 | | | 47. | 47,616 |
| Unknow n #MCB-1321557 | | | 47. | 4,800 |
| Total Direct | | | | 5,560,624 |
| Pass-Through | | | | |
| Engineering Grants | Alabama State University | HRD-0734232 | 47.041 | 217 |
| Mathematical and Physical Sciences | Florida State University | NSF#DMR-1229217/FSU 22700-520-031355 | 47.049 | 45,671 |
| Biological Sciences | University of Florida | IOS-1051890 | 47.074 | 43,929 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|--------------------------------------|-------------------------------------|----------------|-----------------------|
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED | | | | |
| National Science Foundation, continued | | | | |
| Biological Sciences | low a State University | IOS-1257857 | 47.074 | 22,071 |
| | | | | 66,000 |
| Education and Human Resources | Tuskegee University | DUE-1102997 | 47.076 | 224,252 |
| Education and Human Resources | Tuskegee University | HRD-1137681 | 47.076 | 54,841 |
| Education and Human Resources | STEVENS INSTITUTE OF TECHNOLOGY | 0833076 | 47.076 | 147 |
| | | | | 279,240 |
| Office of Europeants Decreased Office late Occupation Decreased | Todaya Hidaya X | FD0 4450000 | 47.004 | 770.077 |
| Office of Experimental Program to Stimulate Competitive Research | Tuskegee University | EPS-1158862 IIP-1058155 | 47.081 47. | 776,677 |
| Contract Total Pass-Through | Sioux Manufacturing Corporation | IIP-1036133 | 47. | 1,167,856 |
| Total Fass-Tillough | | | | 1,107,030 |
| ARRA Direct | | | | |
| ARRA - 0838773 | | | 47.082 | 143,205 |
| ARRA - 0906316 | | | 47.082 | 8,857 |
| ARRA - 0838844 | | | 47.082 | 3,207 |
| Total ARRA Direct | | | | 155,269 |
| ARRA Pass-Through | | | | |
| ARRA - UAH 2011-017 | University of Alabama in Huntsville | EPS-1006661 | 47.082 | 5,594 |
| Total ARRA Pass-Through | Cini otony di vilazania in viano ino | | 002 | 5,594 |
| | | | | |
| Total National Science Foundation | | | | 6,889,343 |
| Department of Veterans Affairs | | | | |
| Direct | | | | |
| Contract - Intergovernmental Personnel Agreements | | | 64. | 3,119,097 |
| Contract #VA247-13-C-0156 | | | 64. | 145,557 |
| Contract #VA247-P-0675 | | | 64. | 131,609 |
| Contract #VA247-12-P-5068 | | | 64. | 50,463 |
| Total Direct | | | | 3,446,726 |
| Total Department of Veterans Affairs | | | | 3,446,726 |

| Federal Grantor | Pass-Through Grantor | Contract/Award or Pass-Through Num | CFDA Number | Total Expenditures |
|---|--|---|--------------------------|--|
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED Department of Energy Direct | | | | |
| Fossil Energy Research and Development Stewardship Science Grant Program Total Direct | | | 81.089 81.112 | 379,920 182,208 562,128 |
| Pass-Through | | | | |
| Office of Science Financial Assistance Program Office of Science Financial Assistance Program | University of Alabama in Huntsville University of Alabama in Tuscaloosa | DE-SC0006652 DE-FG02-08ER46537 | 81.049 81.049 | 169,119 88,305 257,424 |
| Conservation Research and Development | Caterpillar Inc | DEEE0005980 | 81.086 | 149,829 |
| Fossil Energy Research and Development Fossil Energy Research and Development | ADVANCED RESOURCED INTERNATIONAL MONTANA STATE UNIV-BOZEMAN | EP-P28631/C13564 DE-FE0004478 | 81.089 81.089 | 74,481 66,688 141,169 |
| Stew ardship Science Grant Program Stew ardship Science Grant Program | Carnegie Institute of Washington Carnegie Institute of Washington | DE-FC52-08NA285544 DE-NA002006 | 81.112 81.112 | 33,448 12,514 45,962 |
| Contract Contract Contract Unknow n Unknow n Total Pass-Through | University of California Lawren Livermore Natl Lab UT-Battelle, LLC UT-Battelle, LLC Sandia National Laboratories Sandia National Laboratories | DE-AC52-07NA27344 DE-AC05-00OR22725 DE-AC05-00OR22726 1198675 PO# 1330625 | 81. 81. 81. 81. | 42,624 5,685 1,210 249,741 68,805 962,449 |
| ARRA Direct ARRA - DE-FE0002224 Total ARRA Direct | | | 81.133 | 44,904 44,904 |
| Total Department of Energy | | | | 1,569,481 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|---|---|-------------------------------------|------------------|-----------------------|
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED Department of Education | | | | |
| Direct National Institute on Disability and Rehabilitation Research | | | 84.133 | 3.574.180 |
| Graduate Assistance in Areas of National Need | | | 84.200 | 57,298 |
| Special Ed - Personnel Dev't to Improve Services and Results for Children | | | 84.325 | 88,301 |
| Total Direct | | | | 3,719,779 |
| Pass-Through | | | | |
| National Institute on Disability and Rehabilitation Research | Rehabilitation Institute of Chicago | H133E120010 | 84.133 | 87,587 |
| National Institute on Disability and Rehabilitation Research | THE INSTITUTE FOR REHABILITATION AND RESEARCH | H133B090023 | 84.133 | 38,071 |
| National Institute on Disability and Rehabilitation Research | University of Washington | H133A060107A; UW-341166 | 84.133 | 17,339 |
| National Institute on Disability and Rehabilitation Research | Craig Hospital | H133G090013 | 84.133 | 1,500 |
| National Institute on Disability and Rehabilitation Research | The University of Montana | H133B080023-11 | 84.133 | 868 145,365 |
| Total Pass-Through | | | | 145,365 |
| Total Department of Education | | | | 3,865,144 |
| Department of Health and Human Services | | | | |
| Direct | | | | |
| Chronic Diseases: Research, Control, and Prevention | | | 93.068 | 73,285 |
| Family Smoking Prevention and Tobacco Control Act Regulatory Rsrch | | | 93.077 | 69,487 |
| Food and Drug Administration_Research | | | 93.103 | 8,371 |
| Environmental Health Oral Diseases and Disorders Research | | | 93.113 | 1,099,395 |
| Centers for Res. and Demo. for Health Promotion and Disease Prevention | | | 93.121 93.135 | 9,010,749 994,166 |
| Coord. Serv.and Access to Res. for Women, Infants, Children and Youth | | | 93.153 | 724,726 |
| Research Related to Deafness and Communication Disorders | | | 93.173 | 340,561 |
| Research and Training in Complementary and Alternative Medicine | | | 93.213 | 98,305 |
| National Research Service Awards_Health Services Research Training | | | 93.225 | 291,032 |
| Research on Healthcare Costs, Quality and Outcomes | | | 93.226 | 1,829,843 |
| National Center on Sleep Disorders Research | | | 93.233 | 335,771 |
| Mental Health Research Grants | | | 93.242 | 5,884,649 |
| Geriatric Academic Career Awards | | | 93.250 | 137,845 |
| Occupational Safety and Health Program | | | 93.262 | 1,714,259 |
| Alcohol Research Programs | | | 93.273 | 1,187,790 |

| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED Department of Health and Human Services, continued Drug Abuse and Addiction Research Programs Pass-Through Grantor Contract/Award or Pass-Through Num Number Contract/Award or Pass-Through Num Number 8 93.279 | 799,901 96,467 66,095 |
|---|-----------------------------|
| Department of Health and Human Services, continued | 96,467 66,095 |
| Department of Health and Human Services, continued | 96,467 66,095 |
| | 96,467 66,095 |
| bridg / todoc drid / todocion i tograno | 96,467 66,095 |
| Mental Health Research Career/Scientist Development Awards 93.281 | 66,095 |
| Mental Health National Research Service Awards for Research Training 93.282 | , |
| The Affordable Care Act: CDC and Prevention_Investigations 93.283 | 1,046,764 |
| Discovery/Applied Res. for Tech. Innovations to Improve Human Health 93.286 | 365,187 |
| Minority Health and Health Disparities Research 93.307 | 3,332,409 |
| Trans-NIH Research Support 93.310 | 1,636,321 |
| National Center for Advancing Translational Sciences 93.350 | 5.361.449 |
| Nursing Research 93.361 | 1,338,963 |
| National Center for Research Resources 93.389 | 121,262 |
| Cancer Construction 93.392 | 32 |
| Cancer Cause and Prevention Research 93.393 | 4,550,108 |
| Cancer Detection and Diagnosis Research 93.394 | 2,074,007 |
| Cancer Treatment Research 93.395 | 4,416,776 |
| Cancer Biology Research 93.396 | 1,994,662 |
| Cancer Centers Support Grants 93.397 | 13,223,953 |
| Cancer Research Manpower 93.398 | 1,434,621 |
| The Patient Protection and Affordable Care Act of 2010 (ACA) | 147,197 |
| Cardiovascular Diseases Research 93.837 | 15,205,228 |
| Lung Diseases Research 93.838 | 5,968,481 |
| Blood Diseases and Resources Research 93.839 | 2,528,288 |
| Arthritis, Musculoskeletal and Skin Diseases Research | 9,605,428 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research 93.847 | 17,968,659 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders 93.853 | 15,246,764 |
| Allergy, Immunology and Transplantation Research | 30,858,002 |
| Biomedical Research and Research Training 93.859 | 6,675,221 |
| Population Research 93.864 | 244,060 |
| Child Health and Human Development Extramural Research | 14,097,196 |
| Aging Research 93.866 | 6,246,052 |
| Vision Research 93.867 | 3,782,628 |
| International Research and Research Training 93.989 | 172,313 |
| Contract #HHSN268200900047C OPTION 1 93. | 2,885,663 |
| Contract #HHSN266200400073C 93. | 2,351,627 |
| Contract #HHSN268201100025C 93. | 1,579,222 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|----------------------|-------------------------------------|----------------|-----------------------|
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED | | | | |
| Department of Health and Human Services, continued | | | | |
| Contract #HHSN263201200010C | | | 93. | 942,643 |
| Contract #HHSN272201100016I | | | 93. | 940,829 |
| Contract #N01-HC-95095 OP#2 | | | 93. | 914,141 |
| Contract #N01-AI-30025 | | | 93. | 736,126 |
| Contract #N01-CN-75022-70 | | | 93. | 733,965 |
| Contract #HHSN268200900047C | | | 93. | 677,918 |
| Contract #HHSN261201200021I | | | 93. | 643,861 |
| Contract #HHS-N-260-2005-0008-C | | | 93. | 592,257 |
| Contract #HHSN272201100037C | | | 93. | 569,065 |
| Contract #N01-HC-95095 OPTION #3 | | | 93. | 568,298 |
| Contract #HHSN272201100038C | | | 93. | 530,414 |
| Contract #HHSN268200736191C | | | 93. | 473,450 |
| Contract #HHSN272201100034C | | | 93. | 417,375 |
| Contract #HHSN272201100036C | | | 93. | 344,752 |
| Contract #HHSN272201100035C | | | 93. | 337,171 |
| Contract #N01-HC-48047 OPTION 2 | | | 93. | 330,731 |
| Contract #HHSN272201000023C | | | 93. | 254,983 |
| Contract #HHSN261200433001C-521958 | | | 93. | 179,532 |
| Contract #200-2007-23684 | | | 93. | 166,838 |
| Contract #200-2011-42023-0002 | | | 93. | 158,036 |
| Contract #N01HC48047 | | | 93. | 155,658 |
| Contract #HHSN268201300026C | | | 93. | 112,477 |
| Contract #N01-Al-30021 | | | 93. | 51,700 |
| Contract #10IPA1003334 | | | 93. | 50,167 |
| Contract #NO1-HC-48047 | | | 93. | 42,588 |
| Contract #IPA BRAY MOLLY S | | | 93. | 18,251 |
| Contract #200-2011-39419 | | | 93. | 8,081 |
| Contract #HHSN272201000027 | | | 93. | 2,366 |
| Contract #HHSN272201300012I | | | 93. | 218 |
| Contract #HHSN311201200193P | | | 93. | 43 |
| Contract #HHSN268200682278C | | | 93. | (103) |
| Unknow n #OAR | | | 93. | 55,149 |
| Total Direct | | | | 212,230,220 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|--|-------------------------------------|----------------|-----------------------|
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED | | | | |
| Department of Health and Human Services, continued | | | | |
| Pass-Through | | | | |
| Global AIDS | University of North Carolina at Chapel Hill | 5U2GP5001421-05 | 93.067 | 171,418 |
| Global AIDS | University of North Carolina at Chapel Hill | 7U2GPS001421-04 | 93.067 | 36,402 |
| Global A IDS | CIDRZ FOUNDATION | 1R01Al099601-01 | 93.067 | 25,458 |
| | | | | 233,278 |
| Comp. Comm. Mental Hith Serv. for Children w / Emotional Disorders | University of Alabama in Tuscaloosa | 1U79SM059049-01 | 93.104 | 141 |
| Environmental Health | Indiana University | 1R01ES021735-01 | 93.113 | 79,820 |
| Environmental Health | YALEUNIV | 1R21ES022875-01 | 93.113 | 50,898 |
| Environmental Health | YALEUNIV | 5U01ES015674-07 | 93.113 | 27,892 |
| Environmental Health | Vivo Biosciences Inc | 2R44ES018004-02A1 | 93.113 | 23,159 |
| Environmental Health | Wayne State University | 5R01ES005823 | 93.113 | 21,440 |
| | | | | 203,209 |
| Oral Diseases and Disorders Research | The Research Foundation of SUNY | 3U01DE18902-04S1 | 93.121 | 178,125 |
| Oral Diseases and Disorders Research | Vista Engineering Inc. | 2R42DE019335-03A1 | 93.121 | 175,527 |
| Oral Diseases and Disorders Research | A GILE SCIENCES INC | 2R44DE021312-02 | 93.121 | 63,868 |
| Oral Diseases and Disorders Research | University of Texas Health Center at San Antonio | 2R01DE015857-05A1 | 93.121 | 33,018 |
| Oral Diseases and Disorders Research | UNIVERSITY AT BUFFALO | 1RD1DE02267301 | 93.121 | 19,568 |
| Oral Diseases and Disorders Research | The Research Foundation of SUNY | DE018902 | 93.121 | 13 |
| | | | | 470,119 |
| Human Genome Research | University of Washington | 5 R01HG005115-03 | 93.172 | 291,824 |
| Human Genome Research | HUDSON ALPHA INSTITUTE FOR BIOTECHNOLOGY | 1UM1HG007301-01 | 93.172 | 20,485 |
| Human Genome Research | University of North Carolina at Chapel Hill | 5 U01 HG004803-03 | 93.172 | 5,961 |
| | | | | 318,270 |
| Research Related to Deafness and Communication Disorders | University of Minnesota | 2R01DC006452-04A2 | 93.173 | 51,333 |
| Research Related to Deafness and Communication Disorders | ADVANCED LIQUID LOGIC INC | 1R44DC012967-01 | 93.173 | 20,980 |
| Research Related to Deafness and Communication Disorders | The Feinstein Institute for Medical Research | 5U01DC007946 | 93.173 | 332 |
| | | | | 72,645 |
| Disabilities Prevention | Hemophilia of Georgia Inc | 1U27DD000862-0 | 93.184 | 50,750 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|---|-------------------------------------|----------------|-----------------------|
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED | | | | |
| Department of Health and Human Services, continued | | | | |
| Research and Training in Complementary and Alternative Medicine | Massachusetts General Hospital | 5U01AT000613 | 93.213 | 36,912 |
| National Center on Sleep Disorders Research | California Pacific Med. Ctr. Res. Inst. | 5R01HL071194-09 | 93.233 | 273,170 |
| Mental Health Research Grants | Johns Hopkins University | UM1 Al068632-07 | 93.242 | 283,972 |
| Mental Health Research Grants | Duke University | 5R01-MH086362 | 93.242 | 147,559 |
| Mental Health Research Grants | University of Washington | R01MH098675 | 93.242 | 44,958 |
| Mental Health Research Grants | Childrens Hospital Medical Center Cincinnati OH | 5R01MH083665 | 93.242 | 11,694 |
| Mental Health Research Grants | Johns Hopkins University | 7 UMA 1068632-07 | 93.242 | 4,400 |
| Mental Health Research Grants | Social & Scientific Systems Inc | 1 U01Al06832-01 | 93.242 | (593) |
| | | | | 491,990 |
| Substance Abuse and Mental Hith Serv_Proj. of Regional/National Sig. | HEALTH SERVICE CENTER | T102320 | 93.243 | 68,404 |
| Substance Abuse and Mental Hlth Serv_Proj. of Regional/National Sig. | University of Colorado Health Sciences Center | 4R33MH089291-03 | 93.243 | 4,971 |
| Substance Abuse and Mental Hlth Serv_Proj. of Regional/National Sig. | HEALTH SERVICE CENTER | SAMHSA/CSAT | 93.243 | 4,136 |
| | | | | 77,511 |
| Occupational Safety and Health Program | MARSHFIELD CLINIC RESEARCH FOUNDATION | 5R21OH010032-02 | 93.262 | 17,222 |
| Occupational Safety and Health Program | MARSHFIELD CLINIC RESEARCH FOUNDATION | 1R21OH010032-01 | 93.262 | 437 |
| | | | | 17,659 |
| Alcohol Research Programs | University of Washington | 1U01AA020793-01 | 93.273 | 70,815 |
| Drug Abuse and Addiction Research Programs | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 3U10DA013727-12 | 93.279 | 329,333 |
| Drug Abuse and Addiction Research Programs | Virginia Commonwealth University | 1R01DA033200-01A1 | 93.279 | 21,437 |
| Drug Abuse and Addiction Research Programs | University of Pittsburgh | 5R01DA026312-03 | 93.279 | 10,895 |
| Drug Abuse and Addiction Research Programs | University of North Carolina at Chapel Hill | 1R01DA030793-02 | 93.279 | 7,616 |
| Drug Abuse and Addiction Research Programs | Emory University | RR36-009/4693598 | 93.279 | 1,406 |
| Drug Abuse and Addiction Research Programs | UNIVERSITY AT BUFFALO | 1R01DA027606-02 | 93.279 | (288) |
| | | | | 370,399 |
| The Affordable Care Act: CDC and Prevention_Investigations | Alabama Dept of Public Health | C20119146 | 93.283 | 192,923 |
| The Affordable Care Act: CDC and Prevention_Investigations | Assoc of American Medical Colleges | U36/CCU319276 | 93.283 | 12,646 |
| | | | | 205,569 |

| Federal Grantor | Pass-Through Grantor | Contract/Award or Pass-Through Num | CFDA Number | Total Expenditures |
|--|---|------------------------------------|----------------|-----------------------|
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED | | | | |
| Department of Health and Human Services, continued | | | | |
| Discovery/Applied Res. for Tech. Innovations to Improve Human Health | MONTANA STATE UNIV-BOZEMAN | 1R01EB012027-01A1 | 93.286 | 212,413 |
| Discovery/Applied Res. for Tech. Innovations to Improve Human Health | Brigham & Womens Hospital | 5U54EB005149-08 | 93.286 | 99,366 |
| Discovery/Applied Res. for Tech. Innovations to Improve Human Health | Brigham & Womens Hospital | 8P41EB015902-15 | 93.286 | 60,773 |
| Discovery/Applied Res. for Tech. Innovations to Improve Human Health | MICHIGAN TECHNOLOGICAL UNIVERSITY | R03EB014844 | 93.286 | 6,465 |
| | | | | 379,017 |
| Minority Health and Health Disparities Research | University of Minnesota | 1U24MD006970-01 | 93.307 | 455,465 |
| Minority Health and Health Disparities Research | JACKSON STATE UNIVERSITY | 1P20MD0006899-01 | 93.307 | 82,534 |
| Minority Health and Health Disparities Research | University of Texas Health Science Ctr at Houston | 5U24MD006941 | 93.307 | 1,738 |
| · | • | | | 539,737 |
| National Center for Advancing Translational Sciences | Boston University Medical Campus | 8UL1RR000157-05 | 93.350 | 4,999 |
| Nursing Research | University of Maryland | 1R01NR012686-01 | 93.361 | 158,921 |
| Nursing Research | University of Texas Health Science Ctr at Houston | 7R21NR011923-03 | 93.361 | 36,884 |
| Nursing Research | University of California in San Diego | 7R01NR011295-03 | 93.361 | 33,738 |
| Nursing Research | University of Alabama in Tuscaloosa | 1R21NR012550-01A1 | 93.361 | 8,506 |
| Nursing Research | University of Michigan | 1R21NR01192301A1 | 93.361 | (17,275) |
| • | • | | | 220,774 |
| Cancer Cause and Prevention Research | Duke University | 1R01CA142081-01A1 | 93.393 | 206,540 |
| Cancer Cause and Prevention Research | University of South Alabama | 1R01CA155638-01A1 | 93.393 | 65,756 |
| Cancer Cause and Prevention Research | University of Massachusetts Worcester | 7R01CA129091-03 | 93.393 | 57,080 |
| Cancer Cause and Prevention Research | Morehouse School of Medicine | 1R01CA166785-01 | 93.393 | 56,218 |
| Cancer Cause and Prevention Research | THE REGENTS OF THE UNIVERSITY OF CALFORNIA | 1R01CA158271-01A1 | 93.393 | 51,256 |
| Cancer Cause and Prevention Research | Morehouse School of Medicine | 1R01CA166785-02 | 93.393 | 22,669 |
| Cancer Cause and Prevention Research | University of Southern California | 1R01CA134786-01A2 | 93.393 | 19,950 |
| Cancer Cause and Prevention Research | University of Massachusetts Worcester | 1R01CA136888-01A1 | 93.393 | 16,111 |
| Cancer Cause and Prevention Research | Johns Hopkins University | 1R01CA140311-01A2 | 93.393 | 10,883 |
| Cancer Cause and Prevention Research | Vanderbilt University | 2 R01CA082729-07A1 | 93.393 | 9,211 |
| Cancer Cause and Prevention Research | H. Lee Moffitt Cancer Center & Research Institute | 3U54CA153509-03S1 | 93.393 | 3,579 |
| Cancer Cause and Prevention Research | Dana-Farber Cancer Institute | 5U01CA93344-08 | 93.393 | 115 |
| | | | | 519,368 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|---|-------------------------------------|----------------|-----------------------|
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED | | | | |
| Department of Health and Human Services, continued | | | | |
| Cancer Detection and Diagnosis Research | University of California in San Diego | R01CA159954 | 93.394 | 14,477 |
| Cancer Treatment Research | University of California in San Diego | 1R01CA148791-02 | 93.395 | 208,623 |
| Cancer Treatment Research | Southeastern Gynecologic Oncology | 27469-02 | 93.395 | 188,755 |
| Cancer Treatment Research | Johns Hopkins University | U01CA137443-01 | 93.395 | 108,962 |
| Cancer Treatment Research | Eastern Cooperative Oncology Group | CA21115 | 93.395 | 107,542 |
| Cancer Treatment Research | University of Michigan | 210CA32102-32 | 93.395 | 83,858 |
| Cancer Treatment Research | Children's Hospital of Philadelphia | U10CA098543 | 93.395 | 79,283 |
| Cancer Treatment Research | University of North Carolina at Chapel Hill | 7D43CA153784-03 | 93.395 | 58,506 |
| Cancer Treatment Research | Children's Hospital of Philadelphia | UM1CA097452 | 93.395 | 54,500 |
| Cancer Treatment Research | Eastern Cooperative Oncology Group | U10CA21115-36 | 93.395 | 53,017 |
| Cancer Treatment Research | Children's Hospital of Philadelphia | 5 U10 CA98543-04 | 93.395 | 41,807 |
| Cancer Treatment Research | Duke University | 1R01CA164751-01A1 | 93.395 | 24,916 |
| Cancer Treatment Research | Eastern Cooperative Oncology Group | U10CA21115 | 93.395 | 10,995 |
| Cancer Treatment Research | University of Wisconsin in Madison | 1R01CA139872-01A1 | 93.395 | 7,746 |
| Cancer Treatment Research | Duke University | CA31946 | 93.395 | 6,728 |
| Cancer Treatment Research | St. Jude Children's Research Hospital | 2U24CA055727-18 | 93.395 | 4,455 |
| Cancer Treatment Research | Natl Childhood Cancer Foundation | U01 CA97452-05 | 93.395 | 4,213 |
| Cancer Treatment Research | University of Chicago | U10 CA31946 | 93.395 | 74 |
| Cancer Treatment Research | Southwest Oncology Group | CA32102 | 93.395 | 30 |
| Cancer Treatment Research | Natl Childhood Cancer Foundation | 5 U10 CA98543-04 | 93.395 | (8,389) |
| | | | | 1,035,621 |
| Cancer Biology Research | Cedars-Sinai Medical Center | 5P01CA098912-07 | 93.396 | 215,146 |
| Cancer Biology Research | HEALTH RESEARCH INC | 1R21CA16457201 | 93.396 | 27,700 |
| Cancer Biology Research | MICHIGAN STATE UNIVERSITY | R21CA1715251 | 93.396 | 12,121 |
| | | | | 254,967 |
| Cancer Centers Support Grants | Johns Hopkins University | 5P50CA 098252-07 | 93.397 | 523,065 |
| Cancer Centers Support Grants | THE METHODIST HOSPITAL RESEARCH INST | U54CA143837-05 | 93.397 | 18,951 |
| Cancer Centers Support Grants | University of New Mexico | U54CA164336-03 | 93.397 | 14,483 |
| Cancer Centers Support Grants | Johns Hopkins University | 5P50CA098252-08 | 93.397 | 4,411 |
| | | | | 560,910 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|---|---|-------------------------------------|----------------|-----------------------|
| DESCRIPCIA AND DEVEL ORMENT OF LISTED, CONTINUED | | | | |
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED Department of Health and Human Services, continued | | | | |
| Cancer Control | Mayo Clinic Rochester | 5U10CA149950-02 | 93.399 | 11,637 |
| Cancer Control | Southwest Oncology Group | CA37429 | 93.399 | (41,315) |
| Cancel Control | Southwest Orcology Group | UN31423 | 90.099 | (29,678) |
| Cardiovascular Diseases Research | University of Louisville Research Foundation, Inc | 2P01HL078825-06 | 93.837 | 417,691 |
| Cardiovascular Diseases Research | Elgavish Paramagnetics Inc | 2R42HL084844-02A1 | 93.837 | 204,401 |
| Cardiovascular Diseases Research | University of Texas Health Center at Tyler | R18HL092955 | 93.837 | 182,006 |
| Cardiovascular Diseases Research | University of Washington | 5U01HL077863-09 | 93.837 | 174,742 |
| Cardiovascular Diseases Research | University of Minnesota | 5R01HL053560-14 | 93.837 | 139,252 |
| Cardiovascular Diseases Research | Medical College of Wisconsin | 1U01HL107437-01 | 93.837 | 138,138 |
| Cardiovascular Diseases Research | University of California in Davis | 2P01HL080101-07A1 | 93.837 | 118,432 |
| Cardiovascular Diseases Research | University of Washington | 3U01HL077863-07S1 | 93.837 | 102,408 |
| Cardiovascular Diseases Research | Fred Hutchinson Cancer Research Center | 5 R01HL05065-03 | 93.837 | 79,753 |
| Cardiovascular Diseases Research | Fred Hutchinson Cancer Research Center | 5 R01HL05065-02 | 93.837 | 77,115 |
| Cardiovascular Diseases Research | Boston University Medical Campus | 5PO1 HL081587-06A1 | 93.837 | 43,948 |
| Cardiovascular Diseases Research | University of Washington | 1R01HL103612-02 | 93.837 | 31,110 |
| Cardiovascular Diseases Research | Columbia University in the City of New York | 5P01HL088117-05 | 93.837 | 15,851 |
| Cardiovascular Diseases Research | CORINNOVA INC | 1R43HL108512-01A1 | 93.837 | 15,666 |
| Cardiovascular Diseases Research | New York University Medical School | U01HL105907 | 93.837 | 15,402 |
| Cardiovascular Diseases Research | University of Minnesota | 1R01-HL080093 | 93.837 | 14,919 |
| Cardiovascular Diseases Research | Columbia University in the City of New York | 5P01HL088117-03 | 93.837 | 13,898 |
| Cardiovascular Diseases Research | Vanderbilt University | 7K23HL087114-06 | 93.837 | 12,565 |
| Cardiovascular Diseases Research | Northw estern University | R01HL107577-01 | 93.837 | 4,262 |
| Cardiovascular Diseases Research | University of Michigan | U01HL094345 | 93.837 | 3,408 |
| Cardiovascular Diseases Research | YALE UNIV | R01HL081153 | 93.837 | 860 |
| Cardiovascular Diseases Research | Fred Hutchinson Cancer Research Center | 1 R01HL05065-01A1 | 93.837 | (1,697) |
| Cardiovascular Diseases Research | University of Washington | 1R01HL103612-01A1 | 93.837 | (4,393) |
| Cardiovascular Diseases Research | University of California in Davis | 2P01HL080101-06A1 | 93.837 | (5,808) |
| | | | | 1,793,929 |
| Lung Diseases Research | University of Michigan | R01HL094230-01A1 | 93.838 | 206,757 |
| Lung Diseases Research | REGENTS OF THE UNIVERSITY OF MINNESOTA | U01HL074424 | 93.838 | 141,719 |
| Lung Diseases Research | REGENTS OF THE UNIVERSITY OF COLORADO | 1U01HL102235-01A1 | 93.838 | 90,426 |
| Lung Diseases Research | Mayo Clinic Rochester | 5 U01 Al069544 | 93.838 | 44,895 |

| | | | CFDA | Total |
|--|--|-------------------------------------|--------|--------------|
| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | Number | Expenditures |
| PERSONAL AND DEVEL ORDERED OF HOTER CONTENTS | | | | |
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED | | | | |
| Department of Health and Human Services, continued | Helicans to a Colone de Health Octobres Octobre | 00001 004000 0004 | 00.000 | 00.454 |
| Lung Diseases Research | University of Colorado Health Sciences Center | 3P50HL084923-05S1 | 93.838 | 33,154 |
| Lung Diseases Research | Brigham & Womens Hospital | 5U01HL102225-03 | 93.838 | 26,546 |
| Lung Diseases Research | University of Pennsylvania | 5U01HL086622-03 | 93.838 | 20,199 |
| Lung Diseases Research | Brigham & Womens Hospital | 1R01HL107246 | 93.838 | 10,734 |
| Lung Diseases Research | Duke University | 1U01HL080413-01 | 93.838 | 7,014 |
| Lung Diseases Research | National Jewish Medical and Research Center | 2R01HL089897 | 93.838 | 2,104 |
| Lung Diseases Research | Johns Hopkins University | R01HL68927 | 93.838 | 1,095 |
| Lung Diseases Research | Children's Hospital of Philadelphia | 5R01HL098087-02 | 93.838 | (5,043) |
| | | | | 579,600 |
| Blood Diseases and Resources Research | Baylor College of Medicine | 5R01HL095647-04 | 93.839 | 67,044 |
| Blood Diseases and Resources Research | Children's Hospital of Philadelphia | 5P01HL064190-12 | 93.839 | 49,558 |
| Blood Diseases and Resources Research | University of Pennsylvania | 5R01HL066176-10 | 93.839 | 14,701 |
| Blood Diseases and Resources Research | Baylor College of Medicine | 7R01HL095647-03 | 93.839 | (65,946) |
| | , , | | | 65,357 |
| | | | | |
| Arthritis, Musculoskeletal and Skin Diseases Research | University of Washington | 1U01AR057954-04 | 93.846 | 384,932 |
| Arthritis, Musculoskeletal and Skin Diseases Research | Childrens Hospital Medical Center Cincinnati OH | 5P60AR047784-09 | 93.846 | 5,351 |
| Arthritis, Musculoskeletal and Skin Diseases Research | Boston University Medical Campus | 5R01AR062506-01A1 | 93.846 | 4,066 |
| Arthritis, Musculoskeletal and Skin Diseases Research | Johns Hopkins University | 1R21AR062269-01A1 | 93.846 | 2,427 |
| Arthritis, Musculoskeletal and Skin Diseases Research | Boston University Medical Campus | 5P60AR047785-12 | 93.846 | 1,384 |
| | | | | 398,160 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | Cleveland Clinic Foundation | 5U01DK082236-05 | 93.847 | 434,096 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | Cleveland Clinic Foundation | 5U01DK082236 | 93.847 | 380,425 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | Pennington Biomedical Research Center | 9R01DK089641 | 93.847 | 198,117 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | Washington University in St Louis | 5U01DK082315-05 | 93.847 | 193,236 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | DISCOVERY BIOMED LLC | 2R44DK084658-02A1 | 93.847 | 189,783 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | Mount Sinai School of Medicine | 5U54DK083909-03 | 93.847 | 162,921 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | Kaiser Foundation Research Institute | R01 DK084997-01A1 | 93.847 | 138,814 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | University of Alaska in Fairbanks | 1R01DK074842-01A1 | 93.847 | 128.832 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | Wake Forest University School of Medicine | R01DK83527 | 93.847 | 115,032 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | The George Washington University | 1U01DK098246-01 | 93.847 | 108,508 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | University of California in San Diego | 7R01DK084063-02 | 93.847 | 86,696 |
| ,,,, and . and . j | The state of the s | | 33.011 | 00,000 |

| Federal Grantor | Pass-Through Grantor | Contract/Award or Pass-Through Num | CFDA Number | Total Expenditures |
|--|---|------------------------------------|----------------|-----------------------|
| | | | | |
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED | | | | |
| Department of Health and Human Services, continued | | | | |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | University of Texas Southwestern Medical Center | 5U01DK058369-12 | 93.847 | 85,311 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | Emory University | 1DP3DK094346-01 | 93.847 | 59,426 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | Mayo Clinic Rochester | 5U54DK083908-04 | 93.847 | 58,600 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | Columbia University in the City of New York | 5R01DK052431-18 | 93.847 | 55,761 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | Mayo Clinic Rochester | 5U01DK056957-12 | 93.847 | 34,675 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | New England Research Institute | U01DK058229-10 | 93.847 | 31,369 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | Kaiser Foundation Research Institute | 5R01DK090047-01A1 | 93.847 | 18,965 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | FAST BioMedical | 1R44DK093274-01 REVISED | 93.847 | 18,656 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | Mayo Clinic Rochester | 2 U01 DK056957 | 93.847 | 17,399 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | Childrens Hospital Medical Center Cincinnati OH | 5UM1 DK072493-07 | 93.847 | 14,507 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | BOSTON MEDICAL CENTER | 1R01DK090029-01A1 | 93.847 | 4,543 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | Children's Hospital of Philadelphia | 1R01DK085212-01A1 | 93.847 | 3,688 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | Childrens Hospital Medical Center Cincinnati OH | 2UM1 DK072493-06 | 93.847 | 976 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | University of Pittsburgh | 5U01DK075803-04 | 93.847 | 554 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | University of Pennsylvania | 5R01DK089738-05 | 93.847 | 366 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | University of Pittsburgh | 1R01DK77906-01A2 | 93.847 | 285 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | Wayne State University | 2U01DK074062-06 | 93.847 | 103 |
| | | | | 2,541,644 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | Mount Sinai School of Medicine | 5U01NS045719-07 | 93.853 | 1,231,679 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | University of British Columbia | 2 U01 NS038529-09 | 93.853 | 650,214 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | UMDNJ/Rutgers | 2R01NS038384-12 | 93.853 | 487,175 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | Johns Hopkins University | 7R01NS075047-02 | 93.853 | 331,455 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | Massachusetts General Hospital | 5P50NS037409-13 | 93.853 | 258,682 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | CHILDREN'S HOSPITAL BOSTON | 1U01NS082320-01 | 93.853 | 245,641 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | Arizona State University | 7R01NS061846-04 | 93.853 | 191,477 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | University of Wisconsin in Madison | 5P01NS042803-09 | 93.853 | 185,060 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | BOSTON MEDICAL CENTER | 1R01NS070307-01A1 | 93.853 | 152,258 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | University of Chicago | 1U01NS069997-03 | 93.853 | 123,187 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | University of California in San Francisco | 1U01NS058634-01A2 | 93.853 | 106,413 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | University of Florida | R01NS073346 | 93.853 | 57,160 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | Johns Hopkins University | 5U01NS062851-03 | 93.853 | 55,567 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | University of Texas Health Science Ctr at Houston | 5P50NS044227-07 | 93.853 | 40,882 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | THE REGENTS OF THE UNIVERSITY OF CALFORNIA | R01NS071463 | 93.853 | 40,302 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|---|---|----------------|-----------------------|
| | | | | |
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED | | | | |
| Department of Health and Human Services, continued | | | | |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | REGENTS OF THE UNIVERSITY OF MINNESOTA | 1U01NS062091-01A2 | 93.853 | 33,632 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | University of California in San Diego | P50NS044148-07 | 93.853 | 33,140 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | UMDNJ/Rutgers | R01 NS38384 | 93.853 | 23,217 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | Medical College of Wisconsin | 5R01NS035929-11 | 93.853 | 20,111 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | Childrens Hospital Medical Center Cincinnati OH | 2U01NS045911-06A2 | 93.853 | 18,515 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | Emory University | 2U01NS038455-11A1 | 93.853 | 17,654 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | Mount Sinai School of Medicine | U01NS045719 | 93.853 | 17,228 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | THE UNIVERSITY OF CALIFORNIA | R01NS053998 | 93.853 | 14,453 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | Childrens Hospital Medical Center Cincinnati OH | 5R01NS065840-02 | 93.853 | 6,383 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | GEORGE MASON UNIVERSITY | 1R21NS070740-01A1 | 93.853 | 4,976 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | Washington University in St Louis | 5U01NS042804-06 | 93.853 | 3,664 |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | Massachusetts General Hospital | 5P50NS037409 | 93.853 | (445) |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 1U01NS058728-01A1 | 93.853 | (5,472) |
| Extramural Res. Programs in Neurosciences and Neurological Disorders | University of Texas Health Science Ctr at Houston | 3P50NS044227-0851 | 93.853 | (13,498) |
| | | | | 4,330,710 |
| Allergy, Immunology and Transplantation Research | Fred Hutchinson Cancer Research Center | 5U01Al068614 | 93.855 | 838,731 |
| Allergy, Immunology and Transplantation Research | Emory University | 2R01Al064060-06A1 | 93.855 | 603,652 |
| Allergy, Immunology and Transplantation Research | Brigham & Womens Hospital | 7UM1A1068636-07 | 93.855 | 500,652 |
| Allergy, Immunology and Transplantation Research | Emory University | U01Al084150-01 | 93.855 | 387,596 |
| Allergy, Immunology and Transplantation Research | Florida State University | 1P01AI074805-01A1/FSU#227000-520-023294 | 93.855 | 358,354 |
| Allergy, Immunology and Transplantation Research | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 1P01Al083194-01 | 93.855 | 240,791 |
| Allergy, Immunology and Transplantation Research | University of North Carolina at Chapel Hill | 3U54Al057157-07 | 93.855 | 214,339 |
| Allergy, Immunology and Transplantation Research | University of Minnesota | 1 U19 Al070119-07 | 93.855 | 169,774 |
| Allergy, Immunology and Transplantation Research | University of California in Davis | 1R01Al097629-01 | 93.855 | 149,193 |
| Allergy, Immunology and Transplantation Research | University of California in Davis | 2R56Al049342-10 | 93.855 | 147,901 |
| Allergy, Immunology and Transplantation Research | University of Pennsylvania | 5U01Al082211-04 | 93.855 | 137,055 |
| Allergy, Immunology and Transplantation Research | Duke University | 5U19Al067854 | 93.855 | 112,134 |
| Allergy, Immunology and Transplantation Research | University of California in Davis | 2R56Al049342-10A1 | 93.855 | 89,929 |
| Allergy, Immunology and Transplantation Research | University of North Carolina at Chapel Hill | 5U54-Al57157-11 | 93.855 | 88.300 |
| Allergy, Immunology and Transplantation Research | University of North Carolina at Chapel Hill | 7UM1A1069455-06 | 93.855 | 87.510 |
| Allergy, Immunology and Transplantation Research | University of Pennsylvania | 5U01Al082211-05 | 93.855 | 82,318 |
| Allergy, Immunology and Transplantation Research | Albert Einstein College of Medicine of Yeshiva U | 1R01-Al097096-01A1 | 93.855 | 54,770 |
| Allergy, Immunology and Transplantation Research | Johns Hopkins University | 1 U01 Al069918-07 | 93.855 | 49,032 |
| Anorgy, mananology and transplantation resourch | Commo i opinito officiony | 1 001 /1000010 0/ | 33.033 | 75,052 |

| | | | CFDA | Total |
|--|--|-------------------------------------|--------|--------------|
| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | Number | Expenditures |
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED | | | | |
| Department of Health and Human Services, continued | | | | |
| Allergy, Immunology and Transplantation Research | Microbiotix, Inc | 2R44A1082799 | 93.855 | 46,904 |
| Allergy, Immunology and Transplantation Research | University of Texas at ⊟ Paso | 1R01AI102663-01 | 93.855 | 44,926 |
| Allergy, Immunology and Transplantation Research | THE REGENTS OF THE UNIVERSITY OF CALFORNIA | 1R01Al097629 | 93.855 | 43,303 |
| Allergy, Immunology and Transplantation Research | Duke University | 5U19Al056363-09 | 93.855 | 42.677 |
| Allergy, Immunology and Transplantation Research | THE REGENTS OF THE UNIVERSITY OF CALFORNIA | 5 U01 Al083005 | 93.855 | 40.318 |
| Allergy, Immunology and Transplantation Research | Fred Hutchinson Cancer Research Center | 5 UM1 A 1068614-07 | 93.855 | 40,318 |
| Allergy, Immunology and Transplantation Research | CHILDREN'S HOSPITAL BOSTON | 1U01 Al077816-05 | 93.855 | 31,682 |
| Allergy, Immunology and Transplantation Research | Emory University | 2R01Al071002-06A1 | 93.855 | 26.806 |
| Allergy, Immunology and Transplantation Research | GEORGE MASON UNIVERSITY | 2R01Al0043894-11A2 | 93.855 | 24,332 |
| Allergy, Immunology and Transplantation Research | Medical College of Wisconsin | 5R01Al078713-09 | 93.855 | 20,659 |
| Allergy, Immunology and Transplantation Research | Medical College of Wisconsin | 5R01Al078713-09 5R01Al078713-08 | 93.855 | 19,688 |
| Allergy, Immunology and Transplantation Research | Johns Hopkins University | 1 U01 Al069918-08 | 93.855 | 16.086 |
| Allergy, Immunology and Transplantation Research | Microbiotix, Inc | 1 R43 DE023005 | 93.855 | 15,431 |
| Allergy, Immunology and Transplantation Research | THERA PEUTICS SYSTEMS RESEARCH LAB | 1R43Al00401-01A1 | 93.855 | 13,431 |
| Allergy, Immunology and Transplantation Research | Brigham & Womens Hospital | 5UM1A 1068636-07 | 93.855 | 13,142 |
| Allergy, Immunology and Transplantation Research | University of Georgia | 1R21Al096364-01A1 | 93.855 | 13,142 |
| Allergy, Immunology and Transplantation Research | Southern Research Institute | 1R21AI101924 | 93.855 | , - |
| 67. 67 1 | | = | | 9,126 |
| Allergy, Immunology and Transplantation Research | Virginia Commonw ealth University | 1R56Al081837-01A1 | 93.855 | 1,875 |
| Allergy, Immunology and Transplantation Research | Duke University | 5U19A1056363-08 | 93.855 | 253 |
| Allergy, Immunology and Transplantation Research | University of Texas at ⊟ Paso | 5R01A1077413-02 | 93.855 | (55) |
| Allergy, Immunology and Transplantation Research | Brigham & Womens Hospital | 5U01Al063623-04 | 93.855 | (290) |
| Allergy, Immunology and Transplantation Research | CHILDREN'S HOSPITAL BOSTON | 1U01 Al077816-03 | 93.855 | (1,365) |
| Allergy, Immunology and Transplantation Research | Social & Scientific Systems Inc | UM1 A1068636-06 | 93.855 | (3,688) |
| | | | | 4,768,804 |
| Biomedical Research and Research Training | SOLUBLE THERA PEUTICS, LLC | 2R42GM088958-02 | 93.859 | 208,557 |
| Biomedical Research and Research Training | University of Illinois at Chicago | 1R01GM096191-03 | 93.859 | 127,195 |
| Biomedical Research and Research Training | Technion(Israel Institute of Technology) R& D Foundation | 1R01GM094792-02 | 93.859 | 86,299 |
| Biomedical Research and Research Training | Technion(Israel Institute of Technology) R& D Foundation | 4R01GM094792-03 | 93.859 | 78,188 |
| Biomedical Research and Research Training | University of Pittsburgh | 2P50GM082251-06 | 93.859 | 52,818 |
| Biomedical Research and Research Training | University of Georgia | 5P01GM08535404 | 93.859 | 6,211 |
| Biomedical Research and Research Training | University of Pennsylvania | 1R01GM088566-01 | 93.859 | 2,841 |
| Biomedical Research and Research Training | University of Pittsburgh | 5P50GM076659-05 | 93.859 | 106 |
| - | | | | 562,215 |

| | | | CFDA | Total |
|--|---|-------------------------------------|--------|--------------|
| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | Number | Expenditures |
| DECEADOU AND DEVEL ORMENT OF HOTEL CONTINUED | | | | |
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED Department of Health and Human Services, continued | | | | |
| Population Research | YALEUNIV | 5U10HD055925-04 | 93.864 | (1,934) |
| r opulation nesearch | I ALL ON | 30101100333923-04 | 93.004 | (1,334) |
| Child Health and Human Development Extramural Research | Harvard School of Public Health | 5 U01 HD052102-08 | 93.865 | 349,818 |
| Child Health and Human Development Extramural Research | RTI International | 5U10HD034216-15 | 93.865 | 202,694 |
| Child Health and Human Development Extramural Research | University of Utah | 5K12HD047349-09 | 93.865 | 91,576 |
| Child Health and Human Development Extramural Research | University of Maryland | R01HD067126 | 93.865 | 82,004 |
| Child Health and Human Development Extramural Research | Duke University | 1R01HD057956-01 | 93.865 | 81,461 |
| Child Health and Human Development Extramural Research | Pennsylvania State University (The) | 1R01HD066982-01 | 93.865 | 52,790 |
| Child Health and Human Development Extramural Research | Oregon Health & Sciences University | 1R01HD0696910-01A1 | 93.865 | 51,946 |
| Child Health and Human Development Extramural Research | University of Utah | 5K12HD047349 | 93.865 | 26,138 |
| Child Health and Human Development Extramural Research | University of Maryland | 1R01HD067126 | 93.865 | 19,985 |
| Child Health and Human Development Extramural Research | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY | 7U01HD044253-08 | 93.865 | 18,133 |
| Child Health and Human Development Extramural Research | BENTON TECHNOLOGIES INC | 1R43HD072823-01 | 93.865 | 10,623 |
| Child Health and Human Development Extramural Research | University of Wisconsin in Madison | 1R01HD071089-01A1 | 93.865 | 8,754 |
| Child Health and Human Development Extramural Research | University of North Carolina at Greensboro | 1R15HD071431-01A1 | 93.865 | 5,736 |
| Child Health and Human Development Extramural Research | Childrens Hospital Medical Center Cincinnati OH | 5R01HD059140-02 | 93.865 | 4,264 |
| Child Health and Human Development Extramural Research | University of Michigan | 2 U01 HD041249-06 | 93.865 | (47) |
| | | | | 1,005,875 |
| Aging Research | University of Florida | 9R01AG033906-06 | 93.866 | 426,481 |
| Aging Research | University of low a | 1R01AG033035-01A2 | 93.866 | 416,178 |
| Aging Research | University of Pennsylvania | 3U01AG030644-02S3 | 93.866 | 415,121 |
| Aging Research | University of Southern California | 1R01AG037561-01A1 | 93.866 | 127,488 |
| Aging Research | University of Kentucky Research Foundation | 1R01AG034605 | 93.866 | 88,131 |
| Aging Research | Alzheimer's Disease Cooperative Study | 2U01AG24904-06 | 93.866 | 71,232 |
| Aging Research | University of Pennsylvania | 1R01AG037679-01A1 | 93.866 | 37,322 |
| Aging Research | University of California in San Francisco | R01AG033592 | 93.866 | 18,534 |
| Aging Research | REGENTS OF THE UNIVERSITY OF MINNESOTA | 7R01AG031846-04 | 93.866 | 9,003 |
| Aging Research | University of Louisville Research Foundation, Inc | 5R01AG024040-03 | 93.866 | 1,217 |
| | · | | | 1,610,707 |
| Vision Research | Emory University | 5 U10 EY013272-07 | 93.867 | 236,195 |
| Vision Research | University of California in San Diego | 1R01EY019869-01 | 93.867 | 161,914 |
| Vision Research | Duke University | 1R01EY019126-01 | 93.867 | 97,789 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|--|-------------------------------------|----------------|-----------------------|
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED | | | | |
| Department of Health and Human Services, continued | | | | |
| Vision Research | Wake Forest University School of Medicine | R01HL098445 | 93.867 | 81,375 |
| Vision Research | Duke University | 1R01EY018405-01 | 93.867 | 67,561 |
| Vision Research | St Lukes Roosevelt Hospital Center | 1U10EY017281-01A1 | 93.867 | 20,997 |
| Vision Research | SMART ENGINEERING | 1R43EY021408-01 | 93.867 | 7,704 |
| Vision Research | University of California in San Diego | 2U10EY14267-06 | 93.867 | 7,147 |
| Vision Research | Jaeb Center for Health Research Inc | U10EY11751 | 93.867 | 630 |
| | | | | 681,312 |
| HIV Prevention Activities_Health Department Based | Alabama Dept of Public Health | 1U62PS003632-01 PS12-1201 | 93.940 | 570,822 |
| Tuberculosis Demo. Research, Public and Professional Ed | CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA | 3U2GGH000226-02S1 | 93.947 | 90,532 |
| Block Grants for Prevention and Treatment of Substance Abuse | Jefferson Blount St Clair Mental Health/MR Authori | B1 AL SAPT | 93.959 | (27,490) |
| International Research and Research Training | UNIV OF ZAMBIA | 1R24TW008873-01 REVISED | 93.989 | 29,166 |
| International Research and Research Training | University of Washington | 5U2TW007374-02 | 93.989 | 25,595 |
| International Research and Research Training | THE FLORIDA INTL UNIVERSITY OF BOARD OF TRUSTEES | 1D43TW009125-01 | 93.989 | 17,395 |
| · | | | | 72,156 |
| Contract | University of Rochester | HHSN27220120000SC | 93. | 417,932 |
| Contract | Westat Corporation | HHSN275201300003C | 93. | 264,261 |
| Contract | Westat Corporation | N01-DH-3-3345 | 93. | 94,743 |
| Contract | Altarum Institute | GS-10F-026/HHSN271201100111U | 93. | 84,695 |
| Contract | University of California in San Francisco | HHSN26620040074C | 93. | 74,067 |
| Contract | Massachusetts General Hospital | HHSN271201100006I | 93. | 62,453 |
| Contract | University of Pennsylvania | HHSN268200800003C | 93. | 55,001 |
| Contract | University of California in San Francisco | N01-Al-15416 | 93. | 48,618 |
| Contract | University of Wisconsin in Madison | N01-CN-35153 | 93. | 42,652 |
| Contract | Duke University | HHSN272200900023C | 93. | 34,988 |
| Contract | RAND Corporation | HHSM-500-2005-000281 | 93. | 33,705 |
| Contract | University of Texas Southwestern Medical Center | N01-HB-07159 | 93. | 31,924 |
| Contract | University of Illinois at Chicago | 200-2011-40306 | 93. | 30,292 |
| Contract | EMMES Corporation | HHS-N-260-2005-00007-C | 93. | 27,782 |
| Contract | Southern Research Institute | NO1-CO-12400 | 93. | 27,169 |
| Contract | Abt Associates Inc | HHSA290201000031I | 93. | 26,959 |
| Contract | University of Cincinnati | HHSF223201110112A | 93. | 25,832 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|---|-------------------------------------|----------------|-----------------------|
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED | | | | |
| Department of Health and Human Services, continued | | | | |
| Contract | Wake Forest University School of Medicine | HHSN26800900019 C | 93. | 23,412 |
| Contract | Washington University in St Louis | HHSN261201000061C | 93. | 23,200 |
| Contract | University of Texas Southwestern Medical Center | HHSN268201200019C | 93. | 10,271 |
| Contract | Duke University | HHSN27500003I | 93. | 9.672 |
| Contract | Duke University | HHSN2752010000031 | 93. | 9,059 |
| Contract | THE REGENTS OF THE UNIVERSITY OF CALFORNIA | N01-CN-35160 | 93. | 4,684 |
| Contract | Harvard Pilgrim Health Care, Inc. | HHSF223009100061-0002 | 93. | 3,978 |
| Contract | New England Research Institute | N 01HC45207 | 93. | 2,689 |
| Contract | University of Maryland | SR00002242 | 93. | 2,296 |
| Contract | Duke University | HHSN-2752010000031 | 93. | 1,268 |
| Contract | University of Michigan | NHBL-HV-10-14/HHSN268201100026C | 93. | 1,192 |
| Contract | University of California in San Francisco | N01-AI-40074 | 93. | (5,747) |
| Contract | ROCKLAND IMMUNOCHEMICALS, INC | HHSN261201100104C | 93. | (5,906) |
| Contract | University of Michigan | N01-CN-35110 | 93. | (7,593) |
| Unknow n | University of Texas Health Science Ctr at Houston | U01HL077863-06S2 | 93. | 681,824 |
| Unknow n | Georgetown University | U10HD036801 | 93. | 527,005 |
| Unknow n | RTI International | 1U01HD069031 | 93. | 199,123 |
| Unknow n | Children's Hospital of Philadelphia | U10CA098543 | 93. | 178,183 |
| Unknow n | RADIATION MONITORING DEVICES INC | 2R44EY019197-02 | 93. | 133,549 |
| Unknow n | University of California in San Diego | CTA-12-UAB-(NGF)M-001DCS | 93. | 100,701 |
| Unknow n | Alabama Dept of Public Health | BRFSS 2013-2014 | 93. | 91,835 |
| Unknow n | LEGACY RESEARCH | R01EY011610 | 93. | 89,957 |
| Unknow n | American College of Radiology | U10CA21661 | 93. | 62,257 |
| Unknow n | The Children's Mercy Hospital | 04-0023 | 93. | 43,942 |
| Unknow n | EMMES Corporation | 1U01NS026835-01A1 | 93. | 43,091 |
| Unknow n | Wake Forest University School of Medicine | U01AG029824 | 93. | 40,412 |
| Unknow n | American College of Radiology | CA80098 | 93. | 37,437 |
| Unknow n | Social & Scientific Systems Inc | BRS-IPHRM-S-08-00056 | 93. | 35,306 |
| Unknow n | Jaeb Center for Health Research Inc | UNKNOWN | 93. | 35,258 |
| Unknow n | Alabama Dept of Public Health | 1U58DP003854-01 | 93. | 31,926 |
| Unknow n | University of South Florida | U01 DK061055 | 93. | 13,587 |
| Unknow n | Duke University | NONE | 93. | 7,727 |
| Unknow n | Johns Hopkins University | 3 U01DK062431-11S1 | 93. | 5,567 |
| Unknow n | Johns Hopkins University | U01CA137443 | 93. | 4,571 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|---|--|----------------|-----------------------|
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED | | | | |
| Department of Health and Human Services, continued | Link and the of Manusian d | 41 104 N 10000000 04 | 00 | 0.400 |
| Unknow n | University of Maryland | 1U01NS069208-01 | 93. | 3,463 |
| Unknow n | Emory University | U54NS065701 | 93. | 2,329 |
| Unknow n | HEALTH SERVICE CENTER | SP017302 | 93. | 2,217 |
| Unknow n | Children's Hospital of Philadelphia | CHOP ACTIVITY 325813-FP00010263-SUB03-01 | 93. | 2,000 |
| Unknow n | Joslin Diabetes Center, Inc | 5U01DK074556-03 | 93. | 1,912 |
| Unknow n | Columbia University in the City of New York | U01NS051483 | 93. | 1,489 |
| Unknow n | CELLEX, INC | 1R44Al082728-02 | 93. | 1,458 |
| Unknow n | RTI International | 0212789 | 93. | 597 |
| Unknow n | University of Minnesota | 5K23DK087919-04 | 93. | 594 |
| Unknow n | Johns Hopkins University | U01CA137443-01 | 93. | 179 |
| Unknow n | NEW ENGLAND RESEARCH INSTITUTES INC | U01DK58234 | 93. | (7,522) |
| Total Pass-Through | | | | 29,262,550 |
| ARRA Direct | | | | |
| ARRA - 3U01HD040533-09S1 | | | 93.701 | 679,025 |
| ARRA - 3P30CA013148-38S9 | | | 93.701 | 394,414 |
| ARRA - 3P60MD000502-08S1 | | | 93.701 | 171,239 |
| ARRA - 5RC2EB011412-02 | | | 93.701 | 155,290 |
| ARRA - 3P30NS057098-05S1 | | | 93.701 | 135,647 |
| ARRA - 1P30DE020744-01 | | | 93.701 | 114,066 |
| ARRA - 5RC2AR058964-02 | | | 93.701 | 112,576 |
| ARRA - 3P30DK079337-02S1 | | | 93.701 | 57,973 |
| ARRA - 1R01HD054960-01A2 | | | 93.701 | 35,323 |
| ARRA - 5RC2AR058951-02 | | | 93.701 | 20,225 |
| ARRA - 3R01HL092173-02S2 | | | 93.701 | 16,401 |
| ARRA - 3R21EY018369-01A2S1 | | | 93.701 | 15,221 |
| ARRA - 3R01GM082952-02S1 | | | 93.701 | 14,575 |
| ARRA - 5P30NS069324-02 | | | 93.701 | 14,452 |
| ARRA - 3R24Al067039-04S1 | | | 93.701 | 5,559 |
| ARRA - 7R01Al080349-03 | | | 93.701 | 5,471 |
| ARRA - 3R01GM081488-02S1 | | | 93.701 | 5,250 |
| ARRA - 3U54CA118948-04S2 | | | 93.701 | 4,828 |
| ARRA - 1R01HL094518-01A1 | | | 93.701 | 4,557 |
| ARRA - 3R01AG030228-04S1 | | | 93.701 | 4,363 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|----------------------|-------------------------------------|----------------|-----------------------|
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED | | | | |
| Department of Health and Human Services, continued | | | | |
| ARRA - 1P30EB011319-02 | | | 93.701 | 3,461 |
| ARRA - 5R21RR025788-02 | | | 93.701 | 3,119 |
| ARRA - 3U01Al069452-04S1 | | | 93.701 | 2,608 |
| ARRA - 3UL1RR025777-02S1 | | | 93.701 | 2,003 |
| ARRA - 5R01DK082548-02 | | | 93.701 | 1,832 |
| ARRA - 7RC1DE020533-03 | | | 93.701 | 1,789 |
| ARRA - 5P30CA147858-02 | | | 93.701 | 1,353 |
| ARRA - 3P30CA013148-38S5 | | | 93.701 | 1,343 |
| ARRA - 3R01DE017954-03S1 | | | 93.701 | 752 |
| ARRA - 1R21HD061767-01 | | | 93.701 | 735 |
| ARRA - 1R03HD057388-01A2 | | | 93.701 | 725 |
| ARRA - 1P01Al083027-02 | | | 93.701 | 175 |
| ARRA - 3P50CA089019-08S1 | | | 93.701 | 51 |
| ARRA - 1R56Al082249-01A2 | | | 93.701 | 31 |
| ARRA - 3P30CA013148-38S3 | | | 93.701 | 17 |
| ARRA - 5RC1TW008467-02 | | | 93.701 | (64) |
| ARRA - 3U01NS042685-04S1 | | | 93.701 | (230) |
| ARRA - 1R03HL097006-01 | | | 93.701 | (1,703) |
| ARRA - 1RC2MD004778-02 | | | 93.701 | (2,019) |
| ARRA - 3R01NS031234-16S2 | | | 93.701 | (2,328) |
| ARRA - 3R01HD053055-04S1 | | | 93.701 | (2,831) |
| ARRA - 7R01AR055307-03 | | | 93.701 | (7,141) |
| ARRA - 3P30CA013148-38S4 | | | 93.701 | (9,812) |
| ARRA - 3U54CA118948-04S1 | | | 93.701 | (26,155) |
| | | | | 1,934,166 |
| ARRA - 1R18HS01923901 | | | 93.715 | 639,855 |
| ARRA - 1K12HS01946501 | | | 93.715 | 493,577 |
| ARRA - 1T32HS01946301 | | | 93.715 | 109,867 |
| | | | | 1,243,299 |
| ARRA - HHSN268200900047C | | | 93. | 19,917 |
| Total ARRA Direct | | | | 3,197,382 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|---|-------------------------------------|----------------|-----------------------|
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED | | | | |
| Department of Health and Human Services, continued | | | | |
| ARRA Pass-Through | | | | |
| ARRA - DUKE 203-0666 | Duke University | 1UC4NR012584 | 93.701 | 78,269 |
| ARRA - 0007248-C | University of Texas Health Science Ctr at Houston | 3P50NS044227-07S3 | 93.701 | 69,267 |
| ARRA - MT SINAI 0256-9131-4609 | Mount Sinai School of Medicine | 3U01Al063594-07S1 | 93.701 | 18,304 |
| ARRA - VUMC 40572 | Vanderbilt University | 1RC4MH092755-01 | 93.701 | 17,047 |
| ARRA - M12A11304 (AS0201) | YALE UNIV | 3U10HD055925-02S1REVISED | 93.701 | 3,171 |
| ARRA - U OF MIAMI PO-M154677 | UNIVERSITY OF MIAMI | 1R01HD060325-01 | 93.701 | 3,143 |
| ARRA - JHU ABTC 0903 | Johns Hopkins University | U01CA137433 | 93.701 | 1,665 |
| ARRA - ACRIN 4701 | American College of Radiology | 1R01HS019403-01 | 93.701 | 1,314 |
| ARRA - UF09227 | University of Florida | 3R01AG033906-06S1 | 93.701 | 178 |
| ARRA - U of MD,Balt - SR00001493 | University of Maryland | 3U01DK060397-08S2 | 93.701 | 46 |
| ARRA - U TX33188/98113850PO33513-2000 | University of Texas MD Anderson Center | 5 RC2 CA148263-02 | 93.701 | (651) |
| ARRA - UAB-506012-PO#3100183496 | The Feinstein Institute for Medical Research | 5RC2AR059092-02 | 93.701 | (691) |
| ARRA - CHILD ONC GROUP 19192 | Natl Childhood Cancer Foundation | 3U01CA097452-07S2 | 93.701 | (891) |
| ARRA - CMH 09-0017 | The Children's Mercy Hospital | 3U01DK066143-07S1 | 93.701 | (2,400) |
| ARRA - BRS-IMPCT-Q-06-00115-T010-ARRA | Social & Scientific Systems Inc | 3U01Al068632-05S2 | 93.701 | (2,670) |
| ARRA - DUKE SPS#165191/174373 | Duke University | RC2A R058934 | 93.701 | (2,935) |
| | , | | | 182,166 |
| ARRA - 217197 | Massachusetts General Hospital | R01HS019371 | 93.715 | 313,886 |
| ARRA - 4213/ACCT#432843/ORG10535 | Rutgers, The State University of New Jersey | 1R01HS020097-01 | 93.715 | 75,553 |
| | | | | 389,439 |
| ARRA - MUSC10-116 | MEDICAL UNIVERSITY OF SOUTH CAROLINA | HHSN75200800014C | 93. | 112,513 |
| ARRA - SRI S10-005 | Southern Research Institute | N01-CO-12400 | 93. | (4,537) |
| Total ARRA Pass-Through | | | | 679,581 |
| Total Department of Health and Human Services | | | | 245,369,733 |
| Corporation for National and Community Services | | | | |
| Direct | | | | |
| Contract #HHSN272201000027 | | | 94. | 357,700 |
| Total Direct | | | | 357,700 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|-------------------------------|-------------------------------------|----------------|-----------------------|
| RESEARCH AND DEVELOPMENT CLUSTER, CONTINUED | | | | |
| Corporation for National and Community Services, continued | | | | |
| Pass-Through Social Innovation Fund | AIDS UNITED | NONE | 94.019 | 35,000 |
| Contract | American College of Radiology | UNKNOWN | 94.019 94. | 2,280 |
| Total Pass-Through | Afficial College of Radiology | ONNINOWIN | 34. | 37,280 |
| Total Corporation for National and Community Services | | | | 394,980 |
| Department of Homeland Security | | | | |
| Pass-Through | | | | |
| Unknown | Cazador LLC | DNDO | 97. | (57,252) |
| Total Pass-Through | | | | (57,252) |
| Total Department of Homeland Security | | | | (57,252) |
| U. S. Agency for International Development | | | | |
| Pass-Through | | | | |
| USAID Dev. Partnerships for University Cooperation and Development | University of Georgia | ECGA00070000100 | 98.012 | 28,434 |
| Unknown | FUTURES GROUP | AID-OAA-A-10-00067 | 98. | 28,212 |
| Unknow n | Intl Aids Vaccine Initiative | GPO-A-00-06-00006-00 | 98. | 17,746 |
| Total Pass-Through | | | | 74,392 |
| Total U. S. Agency for International Development | | | | 74,392 |
| TOTAL RESEARCH AND DEVELOPMENT CLUSTER | | | | 282,352,310 |
| STUDENT FINANCIAL AID CLUSTER | | | | |
| Department of Education | | | | |
| Direct | | | | |
| Federal Supplemental Education Opportunity Grant | | | 84.007 | 739,857 |
| Federal Work-Study Program | | | 84.033 | 1,018,239 |
| Federal Pell Grant | | | 84.063 | 17,036,485 |
| Direct Student Loans | | | 84.268 | 130,083,267 |
| Teacher Ed. Assistance for College and Higher Ed. Grants (TEACH) | | | 84.379 | 100,374 |
| Total Direct | | | | 148,978,222 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|---------------------------|-------------------------------------|------------------|-----------------------------------|
| STUDENT FINANCIAL AID CLUSTER, CONTINUED Department of Education, continued Total Department of Education | | | | 148,978,222 |
| Department of Health and Human Services Direct Nurse Faculty Loan Program Schlps for Hith Professions Students from Disadvantaged Backgrounds Total Direct | | | 93.264 93.925 | 292,686 1,133,567 1,426,253 |
| Total Department of Health and Human Services | | | | 1,426,253 |
| TOTAL STUDENT FINANCIAL AID CLUSTER | | | | 150,404,475 |
| HEAD START Department of Health and Human Services Direct Head Start Total Direct | | | 93.600 | 935,562 935,562 |
| Total Department of Health and Human Services | | | | 935,562 |
| TOTAL HEAD START | | | | 935,562 |
| OTHER PROGRAMS Department of Agriculture Direct Scientific Cooperation and Research Total Direct | | | 10.961 | 7,286 7,286 |
| Pass-Through Child and Adult Care Food Program Total Pass-Through | Alabama Dept of Education | ADS-0000 | 10.558 | 16,199 16,199 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|-------------------------------|-------------------------------------|----------------|-----------------------|
| OTHER PROGRAMS, CONTINUED Department of Agriculture, continued Total Department of Agriculture | | | | 23,485 |
| <u>Department of Defense</u> Direct | | | | |
| Contract - Post 9/11 GI Bill | | | 12. | 2,818,655 |
| Contract - Navy Unknown | | | 12. | 557,016 |
| Contract - Go Army Contract - Health Profession Students | | | 12. 12. | 258,918 230,903 |
| Contract - Air Force Unknown | | | 12. | 207,079 |
| Contract #FA4417-11-P-R045 | | | 12. | 92,556 |
| Contract - Medical Department Center and School | | | 12. | 59,562 |
| Contract - Army Corp of Engineers | | | 12. | 6,191 |
| Contract - Coast Guard Unknown | | | 12. | 6,000 |
| Total Direct | | | | 4,236,880 |
| Pass-Through | | | | |
| Comp. Grants:Promoting K-12 Student Achv at Mitry-Connected Schls | SUMTER SCHOOL DISTRICT | HE1254-12-1-0008 | 12.556 | 13,370 |
| Total Pass-Through | | | | 13,370 |
| | | | | |
| Total Department of Defense | | | | 4,250,250 |
| Department of Housing and Urban Development | | | | |
| Direct | | | | |
| Supportive Housing Program | | | 14.235 | 611,828 |
| Total Direct | | | | 611,828 |
| | | | | |
| Total Department of Housing and Urban Development | | | | 611,828 |
| Department of Justice | | | | |
| Pass-Through | | | | |
| Unknow n | Jefferson County Commission | 2012-DC-BX-008 | 16. | 90,147 |
| Unknown | Alabama Dept of Public Health | 2012-PM-BX-0008 | 16. | 50,017 |
| Unknow n | Alabama Dept of Corrections | 2012-CZ-BX-0013 | 16. | 47,710 |
| Total Pass-Through | | | | 187,874 |

| Federal Grantor | Pass-Through Grantor | Contract/Award or Pass-Through Num | CFDA Number | Total Expenditures |
|--|--------------------------------|------------------------------------|----------------|---------------------------|
| OTHER PROGRAMS, CONTINUED Department of Justice, continued Total Department of Justice | | | | 187,874 |
| Department of State Direct Professional and Cultural Exchange Programs - Citizen Exchanges Total Direct | | | 19.415 | 925 925 |
| Total Department of State | | | | 925 |
| Department of Transportation Direct NHTSA Discretionary Safety Grants Total Direct | | | 20.614 | 439,409 439,409 |
| Pass-Through Unknow n Total Pass-Through | Alabama Dept of Transportation | K-12-1510 | 20. | 169,520 169,520 |
| Total Department of Transportation | | | | 608,929 |
| National Foundation on the Arts and the Humanities Pass-Through Unknow n Total Pass-Through | Alabama Council on the Arts | 2013-20704 | 45. | 2,150 2,150 |
| Total National Foundation on the Arts and the Humanities | | | | 2,150 |
| Department of Veterans Affairs Direct Contract - Intergovernmental Personnel Agreements Total Direct | | | 64. | 264,171 264,171 |
| Total Department of Veterans Affairs | | | | 264,171 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|---|--|-------------------------------------|--|---|
| OTHER PROGRAMS, CONTINUED Department of Energy Direct Energy Eff. and Renew able Energy Info. Dissemination, Outreach, Train. Total Direct | | | 81.117 | 127,725 127,725 |
| Pass-Through Contract Total Pass-Through | Oak Ridge Associated Universities | DE-AC05-06OR23100 | 81. | 39,071 39,071 |
| Total Department of Energy Department of Education-TRIO Cluster Direct TRIO_Student Support Services TRIO_McNair Post-Baccalaureate Achievement Total Direct | | | 84.042 84.217 | 166,796 5,108 27,362 32,470 |
| Total Department of Education-TRIO Cluster | | | | 32,470 |
| Department of Education Direct Bilingual Education Graduate Assistance in Areas of National Need Special Ed-Personnnal Dev to Improve Serv and Results for Children Special Ed-Tech Assist and Dissemination to Improve Serv and Research Transition to Teaching English Language Acquisition State Grants Total Direct | | | 84.195 84.200 84.325 84.326 84.350 84.365 | 10,158 226,450 442,386 173,820 384,401 768,159 2,005,374 |
| Pass-Through Special Education_Grants to States Special Education_Grants to States | Alabama Dept of Education Alabama Dept of Education | UNKNOWN UNKNOWN | 84.027 84.027 | 72,895 2,827 75,722 |
| Special Ed-Personnel Dev to Improve Serv and Results for Children | Salus University | H325V090001 | 84.325 | 52,950 |

| Federal Grantor | Pass-Through Grantor | Contract/Award or Pass-Through Num | CFDA Number | Total Expenditures |
|---|----------------------------------|------------------------------------|----------------|-----------------------|
| OTHER PROGRAMS, CONTINUED | | | | |
| Department of Education, continued | | | | |
| Arts in Education | Birmingham City Schools | STRAIGHT A'S | 84.351 | 42,333 |
| Mathematics and Science Partnerships | Alabama Dept of Education | U100610 | 84.366 | 446,194 |
| Mathematics and Science Partnerships | Alabama Dept of Education | UNKNOWN | 84.366 | 234,305 |
| Mathematics and Science Partnerships | Alabama Dept of Education | AMSTI | 84.366 | 221,086 |
| Mathematics and Science Partnerships | The University of Mississippi | 4276 | 84.366 | 39,884 |
| | | | | 941,469 |
| Improving Teacher Quality State Grants | Alabama Dept of Education | U300296 | 84.367 | 237,270 |
| Improving Teacher Quality State Grants | Alabama Comm on Higher Education | PL 107-110 | 84.367 | 168,183 |
| Improving Teacher Quality State Grants | Alabama Comm on Higher Education | UNKNOWN | 84.367 | 120,344 |
| Improving Teacher Quality State Grants | NATIONAL WRITING PROJECT | 04-AL08-SEED2012 | 84.367 | 62,728 |
| Improving Teacher Quality State Grants | Alabama Dept of Education | C2U0161 | 84.367 | 13,434 |
| Improving Teacher Quality State Grants | Alabama Dept of Education | C3U0534 | 84.367 | 4,456 |
| | | | | 606,415 |
| School Improvement Grants | Alabama Dept of Education | 312184-005215-1780650 | 84.377 | 162,410 |
| School Improvement Grants | Alabama Dept of Education | C2U0181 | 84.377 | 280 |
| | | | | 162,690 |
| National Writing Project Corp | Alabama Dept of Education | NATIONAL WRITING PROJECT | 84.928 | 13,825 |
| Total Pass-Through | | | | 1,895,404 |
| Total Department of Education | | | | 3,900,778 |
| Department of Health and Human Services | | | | |
| Direct | | | | |
| Training in General, Pediatric, and Public Health Dentistry | | | 93.059 | 149,031 |
| Public Health Emergency Preparedness | | | 93.069 | 399,838 |
| Maternal and Child Health Federal Consolidated Programs | | | 93.110 | 2,108,187 |
| Oral Diseases and Disorders Research | | | 93.121 | 750 |
| Nurse Anesthetist Traineeships | | | 93.124 | 9,736 |
| Human Genome Research | | | 93.172 | 55,230 |
| Nursing Workforce Diversity | | | 93.178 | 301,922 |
| | | | | |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|----------------------|-------------------------------------|----------------|-----------------------|
| | · · | | | |
| OTHER PROGRAMS, CONTINUED | | | | |
| Department of Health and Human Services, continued | | | | |
| Disabilities Prevention | | | 93.184 | 1,087,390 |
| Grants to States to Support Oral Health Workforce Activities | | | 93.236 | 465,820 |
| Substance Abuse and Mental HIth Serv_Proj. of Regional/National Sig. | | | 93.243 | 757,409 |
| Advanced Nursing Education Grant Program | | | 93.247 | 1,180,922 |
| Public Health Training Centers Program | | | 93.249 | 31,522 |
| The Affordable Care Act: CDC and Prevention_Investigations | | | 93.283 | 913,445 |
| Minority Health and Health Disparities Research | | | 93.307 | 15,855 |
| Trans-NIH Research Support | | | 93.310 | 52,038 |
| Research Infrastructure Programs | | | 93.351 | 484,454 |
| Advanced Education Nursing Traineeships | | | 93.358 | 424,838 |
| Nurse Education, Practice Quality and Retention Grants | | | 93.359 | 772,375 |
| National Center for Research Resources | | | 93.389 | 27,092 |
| Cancer Cause and Prevention Research | | | 93.393 | 2,360 |
| Cancer Treatment Research | | | 93.395 | 11,052 |
| Cancer Research Manpower | | | 93.398 | 891,273 |
| ACA Public Health Traning Centers Program, Resources Development | | | 93.516 | 571,273 |
| Health Care Innovation Awards (HCIA) | | | 93.610 | 2,330,612 |
| Strong Start for Mothers and New borns | | | 93.611 | 107,089 |
| Univ Centers for Excellence in Dev Disabilties Ed., Res, and Serv | | | 93.632 | 537,149 |
| Prevention Public Health Fund 2012: Viral Hepatitis Education | | | 93.740 | 78,688 |
| Health Careers Opportunity Program | | | 93.822 | 464,918 |
| Area Health Education Centers Infrastructure Development Awards | | | 93.824 | 266,139 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | | | 93.847 | 7,456 |
| Extramural Rsrch Prgrms in Neurosciences and Neurological Disorders | | | 93.853 | 29,737 |
| Biomedical Research and Research Training | | | 93.859 | 570,772 |
| Child Health and Human Development Extramural Research | | | 93.865 | 3,209 |
| Aging Research | | | 93.866 | 7.180 |
| Grants for Primary Care Training and Enhancement | | | 93.884 | 156,559 |
| Grants to Provide Outpatient Early Intervention Serv with Respect to HIV | | | 93.918 | 742,997 |
| RW HIV/A IDS Dental Reimb and Comm Based Dental Partnership Grant | | | 93.924 | 6,472 |
| HIV Demonstration, Research, Public and Professional Ed Projects | | | 93.941 | 626,810 |
| Prevention and Public Health Fund (PPHF) Public Health Traineeships | | | 93.964 | 30,000 |
| PPHF-2012 Geriatric Education Centers | | | 93.969 | 230,345 |
| Preventive Health Services_STD Control Grants | | | 93.977 | 154,116 |

| Federal Grantor | Federal Grantor Pass-Through Grantor Con | | CFDA Number | Total Expenditures | |
|--|--|---|----------------------------|---------------------------------------|--|
| OTHER PROGRAMS, CONTINUED Department of Health and Human Services, continued Contract #200-2011-40834 Total Direct | | | 93. | 35,160 17,099,220 | |
| Pass-Through Global AIDS Global AIDS Global AIDS | CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA UNIV OF ZAMBIA UNIV OF ZAMBIA | 1U2G GH000226-01 1U2GGH000109-02 1U2GGH000109-01 | 93.067 93.067 93.067 | 74,966 17,791 767 93,524 | |
| Public Health Emergency Preparedness Public Health Emergency Preparedness | Alabama Dept of Public Health Mississippi Dept of Health | 1U90TP000500-01 1U90TP000530-01 | 93.069 93.069 | 73,709 24,648 98,357 | |
| Project Grants and Coop Agreements for Tuberculosis Control Programs Project Grants and Coop Agreements for Tuberculosis Control Programs | Alabama Dept of Public Health Alabama Dept of Public Health | 5U52PS400489-30 U52/CCU400489 | 93.116 93.116 | 36,321 (1,728) 34,593 | |
| Emergency Medical Services for Children | Alabama Dept of Public Health | H33MC06713 | 93.127 | 8,760 | |
| AIDS Education and Training Centers AIDS Education and Training Centers AIDS Education and Training Centers | Emory University Emory University University of South Florida | 5 H4A HA00067-05 2H4AHA00067-09-00 H4AHA00049 | 93.145 93.145 93.145 | 154,169 25,528 4,276 183,973 | |
| Substance Abuse and Mental Hith Serv_Proj. of Regional/National Sig. Substance Abuse and Mental Hith Serv_Proj. of Regional/National Sig. | Aids Alabama Jefferson Blount St Clair Mental Health/MR Authori | 1H79Tl019749-01 NONE-STATE CODE 8061-0000-1100 AND 8040-0000 | 93.243 93.243 | 45,593 2,486 48,079 | |
| Hith System Strengthening and HIV/AIDS Prev, Care and Treatment | ADDIS ABABA UNIVERSITY | T84HA21124-03-00 | 93.266 | 164,253 | |
| Cancer Treatment Research Cancer Treatment Research | The Gynecologic Oncology Group The Gynecologic Oncology Group | CA27469 CA27469-33 | 93.395 93.395 | 10,200 8,986 19,186 | |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|---|--|-------------------------------------|----------------|-----------------------|
| OTHER PROGRAMS, CONTINUED | | | | |
| Department of Health and Human Services, continued | | | | |
| ACA Maternal, Infant, and Early Childhood Home Visiting Program | Alabama Dept of Children's Affairs | UNKNOWN | 93.505 | 6,480 |
| PPHF 2012 National Public Health Improvement Initiative | Alabama Dept of Public Health | 5U58CD001273 | 93.507 | 53,770 |
| Health Care Innovation Awards (HCIA) | Alabama Quality Assurance Foundation | 1E1CMS331087-01-00 | 93.610 | 91,419 |
| Health Care Innovation Awards (HCIA) | CITY COLLEGE OF SAN FRANCISCO | FIO-120927-B4-B | 93.610 | 36,508 |
| | | | | 127,927 |
| Developmental Disabilities Basic Support and Advocacy Grants | Alabama Dept of Mental Health & Mental Retardation | ALBS01 | 93.630 | 19,329 |
| Prevention Public Health Fund 2012: Viral Hepatitis Prevention | CDC Foundation | MOA # 391-13 SC | 93.736 | 63,521 |
| Children's Health Insurance Program | Alabama Dept of Public Health | 7500515 | 93.767 | 331,603 |
| Medical Assistance Program | Jefferson Blount St Clair Mental Health/MR Authori | B1 AL SAPT | 93.778 | 107,780 |
| Cardiovascular Diseases Research | TERUMO BCT INC | CTS-5001-REVISION B | 93.837 | 5,092 |
| Cardiovascular Diseases Research | Johns Hopkins University | 1R34HL108756-01 REVISED | 93.837 | 2,949 |
| | | | | 8,041 |
| Lung Diseases Research | Duke University | 012 | 93.838 | 42,593 |
| Allergy, Immunology and Transplantation Research | Emory University | 7P01AI078907-03 | 93.855 | 308,121 |
| National Bioterrorism Hospital Preparedness Program | Alabama Dept of Public Health | 1U90TP000500-01 | 93.889 | 100,000 |
| HIV Care Formula Grants | United Way of Central Alabama Inc | HRSA-10-055 | 93.917 | 1,326,827 |
| HIV Prevention Activities_Health Department Based | Alabama Dept of Public Health | U62/CCU423485 | 93.940 | 41,016 |
| HIV Prevention Activities_Health Department Based | Alabama Dept of Public Health | U62/PSU423485 | 93.940 | 16,666 |
| | | | | 57,682 |
| Coop. Agree. to Support State-Based Safe Motherhood and Infant Hith In. | Alabama Dept of Public Health | 1U01DP003150-01 | 93.946 | 4,700 |
| Tuberculosis Demonstration, Research, Public and Professional Ed. | CIDRZ FOUNDATION | 1U01GH000486-01 | 93.947 | 50,515 |
| Preventive Health Services_STD Control Grants | Alabama Dept of Public Health | 5H25P\$001277-03 | 93.977 | 90,732 |
| International Research and Research Training | Vanderbilt University | 5R24TW007988-05 | 93.989 | 45,438 |
| Preventive Health and Health Services Block Grant | Alabama Dept of Public Health | 3B01DP009002-11W1 | 93.991 | 934 |
| Maternal and Child Health Services Block Grant to the States | Alabama Dept of Public Health | B04MC21418 | 93.994 | 23,473 |
| Maternal and Child Health Services Block Grant to the States | Alabama Dept of Public Health | UNKNOWN | 93.994 | 6,278 |
| | | | | 29,751 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|---|-------------------------------------|----------------|-----------------------|
| OTHER PROGRAMS, CONTINUED | | | | |
| Department of Health and Human Services, continued | | | | |
| Contract | Alabama Dept of Children's Affairs | UNKNOWN | 93. | 96,349 |
| Contract | Altarum Institute | HHSN268200900114U/GS-10F-0261K | 93. | 52,667 |
| Contract | Bavarian Nordic A/S | HHS0100200700034C | 93. | 48,803 |
| Contract | ACTURIAL RESEARCH CORPORATION | GS-23F-0058T | 93. | 37,362 |
| Contract | TKC INTEGRATION SERVICES, LLC | 200-2010-34301 | 93. | 32,801 |
| Contract | ICF INCORPORATED LLC | HHSN316201200028W | 93. | 29,424 |
| Contract | Duke University | HHSN-275201000003I | 93. | 27,992 |
| Contract | University of Maryland | HHS-N-276-2011-00004-C | 93. | 1,267 |
| Contract | Duke University | HHSN272201100025C | 93. | 975 |
| Unknow n | Alabama Medicaid Agency | UNKNOWN | 93. | 308,156 |
| Unknow n | Jefferson County Commission | UNKNOWN | 93. | 238,741 |
| Unknow n | Intl Society of Travel Medicine | 1U50CK000189-01 | 93. | 187,250 |
| Unknow n | Alabama Dept of Public Health | PS08-86503CONT11 | 93. | 156,307 |
| Unknow n | NATIONAL REACH COALITION | NONE | 93. | 106,722 |
| Unknow n | NATIONAL REACH COALITION | NRC-REACH | 93. | 98,581 |
| Unknow n | Alabama Dept of Public Health | 1101ALPREP | 93. | 77,772 |
| Unknow n | NATIONAL USA FOUNDATION INC | 298050-NUSAF-01 | 93. | 75,069 |
| Unknow n | Alabama Dept of Public Health | GC-12-298 | 93. | 73,740 |
| Unknow n | Alabama Dept of Public Health | 1U59DD000947-01 | 93. | 61,045 |
| Unknow n | Alabama Dept of Rehabilitation Services | C30870051 | 93. | 32,602 |
| Unknow n | Alabama Dept of Public Health | H33MC06713 | 93. | 14,259 |
| Unknow n | OLMSTED MEDICAL CENTER | R01 HS019408-01 | 93. | 10,100 |
| Unknow n | Alabama Dept of Public Health | 5U59EH000493-04 | 93. | 6,716 |
| Unknow n | Alabama Dept of Public Health | HHS-2010-ACF-YF-PREP-0125 | 93. | 4,841 |
| Unknow n | Alabama Dept of Public Health | BO4MC21418 | 93. | 4,380 |
| Unknow n | AMERICAN PSYCHOLOGICAL ASSOCIATION | 5U50DP001708-02 | 93. | 3,969 |
| Unknow n | SPINA BIFIDA ASSOCIATION | UNKNOWN | 93. | 1,287 |
| Unknow n | Florida Certification Board | 1 UD Tl13590-10 | 93. | 179 |
| Total Pass-Through | | | | 5,215,825 |
| ARRA Direct | | | | |
| ARRA - D5BHP20434 | | | 93.403 | 234,109 |
| ARRA - 1U24OC000023 | | | 93.721 | 96,703 |
| Total ARRA Direct | | | | 330,812 |

| Federal Grantor | Pass-Through Grantor | Contract/Aw ard or Pass-Through Num | CFDA Number | Total Expenditures |
|--|----------------------|-------------------------------------|----------------|--------------------------------------|
| OTHER PROGRAMS, CONTINUED Department of Health and Human Services, continued Total Department of Health and Human Services | | | | 22,645,857 |
| TOTAL OTHER PROGRAMS | | | | 32,695,513 |
| SPECIAL FEDERAL APPROPRIATIONS Miscellaneous Direct John J. Sparkman Center Lister Hill Center for Health Policy Total Direct | | | 99. 99. | 512,600 467,939 980,539 |
| Total Miscellaneous | | | | 980,539 |
| TOTAL SPECIAL FEDERAL APPROPRIATIONS | | | | 980,539 |
| TOTAL FEDERAL | | | | 467,368,399 |

1. Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the "Schedule") summarizes the federal expenditures of The University of Alabama at Birmingham ("UAB"), a campus of The University of Alabama System, under programs of the federal government for the year ended September 30, 2013. The amounts reported as federal expenditures were obtained from UAB's general ledger. Because the Schedule presents only a selected portion of the operations of UAB, it is not intended to and does not present the financial position, changes in net assets and revenues and expenses of UAB. The federal expenditures of Southern Research Institute ("SRI"), a discretely presented component unit of UAB, have not been included within the Schedule as they have been included in a separate schedule of expenditures of federal awards that has been audited by other auditors.

For purposes of the Schedule, federal awards include all grants, contracts, and similar agreements entered into directly between UAB and agencies and departments of the federal government and all subawards to UAB by nonfederal organizations pursuant to federal grants, contracts, and similar agreements. The information in the Schedule is presented in accordance with the provisions of Office of Management and Budget ("OMB") Circular A-133, *Audits of States, Local Governments, and Nonprofit Organizations*.

UAB has obtained Catalog of Federal Domestic Assistance ("CFDA") numbers to ensure that all programs have been appropriately identified in the Schedule. CFDA numbers for applicable programs have been appropriately listed by those programs. Certain contracts and grants are not assigned CFDA numbers and, therefore, CFDA numbers are not listed by these programs.

Negative expenditures represent adjustments to prior year expenditures for UAB to reconcile and close the federal awards programs. This results in accurate reporting on a cumulative basis over multiple periods.

UAB is also the subrecipient of federal funds that are reported as expenditures and listed as federal pass-through funds. Pass-through numbers are included for pass-through awards when available. Federal awards other than those indicated as pass-throughs are considered direct.

Subrecipients

Certain funds are passed through to subgrantee organizations by UAB. Expenditures incurred by the subgrantees and reimbursed by UAB are presented in the Schedule. For the year ended September 30, 2013, UAB passed through approximately \$46 million to subgrantee organizations, which is presented in the table below:

| CFDA# | Agency | Total |
|---------|---|---------------|
| | | |
| Various | Research and Development | \$ 42,937,903 |
| 14.235 | Department of Housing and Urban Development | 323,111 |
| 84.366 | Department of Education | 49,764 |
| 93.069 | Department of Health and Human Services | 91,695 |
| 93.110 | Department of Health and Human Services | 48,208 |
| 93.184 | Department of Health and Human Services | 784,966 |
| 93.236 | Department of Health and Human Services | 330,000 |
| 93.243 | Department of Health and Human Services | 268,290 |
| 93.249 | Department of Health and Human Services | 31,652 |
| 93.283 | Department of Health and Human Services | 82,684 |
| 93.307 | Department of Health and Human Services | 17,023 |
| 93.359 | Department of Health and Human Services | 95,284 |
| 93.610 | Department of Health and Human Services | 305,963 |
| 93.822 | Department of Health and Human Services | 114,856 |
| 93.824 | Department of Health and Human Services | 115,508 |
| 93.917 | Department of Health and Human Services | 32,750 |
| 93.941 | Department of Health and Human Services | 253,069 |
| 93.977 | Department of Health and Human Services | 84,143 |
| 93. | Department of Health and Human Services | 276,474 |
| | | \$ 46,243,343 |

2. Summary of Significant Accounting Policies

For purposes of the Schedule, expenditures for federal award programs are recognized on the accrual basis of accounting and in accordance with accounting standards generally accepted in the United States of America. Expenditures for federal student financial aid programs include FDSL, Perkins, and Pell program grants to students, the federal share of students' FSEOG program grants, FWS program earnings and administrative cost allowances where applicable.

3. Facilities and Administrative Costs ("F&A Costs")

UAB operates under predetermined fixed F&A cost rates which are effective from October 1, 2011 through September 30, 2015. The predetermined fixed rates were based on 2010 financial information. The base rate for on-campus research is 46.5% for the year ended September 30, 2013. Base rates for other F&A cost recoveries range from 26% to 46.5% for the year ended September 30, 2013.

4. Federal Student Loan Programs

Direct Loan Programs

The Federal Perkins Loan ("Perkins"), Health Professions Student Loan ("HPSL"), Nurse Faculty Loan Program ("NFLP") and Loans to Disadvantaged Students ("LDS") programs are administered directly by UAB, and balances and transactions relating to these programs are included in UAB's basic financial statements.

The balances of loans outstanding at September 30, 2013 and funds advanced by UAB to eligible students during the year ended September 30, 2013 under the federal student loan programs are summarized as follows:

| | (C | Perkins FDA#84.038) | (CI | HPSL FDA#93.342) | (CF | NFLP DA#93.264) | (Cl | LDS FDA#93.342) | | Total |
|--|----|------------------------|-----|---------------------|-----|--------------------|-----|--------------------|----|------------|
| Funds advanced to students during fiscal 2013 | \$ | .,, | * | 122,115 | \$ | 271,274 | \$ | | Ť | .,000, |
| Total loan balance outstanding, September 30, 2013 | \$ | 13,704,809 | \$ | 2,236,137 | \$ | 718,672 | \$ | 506,245 | \$ | 17,165,863 |

The Perkins Loan Cancellations (CFDA# 84.037) for the year ended September 30, 2013 is \$345,780.

Administrative Cost Allowance

During the program year ended June 30, 2013 UAB charged approximately \$189,000 of administrative cost allowance to the Work-Study program.

Federal Direct Loans

The Federal Direct Student Loan Program (CFDA Number 84.268) ("FDSLP") was established under the Higher Education Act of 1965, as amended in the Student Loan Reform Act of 1993. The FDSLP enables an eligible student or parent to obtain a loan to pay for the student's cost of attendance directly through UAB rather than through private lenders. UAB began participation in the FDSLP on July 1, 1994. As a university qualified to originate loans, UAB is responsible for handling the complete loan origination process, including funds management and promissory note functions. UAB is not responsible for collection of these loans.

During the year ended September 30, 2013, UAB processed the following amount of student loans under FDSLP:

| | CFDA # | Total |
|----------------------|--------|---------------|
| Direct Student Loans | 84.268 | \$130,083,267 |



University of Alabama at Birmingham Schedule of Findings and Questioned Costs Year Ended September 30, 2013

Section I - Summary of Auditors' Results

No matters were noted.

| Financial Statements | | | | |
|------------------------------------|---|---------------------|--|--|
| Type of auditors' report issued: | Unmodified | | | |
| Internal control over financial re | eporting: | | | |
| Material weakness(es) ident | ified? | yes <u>X</u> no | | |
| | entified that are not considered to be material weaknesses? | yes X none reported | | |
| Noncompliance material to fi | yes X no | | | |
| Federal Awards | | | | |
| Internal control over major prog | grams: | | | |
| Material weakness(es) identi | yes <u>X</u> no | | | |
| Significant deficiency(ies) ide | yes _X no yes _X none reported | | | |
| Type of auditors' report issued | Unqualified | | | |
| | nat are required to be reported in accordance | V | | |
| with Circular A-133 (section | .510(a ₃)? | X yesno | | |
| Identification of major programs | s: | | | |
| CFDA Number(s) | Name of Federal Program or Cluster | | | |
| Various | Research and Development Cluster | | | |
| Various | Student Financial Aid Cluster | | | |
| 93.600 | Head Start | | | |
| Threshold used to determine | Type A and Type B Programs: | \$ 3,000,000 | | |
| Auditee qualified as low-risk au | uditee? | X yesno | | |
| Section II - Financial Staten | nent Findings | | | |

University of Alabama at Birmingham Schedule of Findings and Questioned Costs Year Ended September 30, 2013

Finding 2013-001: Return of Title IV Funds

Federal Agency: Department of Education
Program: Student Financial Aid Cluster

CFDA #: 84.268, 84.063

Award #: N/A

Award Year: 2012-2013

Criteria

34 CFR, Section 668.22

Condition

UAB performs manual calculations for returns of Title IV funds for students with Pell funds and rounds the resulting amounts to the nearest whole percent (two decimal places). As a result, for 3 out of a sample of 40 students, UAB inappropriately gave the 100% earned exemption to a student with a completion percentage equal to 60%. An example of the percentage earned guidance is referenced in Volume 5, Chapter 2, of the Federal Student Aid Handbook on page 5-56.

As a result of the exceptions noted above, management performed a retrospective review of all students subject to the withdrawal requirement during fiscal year 2013 and found that 19 total students, including the three students included in the sample, were inappropriately excluded from the return calculation. In our 2012 finding, we reported one student with a completion percentage that was rounded up to 60% and one student with a completion percentage that was less than 60% for which no return of Title IV calculation was performed. No exceptions were identified after May 23, 2013.

Questioned Costs

\$25,687

Cause

The University Student Accounting staff incorrectly interpreted the Title IV Return calculation rounding rules.

Effect

As a result of incorrectly rounding the Title IV Return calculation, the students were given credit for completion of the 60% of the semester and no Return of Title IV funds was made. Therefore, the students were inappropriately over awarded.

Recommendation

We recommend UAB review and modify its processes and controls surrounding the calculation and application of the 60% Rule, referenced above, to ensure that Title IV refunds are accurately and timely calculated. In addition, UAB should refund to the program the amounts for which the students were over awarded.



Financial Affairs

June 27, 2014

Management Views and Corrective Action Plan Year Ended September 30, 2013

The following was noted during the audit of Federal programs in accordance with OMB Circular A-133. Management agrees with this finding and proposes the following Corrective Action Plan:

Finding 2013-001: Return of Title IV Funds

Management's View


One of the University's Student Accounting staff did not have access to perform the Return of Title IV refund calculations in Banner and therefore used a manual calculation and rounded the completion percentage up to 60% in error.

Corrective Action Plan

The University implemented a procedural change effective May 16, 2013 whereby all staff performing the Return of Title IV refund calculations are given access and required to perform the calculation in Banner. In the rare instances when a manual calculation is necessary the University no longer rounds the completion percentage up to 60%. In addition, during June 2013, the University refunded to the programs the over awarded amounts for all nineteen students.

Sincerely,

Chief Financial Officer



University of Alabama at Birmingham Summary Schedule of Prior Audit Findings Year Ended September 30, 2012

Finding Number 2012-1: Administrative Compliance Requirements:

According to 34 CFR, Section 600.21, institutions are required to notify the Department of Education of any changes to third-party servicer contracts within 10 days of the date of the change or action. The University changed its Perkins Loan Program third-party servicer from Campus Partners Student Loan Company to ECSI Corporation, but failed to submit the notification to the Department of Education within the designated timeframe.

Status

The University developed a list of items that are required to be reported to the Department of Education and their deadlines. This list will help ensure that future changes are communicated timely. No changes were made to third-party service contracts in the current year; therefore no exceptions were noted.

Finding Number 2012-2: Return of Title IV Funds:

According to 34 CFR, Section 668.22, when a Title IV calculation is performed, the school must round the percentage to three decimal places. If the student has completed greater than 60% of the period, then 100% of the Title IV funds have been earned. If the student has completed 60% or less of the period, then a return of Title IV funds is due. The University performed manual calculations for returns of Title IV funds for students with Pell funds and rounded the resulting amounts to the nearest whole percent (two decimal points). As a result, for 1 out of a sample of 40 students, the University inappropriately gave the 100% earned exemption to a student with a completion percentage equal to 60%. Additionally, 1 out of a sample of 40 students selected for testing contained less than 60% completion during the period for which no return of Title IV calculation was performed.

Status

Effective May 16, 2013, the University implemented a procedural change whereby all Return of Title IV refunds are calculated in Banner, but if a manual calculation is necessary, it no longer rounds the refunds up to 60%. In addition, on May 23, 2013 the University's IT Department changed the scheduled run time of the report to prevent the exclusion of any student withdrawals in the future. Although similar instances were noted in the 2013 compliance testing (as described in Finding 2013-001), no exceptions were identified after May 23, 2013.


Finding Number 2012-3: Federal Funding Accountability and Transparency Act Reporting:

According to 2 CFR part 170, reporting of grants and contracts under the Federal Funding Accountability and Transparency Act "is required by the end of the month following the month in which the subaward obligation was made." During the prior year audit, the University failed to timely file 10 sub-award and sub-contract reports.

Status

Effective July 30, 2012, the University implemented system and procedural changes to help ensure timely FFATA reporting. No exceptions were identified during the current year audit.

Part IV 2013 Financial Report



UAB is an equal education opportunity institution, and an equal employment opportunity employer.

This report is published by the UAB
Vice President for Financial Affairs and Administration.
Obtain additional copies by writing:
Vice President for Financial Affairs and Administration
The University of Alabama at Birmingham
Birmingham, Alabama 35294

Contents

2 Introduction to UAB Overview/Vision/Mission Highlights

Student Profile

Student Financial Aid

Student Headcount

Faculty Profile

Staff Profile

State Appropriations

Sponsored Grants and Contracts

Hospital

10 Financial Statements

Management's Responsibility for
Financial Reporting
Report of Independent Auditors
Management's Discussion and Analysis
Statements of Net Position
Statements of Revenues, Expenses,
and Changes in Net Position
Statements of Cash Flows
Notes to Financial Statements

58 UAB Administration

59 The Board of Trustees of The University of Alabama

Introduction to UAB

Vision

UAB's vision is to be an internationally renowned research university — a first choice for education and health care.

Mission

UAB's mission is to be a research university and academic health center that discovers, teaches and applies knowledge for the intellectual, cultural, social and economic benefit of Birmingham, the state and beyond.

The University of Alabama at Birmingham (UAB) became an autonomous campus within The University of Alabama System in 1969 and, in the four decades since, has grown into a world-renowned research university and medical center, occupying 86 city blocks in Alabama's largest metropolitan area.

UAB is the state's largest single-site employer with more than 23,000 employees. The university has seen record overall enrollment for five consecutive years, with 18,568 students in fall 2013. As part of that record enrollment, UAB had its largest freshman class ever (1,773), two-thirds of whom live on campus (also a record). Average ACT rose to 25.0 while diversity continued to grow–freshmen are 37% minority and 60% female, and UAB continues to rank among the most diverse campuses nationally in *The Princeton Review*.

UAB attracted more than \$454 million in research funding in FY2012 and currently ranks 31st nationally in federal research funding and 21st in funding from the National Institutes of Health. Researchers and physicians continue serving in top national posts in recent years, including

presidency of the American Cancer Society, the American Heart Association, the National Society for Gynecologic Cancer, and the American Society of Transplantation. In the *Performance Ranking of Scientific Papers for World Universities*, UAB ranks 31st in clinical medicine and 74th in life sciences.

UAB Hospital is the largest hospital in Alabama (and 3rd largest public hospital in the U.S.), housing the state's only level 1 adult trauma center and a world Comprehensive Transplant Institute. UAB Health System treats more than a million patients annually.

The information included in this introduction (pages 2-9) does not include data related to component units of UAB that are discussed in the notes to the financial statements.

2013 Overview

As a globally respected academic medical center, UAB excels at translating research into leading-edge patient care. UAB Hospital is the only hospital in the state to be listed in every issue (24 straight years) of U.S. News & World Report's "America's Best Hospitals," which recognizes only three percent of hospitals nationwide, and ranks first locally for patient satisfaction in HHS surveys.

UAB's Comprehensive Cancer Center, among the first eight such centers to be designated by the National Cancer Institute (NCI) in the early 1970s, remains the only one in Alabama and a six-state region. The Center took a quantum leap recently with the renovation of the Wallace Tumor Institute, which will greatly accelerate research and care with an Advanced Imaging

Facility and the most powerful cyclotron at any U.S. academic medical center.

Students are active participants in a robust research enterprise beginning in their freshman year. UAB now offers new undergraduate programs in biomedical sciences and public health, the BS in Neuroscience is being expanded, and a new BS in Informatics is being developed.


Graduate programs also continue to garner national recognition. In the latest *U.S. News & World Report* "Best Graduate Schools" issue, UAB has 11 programs in the top 25 and five in the top 10, including its master's in health administration that ranks fifth in the nation.

The Scientist online magazine ranks UAB first nationally among public universities in its "Best Places to Work as a Postdoctoral Fellow."

Students continue to earn prestigious national honors and scholarships: In 2012-2013, UAB students won, among other awards, five United Negro College Fund/Merck Research Scholarships (of only 30 awarded nationally); four Goldwater Scholarships; three William Jefferson Clinton Scholarships; and a National Science Foundation Graduate Fellowship.

UAB has an economic impact on Alabama that exceeds \$5 billion annually and supports more than 61,000 jobs state-wide—that's one of every 33 jobs. For every dollar invested by the state, UAB returns \$20. The Innovation Depot, in which UAB is a founding partner, is the largest business incubator in the Southeast, with 92 startup companies and a \$1 billion economic impact over the past four years.

Highlights



*Excludes Advanced Professionals

Student Financial Aid

In fiscal year 2013, 72.6% of UAB's students received student financial aid from UAB. Financial aid disbursements of \$204.7 million were provided from the following sources:

| Federal Government | |
|---------------------|----------------|
| Student Loans | \$ 132,038,739 |
| Grants | 17,876,716 |
| Work-Study | 1,267,472 |
| Subtotal Federal | \$ 151,182,927 |
| State Government | \$ 180,634 |
| University | |
| Loans | \$ 313,520 |
| Scholarships | 53,067,155 |
| Subtotal University | \$ 53,380,675 |
| Total | \$ 204,744,236 |





Student Headcount

Enrollment for the fall semester of the 2012-2013 school year is outlined in the table at right.

| FALL 2012 | | | | |
|----------------------------------|---------------|----------|------------------------|---------|
| | | | FIRST PROFESSIONAL / | |
| | UNDERGRADUATE | GRADUATE | ADVANCED PROFESSIONAL* | TOTAL |
| SCHOOL OF ARTS AND SCIENCES | 6,603 | 628 | 10 | 7,241 |
| SCHOOL OF BUSINESS | 1,812 | 365 | | 2,177 |
| SCHOOL OF EDUCATION | 929 | 748 | | 1,677 |
| SCHOOL OF ENGINEERING | 918 | 407 | 1 | 1,326 |
| UNCLASSIFIED | | 283 | | 283 |
| SUBTOTAL | 10,262 | 2,431 | 11 | 12,704 |
| ACADEMIC HEALTH CENTER: | | | | |
| SCHOOL OF MEDICINE | | | 1,682 | 1,682 |
| SCHOOL OF DENTISTRY | 21 | 1 | 328 | 350 |
| SCHOOL OF OPTOMETRY | | 25 | 190 | 215 |
| SCHOOL OF NURSING | 534 | 1,630 | | 2,164 |
| SCHOOL OF HEALTH PROFESSIONS | 474 | 812 | 9 | 1,295 |
| SCHOOL OF PUBLIC HEALTH | | 383 | 18 | 401 |
| JOINT HEALTH SCIENCES | | 381 | 91 | 472 |
| SUBTOTAL, ACADEMIC HEALTH CENTER | 1,029 | 3,232 | 2,318 | 6,579 |
| | | | | |
| TOTAL ENROLLMENT | 11,291 | 5,663 | 2,329 | 19,283* |

 $^{^{\}star}\mbox{Includes}$ 1,045 first professionals and 1,284 advanced professionals.






State Appropriations

The State appropriations for UAB are made by the Alabama State Legislature based upon a process which involves requests from the Board of Trustees of The University of Alabama, and budget recommendations by the Alabama Commission on Higher Education and the Governor. State funds are appropriated annually from the Educational Trust Fund (ETF) to UAB. For the fiscal year ended September 30, 2013, UAB received direct funding from the ETF in the amount of \$258,429,840.





Sponsored Grants and Contracts


During fiscal year 2013, UAB received \$399.5 million in sponsored grants and contracts revenues (including \$76.3 million of indirect cost recovery). Various federal agencies provided the majority of support for these projects, with the National Institutes of Health (NIH) being the primary sponsor. Nonfederal funding sources include state agencies, local governmental agencies, and a wide variety of private sponsors.

Revenues from grants and contracts (including indirect cost recovery) increased from \$395.9 million

during 2012 to \$399.5 million during 2013, an increase of 0.9% for the period. Revenues from grants and contracts were higher in fiscal years 2011 and 2010 due to federal funding received under the American Recovery and Reinvestment Act (ARRA). UAB received approximately \$26.8 million and \$22.5 million in ARRA funds during the years ending September 30, 2011 and 2010, respectively. These funds dropped to approximately \$500,000 and then to zero for the years ending September 30, 2012 and 2013, respectively.

Grants and Contracts Revenues

Fiscal years ended September 30 (Dollars in millions)



Hospital

The University of Alabama Hospital (the "Hospital") is a 1,157-bed quaternary and tertiary care medical facility and part of the UAB Health System. The Hospital includes North Pavilion, Women and Infant Center, Jefferson Tower, Hillman Building, Spain Wallace Building, Quarterback Tower, North Wing, Spain Rehabilitation Center, West Pavilion, Russell Ambulatory Center, Medical Education Building, Highlands and the Center for Psychiatric Medicine. Other clinical facilities in the UAB Academic Health Center include Smolian Psychiatric Clinic, Engel Psychiatric Day Treatment Center, Lurleen B. Wallace Tumor Institute, and the 1917 Clinic. The Hospital also has strong ties with other governmental and private nonprofit institutions located within and adjacent to the UAB campus, including Veterans Affairs Medical Center and Children's Hospital. Other healthcare facilities in the UAB Health System include The Kirklin Clinic, the Callahan Eye Hospital, Medical West and Baptist Health (located in Montgomery, Alabama).

Hospital Awards and Accolades

Three UAB Medicine specialties are among the nation's top 50 in the 16 categories evaluated at 5,000 U.S. hospitals this year by U.S. News and World Report. The rankings appear in the 2013-14 annual "America's Best Hospitals" special edition issue. In the 2013 annual peer review survey, 323 UAB Medicine physicians in 65 specialties were listed as "Best Doctors" in America. UAB Hospital received the 2013 Women's Choice Award, ranking among America's best hospital's for patient experience. In fiscal year 2012, UAB Hospital has been granted recognition as a Magnet hospital for the third time from the American Nurses Credentialing Center, signifying the hospital's place in an elite group of fewer than 400 hospitals around the world acknowledged as centers for nursing excellence. UAB Hospital was the first hospital in Alabama to earn Magnet status. In July 2012, the Hospital underwent its triennial survey by the Joint Commission. The Hospital was granted full accreditation for another three years.

Operations

The Hospital has continued to experience strong growth from operations in fiscal year 2013. Inpatient discharges increased 2.2% with an increase in adjusted patient discharges of 4.6%. Emergency room visits increased 10.2% during fiscal year 2013. As a result of volume increases, as well as contract improvements and ongoing revenue cycle improvements, patient service revenue net of allowances for contractual discounts, charity care and bad debt expense, increased \$83 million or 7.9% in fiscal year 2013. The Hospital had an increase in net assets of \$88 million in fiscal year 2013.



Selected Hospital operating statistics are outlined below:

| | 2013 | 2012 |
|-----------------------------|---------|---------|
| Beds in service | 1,157 | 1,157 |
| Patient discharges | 49,149 | 48,090 |
| Adjusted patient discharges | 71,339 | 68,205 |
| Patient days | 339,940 | 317,534 |
| Adjusted patient days | 493,974 | 450,422 |
| Operating room cases | 30,586 | 32,605 |
| Emergency department visits | 91,962 | 83,467 |
| Patient origin: | | |
| Jefferson County | 48.3% | 46.5% |
| Other Alabama counties | 45.7% | 47.3% |
| Out of state | 6.0% | 6.2% |





Independent Auditor's Report

To the Board of Trustees of The University of Alabama:

We have audited the accompanying financial statements of The University of Alabama at Birmingham ("UAB"), a campus of The University of Alabama System, which is a component unit of the State of Alabama, as of and for the years ended September 30, 2013 and 2012, and the related notes to the financial statements, which consist of the statements of net position and the related statements of revenues, expenses, and changes in net position and cash flows of UAB and the statements of net position and of revenues, expenses and changes in net position of the Southern Research Institute ("SRI"), UAB's discretely presented component unit.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express opinions on the financial statements based on our audits. We did not audit the financial statements of SRI, UAB's discretely presented component unit, as of December 28, 2012 and December 30, 2011 and for the years then ended. Those statements were audited by other auditors whose report thereon has been furnished to us, and our opinion, insofar as it relates to the amounts included for SRI, is based on the report of the other auditors. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement. The financial statements of Triton Health Systems, L.L.C. and UAB Research Foundation were not audited in accordance with Government Auditing Standards.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to UAB's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of UAB's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions.

Opinions

In our opinion, based upon our audit and the report of the other auditors, the financial statements referred to above present fairly, in all material respects, the respective financial position of UAB and its discretely presented component unit at September 30, 2013 and 2012, and the respective changes in financial position and, where applicable, cash flows thereof for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Emphasis of Matter

As discussed in Note 1, the financial statements of UAB are intended to present the financial position, the changes in financial position and, where applicable, the cash flows of only that portion of the business-type activities of the financial reporting entity of The University of Alabama System that is attributable to the transactions of UAB. They do not purport to, and do not, present fairly the financial position of The University of Alabama System as of September 30, 2013 and 2012, its changes in financial position, or, where applicable, its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America. Our opinion is not modified with respect to this matter.

As discussed in Note 3, UAB has restated its 2012 financial statements for the retrospective application of new accounting standards adopted during 2013. These standards govern the reporting of deferred outflows and deferred inflows of resources, the accounting for debt issuance costs, and the presentation of component units. Our opinion is not modified with respect to this matter.

Other Matters

Required Supplementary Information


Accounting principles generally accepted in the United States of America require that the management's discussion and analysis for the years ended September 30, 2013 and 2012 and required supplementary information on pages 11 through 17 and page 57, respectively, be presented to supplement the basic financial statements. Such information, although not a part of the basic financial statements, is required by the Governmental Accounting Standards Board who considers it to be an essential part of financial reporting for placing the basic financial statements in the appropriate operational, economic, or historical context. We have applied certain limited procedures to the required supplementary information in accordance with auditing standards generally accepted in the United States of America, which consisted of inquiries of management about the methods of preparing the information and comparing the information for consistency with management's responses to our inquiries, the basic financial statements, and other knowledge we obtained during our audit of the basic financial statements. We do not express an opinion or provide any assurance on the information because the limited procedures do not provide us with sufficient evidence to express an opinion or provide any assurance.

Other Information

Our audits were conducted for the purpose of forming opinions on the financial statements that collectively comprise UAB's basic financial statements. The introductory information on pages 2 through 9 of this report is presented for purposes of additional analysis and is not a required part of the basic financial statements. Such information has not been subjected to the auditing procedures applied in the audit of the basic financial statements, and accordingly, we do not express an opinion or provide any assurance on it.

Other Reporting Required by Government Auditing Standards

In accordance with Government Auditing Standards, we have also issued our report dated January 27, 2014 on our consideration of the UAB's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, grant agreements, and other matters, for the year ended September 30, 2013. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with Government Auditing Standards and considering UAB's internal control over financial reporting and compliance.



Management's Discussion and Analysis (Unaudited)

The objective of management's discussion and analysis is to help readers of UAB's financial statements better understand the financial position and operating activities for the fiscal years ended September 30, 2013 and 2012. UAB's financial statements present the financial position, changes in financial position, and the cash flows of the University, the University of Alabama Hospital (the Hospital), and UAB's blended component units. Condensed financial information of UAB's reportable segments is presented at Note 23. GASB Statement No. 14, The Financial Reporting Entity (GASB Statement No. 14), as amended by GASB Statement No. 61, The Financial Reporting Entity: Omnibus-an amendment of GASB Statements No. 14 and No. 34 (GASB Statement No. 61), requires governmental entities to include in their financial statements as component units, organizations that are legally separate entities for which the governmental entity, as a primary organization, is financially accountable. Southern Research Institute (SRI) is a discretely presented component unit of UAB. Blended component units include Hospital Management L.L.C. (LLC), Triton Health Systems, L.L.C. (Triton), and UAB Research Foundation (UABRF). The following discussion and analysis provides an overview of UAB's financial activities. This discussion should be read in conjunction with the financial statements and notes to the financial statements.

Financial Overview

UAB's financial position remained strong, as assets totaled \$3.90, \$3.55 and \$3.36 billion at September 30, 2013, 2012, and 2011. Increases of \$358 million or 10% from 2012 to 2013 were primarily due to cash and investment increases related to the bonds issued during the year, as well as increases in investment assets, the continued growth in accounts receivable and an adjustment to capital assets to correct an understatement in library materials. Increases of \$201 million or 6.0% from 2011 to 2012 were primarily due to increases in investment assets.

Total liabilities increased \$216 million or 19% from September 30, 2012 to September 30, 2013. The increase results primarily from the issuance of bonds during fiscal year 2013, as well as an adjustment to accrued liabilities to correct an understatement in the compensated absences accrual.

Total liabilities decreased \$14 million or 1.0% from September 30, 2011 to September 30, 2012. The decrease results primarily from reductions in bonds payable related to annual principal payments offset by increases in accounts payable and accrued liabilities.

The change in net position reflects the operating, nonoperating and other activity of UAB, which results from revenues, expenses, and gains and losses, and is summarized for the years ended September 30, 2013, 2012, and 2011, as follows:

| | 2013 | 2012 (RESTATED) | 2011 (RESTATED) |
|-------------------------------------|-----------------|-----------------|-----------------|
| TOTAL OPERATING REVENUES | \$2,405,991,627 | \$2,313,144,589 | \$2,156,035,206 |
| TOTAL OPERATING EXPENSES | \$2,674,554,826 | \$2,540,375,605 | \$2,393,802,633 |
| NET OPERATING LOSS | \$(268,563,199) | \$(227,231,016) | \$(237,767,427) |
| TOTAL NONOPERATING INCOME, CAPITAL, | | | |
| ENDOWMENT AND OTHER ACTIVITIES | 410,964,015 | 441,328,646 | 325,954,577 |
| INCREASE (DECREASE) IN NET POSITION | \$142,400,816 | \$214,097,630 | \$88,187,150 |

A majority of UAB's endowment funds are invested in common investment pools established by The Board of Trustees of The University of Alabama (the Board). The funds are invested to maximize total return over the long term, with an appropriate level of risk. Any short term reduction in the fair value of the endowment portfolio will not have a meaningful immediate impact on the portion of investment income available to support current year operating expenses since such distributions are made pursuant to The University of Alabama System's (the System) spending rate policy.

Statements of Net Position

The statement of net position presents the financial position of UAB at the end of the fiscal year, and includes all assets, deferred outflows, liabilities, and deferred inflows recorded on the accrual basis of accounting. The changes in net position are indicators of whether the overall financial condition of UAB has improved or worsened during the year. A summarized comparison of UAB's assets, deferred outflows, liabilities, deferred inflows, and net position at September 30, 2013, 2012, and 2011, is as follows:

| | 2013 | 2012 (RESTATED) | 2011 (RESTATED) |
|--|-------------------|-----------------|-----------------|
| ASSETS AND DEFERRED OUTFLOW OF RE | SOURCES | | |
| Capital Assets, Net | \$1,524,883,924 | \$1,433,681,378 | \$1,421,985,903 |
| Other Assets | 2,379,708,092 | 2,112,597,210 | 1,923,491,748 |
| TOTAL ASSETS | \$3,904,592,016 | \$3,546,278,588 | \$3,345,477,651 |
| Deferred outflow from debt refundings | 12,958,289 | 13,019,885 | 13,722,165 |
| TOTAL ASSETS AND DEFERRED OUTFLOW OF RESOURCES | \$3,917,550,305 | \$3,559,298,473 | \$3,359,199,816 |
| LIABILITIES, DEFERRED INFLOW OF RESO | URCES AND NET POS | ITION | |
| Current Liabilities | \$390,353,766 | \$342,013,574 | \$329,818,205 |
| Noncurrent Liabilities | 961,097,310 | 793,650,118 | 819,804,736 |
| TOTAL LIABILITIES | \$1,351,451,076 | \$1,135,663,692 | \$1,149,622,941 |
| Deferred inflow from debt refundings | 273,518 | 209,886 | 249,610 |
| Net Position | \$2,565,825,711 | \$2,423,424,895 | \$2,209,327,265 |
| TOTAL LIABILITIES, DEFERRED INFLOW OF RESOURCES AND NET POSITION | \$3,917,550,305 | \$3,559,298,473 | \$3,359,199,816 |

At September 30, 2013, the major categories of current assets consist primarily of cash and cash equivalents, short-term investments, and accounts receivable, which totaled \$1.01 billion of the \$1.06 billion and increased \$140.9 million or 16.3% from 2012. The increase is a result of increases in cash related to bond proceeds and growth in short term investments.

At September 30, 2012, the major categories of current assets consist primarily of cash and cash equivalents, short-term investments, and accounts receivable, which totaled \$865.6 million of the \$910.9 million and increased \$120.7 million or 16.2% from 2011. The increase is a result primarily of growth in short term investments.

At September 30, 2013, total current liabilities of \$390.4 million consist primarily of accounts payable, accrued payroll and related benefits, and unearned revenue, which totaled \$357.4 million, compared to \$308.8 million at September 30, 2012, an increase of \$48.6 million or 15.7% from 2012.

At September 30, 2012, total current liabilities of \$342.0 million consist primarily of accounts payable, accrued payroll and related benefits, and unearned revenue, which totaled \$308.8 million, compared to \$300.3 million at September 30, 2011, an increase of \$8.5 million or 2.8% from 2011.

UAB's endowment and life income investments increased \$25.7 million to \$393.4 million from September 30, 2012 to September 30, 2013. This increase resulted from net investment gains and by the establishment of new endowment funds through gifts and the creation of Board-designated quasi-endowments. UAB's endowment funds consist of both permanent and quasi-endowments.

UAB's endowment and life income investments increased \$39.6 million to \$367.7 million from September 30, 2011 to September 30, 2012. This increase resulted from net investment gains and by the establishment of new endowment funds through gifts and the creation of Board-designated quasi-endowments. UAB's endowment funds consist of both permanent and quasi-endowments.

Permanent endowment funds are those funds received from donors with the requirement that the principal remain unspent and invested in perpetuity to produce income to be expended for the purposes specified by the donor. Quasi-endowments consist of restricted or unrestricted funds that have been set aside by actions of the Board to produce income for an established purpose until the time the Board reverses its action. Endowment income supports scholarships, fellowships, professorships, research efforts, and other programs and activities of UAB.

At September 30, 2013, 2012, and 2011 respectively, UAB's investment in the Professional Liability Trust Fund (PLTF) totaled approximately \$50.4,

\$38.9 and \$29.1 million. The \$11.5 million increase from September 30, 2012 to September 30, 2013 is a result of growth in investment values at September 30, 2013. The \$9.8 million increase from September 30, 2011 to September 30, 2012 is a result of growth in investment values at September 30, 2012.

UAB implemented GASB Statement No. 65, *Items Previously Reported as Assets and Liabilities* (GASB Statement No. 65), during fiscal year 2013. As a result, \$12.9 million in bond deferred refunding amounts were reclassified to Deferred Outflows of Resources and \$0.3 million in bond deferred refunding amounts were reclassified to Deferred Inflows of Resources. Prior to this implementation, the amounts were reported in long-term debt.

Capital and Debt Activities

An aspect of UAB's continued growth is an emphasis on the expansion and maintenance of capital assets. UAB continues to implement its long-range capital plan.

Capital assets primarily include land, buildings, fixed equipment systems, and inventoried equipment. The original costs of capital assets increased approximately \$170.8 million and \$114.4 million from September 30, 2012 to September 30, 2013 and from September 30, 2011 to September 30, 2012, respectively. This increase consists primarily of capital expenditures and capital additions totaling \$194.8 million (offset primarily by \$24.0 million in disposals) and \$138.9 million (offset primarily by \$24.6 million in disposals) in 2013 and 2012. Capital additions are comprised primarily of renovation and new construction of research and health care facilities, as well as additions to improve information technology systems. Annual additions were funded with capital funds, grants, gifts of \$14.1 million and \$14.7 million, debt proceeds of \$47.5 million and \$28.2 million, and the remainder by UAB funds designated for capital purchases in 2013 and 2012, respectively.

Capital projects in process at September 30, 2013 include construction of the Abroms-Engel Institute for Visual Arts, renovation of the School of Dentistry and renovation of UAB Highlands Hospital. Capital projects in process at September 30, 2012 include renovation of Wallace Tumor Institute, renovation of the Health Professions Building and construction of the Steam Plant.

UAB's long-term debt related to capital assets, consisting of bonds and capital leases, totaled \$956.1, \$789.6, and \$812.9 million at September 30, 2013, 2012, and 2011, respectively. The increase in debt during 2013 consisted primarily of the bonds issued during the year, partially offset by the refunding of debt outstanding. The decrease in debt during 2012 consisted primarily of the principal payments made in accordance with the debt instruments.

Net Position

Net position represents the residual interest in UAB's assets and deferred outflows after liabilities and deferred inflows are deducted. UAB's net position at September 30, 2013, 2012, and 2011, is summarized as follows:

| | 2013 | 2012 (RESTATED) | 2011 (RESTATED) |
|----------------------------|-----------------|-----------------|-----------------|
| INVESTED IN CAPITAL ASSETS | \$696,323,637 | \$686,141,974 | \$698,603,635 |
| RESTRICTED | | | |
| Nonexpendable | 273,651,082 | 252,844,971 | 228,120,369 |
| Expendable | 212,482,294 | 211,866,065 | 198,958,938 |
| UNRESTRICTED | 1,383,368,698 | 1,272,571,885 | 1,083,644,323 |
| TOTAL NET POSITION | \$2,565,825,711 | \$2,423,424,895 | \$2,209,327,265 |

Net position invested in capital assets represents UAB's capital assets, net of accumulated depreciation and outstanding principal of debt in excess of related bond proceeds attributable to the acquisition, construction, or improvement of those assets. The \$10.2 million increase in 2013 reflects the continued capital asset development in accordance with UAB's long-range capital plan and an adjustment made during the year to capital assets to correct an understatement in library materials, offset by the increase in debt related to the bonds issued during the year. The \$12.5 million decrease in 2012 reflects the continued capital asset development in accordance with UAB's long-range capital plan and decrease in debt due to principal payments made offset of use of bond proceeds attributable to the acquisition, construction of capital assets.

Restricted nonexpendable net position includes UAB's permanent endowment funds and annuity and life income assets that will ultimately become pure endowment funds. The \$20.9 million increase in 2013 results primarily from the increase in fair values of investments and contributions. The \$24.7 million increase in 2012 results primarily from the increase in fair values of investments and contributions.

Restricted expendable net position is subject to externally imposed restrictions governing its use. Restricted expendable net position includes UAB's assets whose use is restricted by an external restriction. The \$0.6 million increase in 2013 results primarily from gifts. The \$12.9 million increase in 2012 results primarily from gifts.

Unrestricted net position includes UAB's assets whose use is not restricted by an external entity. Unrestricted net position increased \$110.8 million and \$188.9 million or 8.7% and 17.4% in 2013 and 2012, respectively.


Although unrestricted net position is not subject to externally imposed restrictions, UAB has designated available unrestricted net position to be used for academic and research programs as well as capital projects.

Statements of Revenues, Expenses, and Changes in Net Position

The statement of revenues, expenses, and changes in net position presents UAB's results of operations, as well as the nonoperating revenues and expenses. Annual state appropriations are classified as nonoperating revenues according to governmental accounting standards, even though the state-appropriated funds are used to support the operations of UAB. Without the nonoperating revenues, in particular the state appropriations and private gifts, UAB would not be able to cover its costs of operations. A summarized comparison of UAB's revenues, expenses and changes in net position for the years ended September 30, 2013, 2012, and 2011 is presented on the following page:

| | 2013 | 2012 (Restated) | 2011 (Restated) |
|---|-----------------|-----------------|-----------------|
| OPERATING REVENUES | | | |
| Student tuition and fees, net | \$146,183,606 | \$130,569,653 | \$115,886,758 |
| Grants and contracts | 373,172,028 | 367,310,018 | 425,566,237 |
| Sales and services | 1,846,805,110 | 1,771,143,308 | 1,577,381,414 |
| Other revenues | 39,830,883 | 44,121,610 | 37,200,797 |
| REVENUES SUPPORTING CORE ACTIVITIES | \$2,405,991,627 | \$2,313,144,589 | \$2,156,035,206 |
| OPERATING EXPENSES | | | |
| Operating expenses | \$2,674,554,826 | \$2,540,375,605 | \$2,393,802,633 |
| OPERATING LOSS | \$(268,563,199) | \$(227,231,016) | \$(237,767,427) |
| NONOPERATING REVENUES (EXPENSES) | | | |
| State educational appropriations | \$258,429,840 | \$268,640,355 | \$254,288,538 |
| Grants and contracts | 26,282,921 | 25,399,912 | 28,927,560 |
| State fiscal stabilization funds | - | 534,136 | 26,819,385 |
| Gifts | 32,067,976 | 32,681,364 | 28,898,475 |
| Investment income (loss) | 87,382,279 | 128,336,597 | (10,822,776) |
| Interest expense | (30,895,769) | (27,978,510) | (29,759,587) |
| Loss on asset disposition, net | (5,265,734) | (662,685) | (422,747) |
| Capital state appropriations | 8,680,247 | 11,076,675 | 9,863,264 |
| Capital gifts and grants | 4,507,902 | 3,602,784 | 7,301,347 |
| Endowment gifts | 9,568,250 | 11,009,612 | 9,561,889 |
| Net other nonoperating (expense) revenue | 20,206,103 | (11,311,594) | 1,299,229 |
| NET NONOPERATING REVENUES AND OTHER CHANGES | \$410,964,015 | \$441,328,646 | \$325,954,577 |
| INCREASE IN NET POSITION | \$142,400,816 | \$214,097,630 | \$88,187,150 |
| Net position, beginning of year | \$2,423,424,895 | \$2,209,327,265 | \$2,121,140,115 |
| NET POSITION, END OF YEAR | \$2,565,825,711 | \$2,423,424,895 | \$2,209,327,265 |
| | | | |

Figures A and A1 are graphic illustrations of revenues by source (both operating and nonoperating), which are used to fund UAB's operating activities for the years ended September 30, 2013 and 2012, respectively.



Gross tuition and fees revenue increased by \$16.0 million and \$14.2 million in 2013 and 2012, respectively. Tuition rates increased 5% in 2013 and 8% in 2012. Total student headcount of 19,283 and 18,777 increased by 506 and 74 or 2.7% and 0.4% in 2013 and 2012, respectively.

UAB recognized \$46.1, \$44.1 and \$39.1 million in gift revenue (composed partially of \$4.4, \$0.5, and \$0.5 million and \$9.6, \$11.0, and \$9.6 million in capital and endowment gifts, respectively) for the years ended September 30, 2013, 2012, and 2011, respectively.

UAB receives state educational appropriations and capital funding from the State of Alabama. UAB recognized educational appropriations and capital funding from the State of Alabama totaling \$267.1, \$279.7, and \$264.2 million, of which \$258.4, \$268.6, and \$254.3 million was from the Educational Trust Fund (ETF), which is included as nonoperating revenue in 2013, 2012, and 2011, respectively. The remaining \$8.7, \$11.1, and \$9.9 million represents Public School and College Authority funds and other state

capital funds in 2013, 2012 and 2011, respectively. UAB received no State Fiscal Stabilization Funds in 2013; however, UAB received \$0.5 and \$26.8 million in State Fiscal Stabilization Funds in 2012 and 2011, respectively.

Net hospital sales and service revenue totaled \$1.28 billion, \$1.19 billion, and \$1.11 billion, an increase of 7.0% and 7.7% from 2012 to 2013 and 2011 to 2012, respectively. This increase results from increased volume, contract improvements, and ongoing revenue-cycle improvement activities.

UAB receives grant and contract revenue from federal, state, local, and private agencies. These funds are used to further the mission of UAB: research, education, and public service. In addition to the funds received in exchange for services performed, UAB received \$0.06, \$3.2, and \$6.8 million in 2013, 2012, and 2011, respectively, in funds to be used to acquire capital assets. Figures B and B1 are illustrations of the breakout of the funding sources for grant and contract revenue for the years ended September 30, 2013 and 2012, respectively.





Figure B: Grants and Contract Revenues





Net investment income decreased \$41.0 million from 2012 to 2013. The decrease is primarily a result of a decline in growth in the fair value of investments. Net investment income increased \$139.2 million from 2011 to 2012. The increase is primarily a result of growth in the fair value of investments. Net investment income for the years ended September 30, 2013, 2012, and 2011, consist of the following components:

| Interest and Dividends \$47,697,584 \$46,221,115 \$51,753,275 |
|---|
| ###################################### |
| Net Increase (Decrease) In the Fair Value Of Investments 29,279,289 74,828,997 (53,902,311) |
| Return on Equity Investments 10,405,406 7,286,485 (8,673,740) |
| \$87,382,279 \$128,336,597 \$(10,822,776) |


A comparative summary of UAB's operating expenses for the years ended September 30, 2013, 2012, and 2011, is as follows:

| | 2013 | 2012 (RESTATED) | 2011 (RESTATED) |
|-------------------------------|-----------------|-----------------|-----------------|
| Salaries, Wages, and Benefits | \$1,327,917,671 | \$1,244,287,467 | \$1,182,131,940 |
| Supplies and Services | 1,227,334,700 | 1,153,881,410 | 1,070,843,029 |
| Depreciation | 98,303,065 | 123,047,954 | 121,815,300 |
| Scholarships and Fellowships | 20,999,390 | 19,158,774 | 19,012,364 |
| | \$2,674,554,826 | \$2,540,375,605 | \$2,393,802,633 |
| | | | |

Salaries, wages, and benefits increased \$83.6 million or 6.7% during 2013 and increased \$62.2 million or 5.3% during 2012. This increase in 2013 is due primarily to the growth of UAB's salary base, benefit costs, and an adjustment to salaries expense to correct an understatement in the compensated absences accrual. This increase in 2012 is due primarily to UAB's growth in salary base and benefit costs. Supplies and services expenses increased \$73.5 million

and \$83.0 million or 6.4% and 7.7% during 2013 and 2012, respectively. This increase is primarily attributable to UAB's continued growth.

In addition to their natural classification, it is also informative to review operating expenses by function. Graphic illustrations of UAB's operating expenses by function for the years ended September 30, 2013 and 2012, respectively, are presented as follows:



Statements of Cash Flows

The statement of cash flows presents the significant sources and uses of cash. UAB's cash, primarily

held in demand deposit accounts, is minimized by sweeping available cash balances into investment accounts on a daily basis.

| 2013 | 2012 (RESTATED) | 2011 (RESTATED) |
|-----------------|---|---|
| \$(179,888,501) | \$(105,779,543) | \$(128,600,656) |
| (15,544,611) | (171,438,508) | (35,096,926) |
| 326,613,818 | 348,365,524 | 346,771,022 |
| (60,852,837) | (127,966,171) | (161,354,526) |
| \$70,327,869 | \$(56,818,698) | \$21,718,914 |
| \$268,824,418 | \$325,643,116 | \$303,924,202 |
| \$339,152,287 | \$268,824,418 | \$325,643,116 |
| | | |
| | \$(179,888,501) (15,544,611) 326,613,818 (60,852,837) \$70,327,869 \$268,824,418 | \$(179,888,501) \$(105,779,543) (15,544,611) (171,438,508) 326,613,818 348,365,524 (60,852,837) (127,966,171) \$70,327,869 \$(56,818,698) \$268,824,418 \$325,643,116 |

UAB used \$179.8, \$105.8, and \$128.6 million of cash for operating activities, offset by \$326.6, \$348.4, and \$346.8 million of cash provided by noncapital financing activities in 2013, 2012 and 2011, respectively. Noncapital financing activities, as defined by the GASB, include state educational appropriations and gifts received for other than capital purposes that are used to support operating expenses.

Cash of \$15.5, \$171.4, and \$35.1 million in 2013, 2012 and 2011, respectively, was used for capital and related financing activities, primarily purchases of capital assets and principal and interest payments on long-term debt, partially offset by sources that included bond proceeds, gifts, and grants and contracts for capital purposes. Cash used in investing activities totaled \$60.9, \$128.0 and \$161.4 million in 2013, 2012 and 2011, respectively.

Economic Factors That Will Affect The Future

As a labor-intensive organization, UAB faces competitive pressures related to attracting and retaining faculty and staff.

The State of Alabama appropriates money each year to UAB for operating costs and nonoperating cash requirements, including capital expenditures. Because the State is mandated by its Constitution to operate with a balanced budget, the State occasionally has reduced its appropriations, through a process known as "proration," when its annual revenues are not expected to meet budgeted appropriations. During the year ending September 30, 2011, the State implemented proration. As the State could implement proration in future years, UAB continues implementing cost-saving measures in order to balance its own budget.

UAB will strive to remain highly competitive in terms of attracting federal grant and contract revenue, primarily from the NIH, as seven individual departments rank among the top ten in their specialties.

Private gifts are an important part of the fundamental support of UAB. Economic pressures affecting donors may also affect the future level of support UAB receives from corporate and individual giving. In October 2013, UAB launched its largest fundraising campaign to date known as "Give something change everything." The fundraising goal is \$1 billion and will run through 2018.

The Hospital faces significant challenges in a dynamic healthcare sector and volatile economic environment. The demand for health care services and the cost of providing them are increasing significantly while the revenues to support these services are diminishing. In addition to cost increases such as rising salary and benefit costs, the Hospital also faces additional costs associated with new technologies, the education and training of health care professionals and provision of care for a disproportionate share of the medically undeserved in Alabama. In recent years, federal legislation has been enacted to slow future rate increases in Medicare and Medicaid and reduce medical education and disproportionate share funding. Management is committed to staying abreast of pertinent issues; implementing appropriate management actions and continuing to provide quality care for all patients.

These financial statements are designed to provide a general overview of the University of Alabama at Birmingham and to demonstrate UAB's accountability. Questions concerning any information provided in this report or requests for additional information should be addressed to the Office of the Vice President for Financial Affairs and Administration, The University of Alabama at Birmingham, AB 1030, 1720 2ND AVE S, BIRMINGHAM AL 35294-0106.

The University of Alabama at Birmingham Statements of Net Position

September 30, 2013 and 2012

| | ocptember of | September 30, 201 | |
|---|--------------|-------------------|---|
| | 2013 | | 2012 (Restated, See Note 3) |
| ASSETS | | | |
| Current Assets: | | | |
| Cash and cash equivalents | \$ 291,18 | 9,097 | \$ 240,433,436 |
| Short term investments | 454,56 | 8,115 | 411,063,144 |
| Accounts receivable, net | 260,75 | 1,683 | 214,137,269 |
| Loans receivable, current portion | 2,31 | 2,259 | 2,403,659 |
| Pledges receivable, current portion | 8,31 | 5,206 | 7,429,210 |
| Inventories | 18,54 | 3,246 | 17,667,360 |
| Other current assets | | 2,285 | 17,727,888 |
| Total current assets | \$ 1,055,82 | | \$ 910,861,966 |
| | | | |
| Noncurrent Assets: | Φ 47.54 | 0.000 | Φ 00.040.005 |
| Cash and cash equivalents designated for capital activities | | | \$ 28,213,325 |
| Restricted cash and cash equivalents | | 0,530 | 177,657 |
| Investments for capital activities | 786,09 | | 722,605,340 |
| Endowment and life income investments | 393,35 | 2,510 | 367,682,509 |
| Investment in Professional Liability Trust Fund | 50,44 | 9,513 | 38,912,815 |
| Other long-term investments | 18,08 | 7,185 | 14,823,313 |
| Loans receivable, net | 15,58 | 6,710 | 16,293,742 |
| Pledges receivable | 11,33 | 7,496 | 12,121,941 |
| Capital assets, net | 1,524,88 | 3,924 | 1,433,681,378 |
| Other noncurrent assets | 1,01 | 2,442 | 904,602 |
| Total noncurrent assets | \$ 2,848,77 | 0,125 | \$ 2,635,416,622 |
| Total Assets | \$ 3,904,59 | 2,016 | \$ 3,546,278,588 |
| DEFERRED OUTFLOW OF RESOURCES | | | |
| Deferred outflow from debt refundings | \$ 12,95 | 8,289 | \$ 13,019,885 |
| Total Deferred Outflow of Resources | \$ 12,95 | 8,289 | \$ 13,019,885 |
| | | | |
| LIABILITIES | | | |
| Current Liabilities: | | | |
| Accounts payable and accrued liabilities | \$ 264,47 | 0,782 | \$ 207,035,410 |
| Deposits | 6,80 | 3,215 | 8,002,251 |
| Unearned revenue-grants | 21,29 | 0,000 | 21,634,481 |
| Unearned revenue-other | 71,63 | 1,320 | 80,106,826 |
| Long-term debt, current portion | 26,15 | 8,449 | 25,234,606 |
| Total current liabilities | \$ 390,35 | 3,766 | \$ 342,013,574 |
| Noncurrent Liabilities | | | |
| Federal advances-loan funds | \$ 14,72 | 7,477 | \$ 14,925,390 |
| Long-term debt, noncurrent portion | 929,94 | | 764,373,896 |
| Other noncurrent liabilities | | 2,883 | 14,350,832 |
| Total noncurrent liabilities | \$ 961,09 | | \$ 793,650,118 |
| Total Liabilities | \$ 1,351,45 | | \$ 1,135,663,692 |
| | ,,,,,, | , | , |
| DEFERRED INFLOW OF RESOURCES | | | |
| Deferred inflow from debt refundings | \$ 27 | 3,518 | \$ 209,886 |
| Total Deferred Inflow of Resources | \$ 27 | 3,518 | \$ 209,886 |
| NET POSITION | | | |
| NET POSITION | Ф 000.00 | 0.607 | ¢ 000 141 074 |
| Invested in capital assets, net of related debt | \$ 696,32 | 3,037 | \$ 686,141,974 |
| Restricted | | 4.005 | |
| Nonexpendable | 273,65 | | 252,844,971 |
| Expendable | 212,48 | | 211,866,065 |
| Unrestricted | 1,383,36 | | 1,272,571,885 |
| Total Net Position | \$ 2,565,82 | 5,711 | \$ 2,423,424,895 |

The University of Alabama at Birmingham Statements of Revenues, Expenses, and Changes in Net Position

Years Ended September 30, 2013 and 2012

| | | 2013 | 201 | 2 (Restated, See Note 3) |
|--|----|---------------|-----|--------------------------|
| Operating Revenues | | | | |
| Tuition and fees | \$ | 193,958,793 | \$ | 175,184,111 |
| Less: scholarship allowance | | (47,144,688) | | (44,449,656) |
| Less: bad debt expense | | (630,499) | | (164,802) |
| Tuition and fees, net | | 146,183,606 | | 130,569,653 |
| Grants and contracts: | | | | |
| Federal | | 319,191,238 | | 317,699,815 |
| State | | 7,140,898 | | 6,155,771 |
| Local | | 1,933,975 | | 314,715 |
| Private | | 44,905,917 | | 43,139,717 |
| Sales and services: | | | | |
| Educational activities | | 58,133,856 | | 55,906,284 |
| Hospital, net of bad debt expense of \$251,725,723 and \$236,995,097 | | 1,278,461,433 | | 1,194,615,262 |
| Other auxiliary enterprises, net of scholarship allowance of \$2,923,579 and \$2,979,415 | | 510,209,821 | | 520,621,762 |
| Other operating revenues | | 39,830,883 | | 44,121,610 |
| Total operating revenues | \$ | 2,405,991,627 | \$ | 2,313,144,589 |
| Onesetting Function | | | | |
| Operating Expenses | Φ. | 4 007 017 07: | Φ. | 4 044 007 467 |
| Salaries, wages and benefits | \$ | 1,327,917,671 | \$ | 1,244,287,467 |
| Supplies and services | | 1,227,334,700 | | 1,153,881,410 |
| Depreciation | | 98,303,065 | | 123,047,954 |
| Scholarships and fellowships | | 20,999,390 | | 19,158,774 |
| Total operating expenses | \$ | 2,674,554,826 | \$ | 2,540,375,605 |
| Operating loss | \$ | (268,563,199) | \$ | (227,231,016) |
| Nonoperating Revenues (Expenses) | | | | |
| Gains and losses | | | | |
| State educational appropriations | \$ | 258,429,840 | \$ | 268,640,355 |
| Federal grants and contracts | | 26,135,938 | | 25,128,105 |
| State grants and contracts | | 116,209 | | 106,859 |
| Private grants and contracts | | 30,774 | | 164,948 |
| State fiscal stabilization funds | | , | | 534,136 |
| Gifts | | 32,067,976 | | 32,681,364 |
| Investment income | | 87,382,279 | | 128,336,597 |
| Interest expense | | (30,895,769) | | (27,978,510) |
| Loss on asset dispositions, net | | (5,265,734) | | (662,685) |
| Net other nonoperating (expense) revenue | | 20,206,103 | | (11,311,594) |
| Net nonoperating revenues | \$ | 388,207,616 | \$ | 415,639,575 |
| Income before other revenues, expanses, gains, and lesses | \$ | 110 644 417 | \$ | 100 400 550 |
| Income before other revenues, expenses, gains, and losses | Ф | 119,644,417 | Þ | 188,408,559 |
| Other Changes in Net Position | | | | |
| Capital and endowment activities | | | | |
| State capital funds | \$ | 8,680,247 | \$ | 11,076,675 |
| Capital grants and contracts | | 60,541 | | 3,150,413 |
| Capital gifts | | 4,447,361 | | 452,371 |
| Endowment gifts | | 9,568,250 | | 11,009,612 |
| Net other changes in net position | \$ | 22,756,399 | \$ | 25,689,071 |
| Increase in net position | \$ | 1/2 /00 016 | \$ | 214 007 620 |
| Net Position, beginning of year (as restated) | | 142,400,816 | | 214,097,630 |
| DELEGROUP DECIDINO DI VEALIAS (ESTATEO) | \$ | 2,423,424,895 | \$ | 2,209,327,265 |

The University of Alabama at Birmingham Statements of Cash Flows

Years Ended September 30, 2013 and 2012

| | | 2013 | 201 | 2 (Restated, See Note 3) |
|--|----|-----------------|-----|--------------------------|
| Cash flows from operating activities | | | | |
| Student tuition and fees | \$ | 143,316,428 | \$ | 134,063,440 |
| Grants and contracts | | 371,421,760 | | 361,818,370 |
| Receipts from sales and services of: | | | | |
| Educational activities | | 57,270,156 | | 59,621,571 |
| Patient services | | 1,246,534,491 | | 1,204,402,577 |
| Auxiliary enterprises, net | | 8,678,653 | | 25,226,907 |
| Premium and administrative fees collected | | 489,079,973 | | 463,931,552 |
| Payment to employees and related benefits | | (1,288,009,574) | | (1,233,285,172) |
| Payment to suppliers | | (1,203,917,930) | | (1,142,547,909) |
| Payment for scholarships and fellowships | | (20,999,390) | | (19,158,339) |
| Other receipts | | 16,736,932 | | 40,147,460 |
| Net cash used in operating activities | \$ | (179,888,501) | \$ | (105,779,543) |
| Cash flows from capital and related financing activities | | | | |
| Proceeds from issuance of capital debt | \$ | 242,071,202 | \$ | 150,364,622 |
| State capital funds | | 8,680,247 | | 11,076,675 |
| Capital grants and contracts | | (92,126) | | 2,758,943 |
| Private gifts | | 4,570,240 | | 478,664 |
| Proceeds from sale of capital assets | | 105,348 | | 167,486 |
| Purchases of capital assets | | (190,440,871) | | (131,629,644) |
| Principal payments on capital debt | | (72,404,606) | | (173,361,203) |
| Interest payments on capital debt | | (32,284,045) | | (31,294,051) |
| Proceeds from sale of repurchase option | | 24,250,000 | | |
| Net cash used in capital and related financing activities | \$ | (15,544,611) | \$ | (171,438,508) |
| Cash flows from noncapital financing activities | | | | |
| State educational appropriations | \$ | 258,429,840 | \$ | 268,640,355 |
| Private gifts | Ť | 41,476,897 | Ť | 45,540,280 |
| Student direct lending receipts | | 129,057,401 | | 129,785,462 |
| Student direct lending disbursements | | (130,080,858) | | (130,038,922) |
| Other deposits | | 29,127,488 | | 32,993,140 |
| Deposits from affiliates | | (1,396,950) | | 1,445,209 |
| Net cash provided by noncapital financing activities | \$ | 326,613,818 | \$ | 348,365,524 |
| Cash flows from investing activities | | | | |
| Interest and dividends from investments, net | \$ | 46,938,552 | \$ | 45,182,564 |
| Collections on note receivable | Ť | 133,356 | Ť | 133,356 |
| Proceeds from sales and maturities of investments | | 50,949,470 | | 60,832,806 |
| Investments in system pooled investment funds | | (87,556,511) | | (145,637,600) |
| Purchases of investments | | (71,317,704) | | (88,477,297) |
| Net cash used in investing activities | \$ | (60,852,837) | \$ | (127,966,171) |
| Net increase (decrease) in cash and cash equivalents | \$ | 70,327,869 | \$ | (56,818,698) |
| Cash and cash equivalents, beginning of year | \$ | 268,824,418 | \$ | 325,643,116 |
| Cash and cash equivalents, end of year | \$ | 339,152,287 | | 268,824,418 |
| Out and out of an analysis of year | Ť | 000,102,201 | | |
| Reconciliation of operating (loss) to net cash used in operating activities | | | | |
| Operating (loss) | \$ | (268,563,199) | \$ | (227,231,016) |
| Adjustments to reconcile operating loss to net cash used in operating activities | * | (==,===,===) | | ,==:,=10) |
| Depreciation expense | \$ | 98,303,065 | \$ | 123,047,953 |
| Changes in assets and liabilities: | * | ,, | | 2,2,200 |
| Accounts receivable, net | \$ | (48, 137, 954) | \$ | 8,943,740 |
| Prepaid expenses and other assets | * | (3,474,523) | | (432,546) |
| Accounts payable and accrued liabilities | | 50,663,669 | | (14,153,560) |
| Deferred revenue | \$ | (8,679,559) | \$ | 4,045,886 |
| Net cash used in operating activities | \$ | (179,888,501) | \$ | (105,779,543) |
| the second opening destribute | Ψ | (1.0,000,001) | Ψ | (100,110,040) |

The University of Alabama at Birmingham Statements of Cash Flows (continued)

Years Ended September 30, 2013 and 2012

| | 2013 | 2012 |
|--|------------------|-----------------|
| Supplemental noncash activities information | | |
| Capital assets acquired included in accounts payable | \$ 10,313,216 | \$ 8,813,669 |
| Interest capitalized | \$ 2,716,551 | \$ 3,048,851 |
| Capital assets acquired through property exchange | \$ | \$ 8,445,450 |

Southern Research Institute A Discretely Presented Component Unit Statements of Net Position

December 28, 2012 and December 30, 2011

| | | 2012 | | 2011 |
|---|-------|--|----|--|
| ASSETS | | | | |
| Current Assets: | | | | |
| Cash and cash equivalents | \$ | 1,045,191 | \$ | 6.336.199 |
| Investments | • | 55,518,482 | , | 51,000,810 |
| Restricted cash and investments | | 10,052,067 | | 9,342,095 |
| Funds held by trustee | | 4,387,874 | | 13,155,690 |
| Accounts receivable, net | | 17,941,413 | | 16,811,896 |
| Other receivables | | 2,578,588 | | 6,637,310 |
| Materials and supplies, net | | 940,744 | | 1,031,947 |
| Prepayments and other current assets | | 1,653,030 | | 2,153,205 |
| Total current assets | \$ | 94,117,389 | \$ | 106,469,152 |
| Noncurrent Assets: | | | | |
| Capital assets: | | | | |
| Land and improvements | \$ | 7,879,459 | \$ | 7,724,636 |
| Buildings and major plant equipment | • | 67,134,025 | , | 60,512,884 |
| Laboratory equipment and fixtures | | 48,621,081 | | 42,994,751 |
| Office furniture and equipment | | 2,559,166 | | 2,267,953 |
| Intangible assets, net | | 2,702,485 | | 2,431,680 |
| | \$ | 128,896,216 | \$ | 115,931,904 |
| Less accumulated depreciation | · | 66,482,636 | · | 60,614,781 |
| · | \$ | 62,413,580 | \$ | 55,317,123 |
| Construction-in-progress | | 9,962,347 | | 7,657,238 |
| | \$ | 72,375,927 | \$ | 62,974,361 |
| Deferred outflow - interest rate swap | | 1,182,857 | | 1,065,176 |
| Goodwill | | , , | | 50,000 |
| Total noncurrent assets | \$ | 73,558,784 | \$ | 64,089,537 |
| Total Assets | \$ | 167,676,173 | \$ | 170,558,689 |
| | | | | |
| LIABILITIES | | | | |
| Current Liabilities: | | | | |
| Accounts payable | \$ | 4,421,228 | \$ | 5,121,862 |
| Accrued liabilities | | 7,543,260 | | 7,956,111 |
| Unearned contract revenue | | 4,902,752 | | 3,274,515 |
| Current maturities of long-term debt and capital lease obligations | | 480,000 | | 480,000 |
| Total current liabilities | \$ | 17,347,240 | \$ | 16,832,488 |
| Noncurrent Liabilities: | | | | |
| Long term dobt and conital loans obligations | \$ | 18,920,000 | \$ | 19,400,000 |
| LUNU-TERM GEDT AND CADITAL TEASE ODIIGATIONS | T) | | | 1,065,176 |
| Long-term debt and capital lease obligations Derivative instrument - interest rate swap | Ψ | | | |
| Derivative instrument - interest rate swap Postretirement benefits | Ψ | 1,182,857 926,985 | | 805,537 |
| Derivative instrument - interest rate swap | φ | 1,182,857 926,985 | \$ | |
| Derivative instrument - interest rate swap Postretirement benefits | | 1,182,857 | | 805,537 21,270,713 38,103,201 |
| Derivative instrument - interest rate swap Postretirement benefits Total noncurrent liabilities Total Liabilities | \$ | 1,182,857 926,985 21,029,842 | | 21,270,713 |
| Derivative instrument - interest rate swap Postretirement benefits Total noncurrent liabilities Total Liabilities NET POSITION | \$ | 1,182,857 926,985 21,029,842 38,377,082 | \$ | 21,270,713 38,103,201 |
| Derivative instrument - interest rate swap Postretirement benefits Total noncurrent liabilities Total Liabilities NET POSITION Invested in capital assets | \$ | 1,182,857 926,985 21,029,842 | | 21,270,713 |
| Derivative instrument - interest rate swap Postretirement benefits Total noncurrent liabilities Total Liabilities NET POSITION Invested in capital assets Restricted | \$ | 1,182,857 926,985 21,029,842 38,377,082 57,363,801 | \$ | 21,270,713 38,103,201 56,250,051 |
| Derivative instrument - interest rate swap Postretirement benefits Total noncurrent liabilities Total Liabilities NET POSITION Invested in capital assets | \$ | 1,182,857 926,985 21,029,842 38,377,082 | \$ | 21,270,713 38,103,201 |

Southern Research Institute A Discretely Presented Component Unit

Statements of Revenues, Expenses, and Changes in Net Position

December 28, 2012 and December 30, 2011

| | | 2012 | | 2011 |
|--|----|------------------------------|----|-------------|
| Operating Revenues | | | | |
| Contract revenues | \$ | 73,373,816 | \$ | 79,646,080 |
| Intellectual property revenues, net of direct expenses | | 6,276,034 | | 10,121,278 |
| Total operating revenues | \$ | 79,649,850 | \$ | 89,767,358 |
| Operating Expenses | | | | |
| Salaries, wages and benefits | \$ | 44,745,102 | \$ | 42,584,470 |
| Supplies and services | | 35,612,460 | | 36,797,977 |
| Depreciation and amortization | | 6,303,232 | | 5,912,682 |
| Total operating expenses | \$ | 86,660,794 | \$ | 85,295,129 |
| Operating (loss) income | \$ | (7,010,944) | \$ | 4,472,229 |
| Nonoperating Revenues (Expenses) Contributions | \$ | 445,650 | \$ | 410,472 |
| Investment income (loss) | | 5,347,214 | | (126,615) |
| Interest expense | | (586,466) | | (410,480) |
| Loss on disposal of assets Net nonoperating revenues (expenses) | \$ | (49,960) 5,156,438 | \$ | (124,250) |
| Net nonoperating revenues (expenses) | Ф | 3,130,436 | Þ | (250,873) |
| (Loss) Income before other revenues, expenses, gains and losses | \$ | (1,854,506) | \$ | 4,221,356 |
| Other Changes in Net Position | | | | |
| Loss from discontinued operations | \$ | (1,301,891) | \$ | (761,290) |
| Net other changes in net position | | (1,301,891) | | (761,290) |
| (Decrease) increase in net position | | (3,156,397) | | 3,460,066 |
| Net Position, beginning of year | \$ | 132,455,488 | \$ | 128,995,422 |
| Net Position, end of year | \$ | 129,299,091 | \$ | 132,455,488 |

The University of Alabama at Birmingham Notes to Financial Statements

September 30, 2013

Summary of Significant Accounting Policies

The University of Alabama at Birmingham (UAB) is one of three campuses of The University of Alabama System (the System), which is a discretely presented component unit of the State of Alabama (the State). The financial statements of UAB are intended to present the financial position, changes in financial position, and the cash flows of only that portion of the business-type activities of the financial reporting entity of the System that is attributable to the transactions of UAB. The System is recognized as an organization exempt from Federal income tax under Section 501(a) of the Internal Revenue Code as an organization described in Section 501(c)(3) of the Internal Revenue Code.

UAB, as a public institution, prepares its financial statements in accordance with accounting principles generally accepted in the United States of America, as prescribed by the Governmental Accounting Standards Board (GASB).

GASB Statement No. 35, Basic Financial Statements and Management's Discussion and Analysis for Public Colleges and Universities (GASB Statement No. 35), establishes standards for external financial reporting for public colleges and universities and requires that resources be classified for accounting and reporting purposes into the following three net position categories:

Invested in Capital Assets:

Capital assets, net of accumulated depreciation and outstanding principal balances of debt attributable to the acquisition, construction, or improvement of those assets.

Restricted:

Nonexpendable: Net position subject to externally imposed stipulations that they be maintained permanently by UAB. Such assets include UAB's permanent endowment funds.

Expendable: Net position whose use by UAB is subject to externally imposed stipulations that can be fulfilled by actions of UAB pursuant to those stipulations or that expire by the passage of time.

Unrestricted:

The net position that is not subject to externally imposed stipulations. Unrestricted net position may be designated for specific purposes by action of management. Substantially all of the unrestricted net position is designated for academic and research programs and initiatives and capital programs.

Corrections of Errors:

During fiscal year 2013, the University deter-

mined that the accrual for compensated absences was improperly calculated as of September 30, 2012 and for several years prior. This error resulted in an understated compensated absences accrual of \$24.8 million as of September 30, 2012 and was created over a multiple year period of time likely beginning in fiscal 2004. This error overstated fiscal 2012 operating expenses and accrued liabilities by \$500,000. In addition, during fiscal year 2013, the University determined that the accrual for library material depreciation expense was improperly calculated as of September 30, 2012 and for several years prior. This error resulted in an understated net property, plant and equipment of \$27.1 million as of September 30, 2012 and was created over a multiple year period of time likely beginning in fiscal 2004. This error overstated fiscal 2012 operating expenses and understated net property, plant and equipment by \$4.86 million. The cumulative errors were corrected in the fiscal 2013 financial statements resulting in an increase in Salary, Wages, and Benefits expense of \$24.8 million and a decrease in Depreciation expense of \$27.15 million, netting to an overall reduction of operating expenses and operating loss of \$2.35 million for the year ended September 30, 2013. Management does not believe these errors are material to the 2013 or to any previously issued financial statements taken as a whole.

UAB reports as a business type activity, as defined by GASB Statement No. 35. Business type activities are those financed in whole or in part by fees charged to external parties for goods or services.

UAB policy states that operating activities as reported by the statement of revenues, expenses, and changes in net position are those that generally result from exchange transactions such as payments received for providing services and payments made for services or goods received. Certain significant revenue streams relied upon for operations are recorded as nonoperating revenues, as defined by GASB Statement No. 35.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. The estimates susceptible to significant changes include those used in determining the allowance for contractual adjustments and uncollectible accounts, valuation of investments, accruals related to compensated absences, allowance for self insurance, estimated amounts due to or from third-party payors, and reserves for general and professional liability claims. Although some variability is inherent in these estimates, management believes that the amounts provided are adequate.

Scope of Statements

UAB is principally comprised of a university (the University) and the University of Alabama Hospital (the Hospital) which are UAB's reportable segments as defined by GASB Statement No. 37, Basic Financial Statements and Management's Discussion and Analvsis-For State and Local Governments: Omnibus an Amendment of GASB Statements No. 21 and No. 34. UAB's financial statements present the financial position, changes in financial position, and the cash flows of the University, the Hospital, and UAB's blended component units. Condensed financial information of UAB's reportable segments is presented at Note 23. GASB Statement No. 14, The Financial Reporting Entity (GASB Statement No. 14), requires governmental entities to include in their financial statements as a component unit, organizations that are legally separate entities for which the governmental entity, as a primary organization, is financially accountable.

In November 2010, the GASB issued Statement No. 61, *The Financial Reporting Entity: Omnibus* (GASB Statement No. 61), effective for UAB's fiscal year beginning October 1, 2012. This Statement modifies the existing requirements for the assessment of component units that should be included in the financial statements of UAB. Refer to Footnote 3 for the cumulative effect that the implementation of GASB Statement No. 61 had on UAB's net position and changes in net position for the years ended September 30, 2013 and 2012.

The by-laws and corporate charter of the Southern Research Institute (SRI) allow UAB to appoint a majority of the board of directors and UAB is financially accountable for SRI. Therefore, management has determined that SRI is a discretely presented component unit of UAB under GASB Statements No. 14 and No. 61. SRI reports financial results under principles prescribed under the GASB. SRI offers research and technology services to support industry and federal government agencies primarily in the areas of drug design and evaluation, environmental controls, materials engineering, and chemical and biological defense. The activities of SRI are maintained using a fiscal calendar year-end that predates UAB's fiscal year-end of September 30. The financial results of SRI are discretely presented in the accompanying financial statements.

The by-laws and corporate charters of the UAB Research Foundation (UABRF) allow UAB to appoint a majority of the board of directors and allow UAB to impose its will on the entity. UABRF operates for the exclusive benefit of UAB. Additionally, Triton Health Systems, L.L.C. (Triton) and UAB Hospital Management, L.L.C. (LLC) have governing bodies that are substantively the same as the governing body of UAB and there is a financial benefit or burden relationship between UAB and these entities. Therefore, management has determined that UABRF, Triton, and LLC (the Blended Component Units) constitute blended component units of UAB under GASB Statements No. 14 and No. 61. The Blended Component Units report financial results under principles prescribed under the GASB.

Triton was formed to advance the educational and

research mission of UAB and to educate and train physicians and other health care professionals. Triton is owned 99% by UAB and 1% by The UAB Educational Foundation (UABEF). UABRF was organized exclusively for charitable, scientific, and educational purposes in order to benefit UAB. The LLC was organized for the exclusive purpose of supporting UAB in connection with the management, administration. and operation of the Hospital, including, without limitation, providing management, administrative, and staffing services to the Hospital, UABRF and the LLC maintain a September 30 year-end. The activities of Triton are maintained using a fiscal calendar year-end that predates UAB's fiscal year-end of September 30. However, interfund cash transactions during the period from January 1 through September 30 have been eliminated. Since Triton qualifies as a major component unit under GASB Statement No. 61, condensed financial information is presented at Note 24. Separate financial statements are available for Triton and UABRF by contacting UAB.

Other significant accounting policies are as follows:

Cash and cash equivalents: For purposes of the statement of cash flows, UAB considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents representing assets of UAB's endowment, life income, and other long-term investments are included in noncurrent investments.

Investments: UAB accounts for its investments. other than land and other real estate held as investments by endowments, in accordance with the provisions of GASB Statement No. 31, Accounting and Reporting for Certain Investments and For External Investment Pools (GASB 31) (see Note 5). Investments in equity securities with readily determinable fair values and all investments in debt securities are recorded at their fair value. UAB invests certain amounts in a commingled investment pool sponsored by the System. The value of the investments in the pools is determined by the System and based on UAB's proportionate share of the net asset value of the investment pools. Fair value for the investment pools is provided by the System, based on the fair value of the underlying investment securities held by each investment pool. Fair value of the underlying securities held in each investment pool is based on quoted market prices or dealer quotes, where available, or determined using net asset values provided by underlying investment partnerships or companies, which primarily invest in readily marketable securities. Certain real estate and non-readily marketable securities held in the System-sponsored Endowment Fund and Prime Fund are carried at cost (Note 5). Investments carried at cost are subject to review for impairment.

UAB accounts for its land and other real estate held as investments by endowments in accordance with GASB Statement No. 52, Land and Other Real Estate Held as Investments by Endowments. Investments are reported in four categories in the statement of net position. Investments recorded as endowment and life income investments are those invested funds considered by management to be of long duration. Other long-term investments include amounts resulting

from UAB's equity investment in other entities, as discussed in Note 5 and Note 20. Investments for capital projects are included in noncurrent assets. All other investments are included as short-term investments.

Inventories: Inventories are carried at the lower of cost or market. Inventories consist primarily of textbooks, medical supplies, and pharmaceuticals.

Accounts receivable: Accounts receivable consist primarily of tuition charged to students and amounts due from Federal, state, and local governments, or private sources, in connection with reimbursement of allowable expenditures made pursuant to UAB's contracts and grants.

Capital assets: All capital assets are carried at cost on date of acquisition (or in the case of gifts, at fair value on the date of donation), less accumulated depreciation (or in the case of assets leased under capital leases, net of accumulated amortization). UAB computes depreciation for buildings and building improvements (15-40 years) and for fixed equipment systems (3-20 years) using a component method. Depreciation of land improvements (40 years), library materials (10 years), and inventoried equipment (3-20 years) is computed on a straight-line basis. The Hospital uses guidelines established by the American Hospital Association to assign useful lives to inventoried equipment.

Capital assets acquired under capital leases are amortized over the shorter of the lives of the respective leases or the estimated useful lives of the assets. Capital assets acquired through federal grants and contracts in which the federal government retains a reversionary interest are capitalized and depreciated. Interest costs, net of any related investment earnings, for certain assets acquired with the proceeds of taxexempt borrowings are capitalized as a component of the cost of acquiring those assets.

Computer software capitalization, which is included as inventoried equipment, includes the costs of software and implementation. Implementation costs include consulting expenses and allocation of internal salaries and fringes for the core implementation team.

Pledges: UAB receives gift pledges and bequests of financial support. Revenue is recognized when a pledge representing an unconditional promise to give is received and all eligibility requirements, including time requirements, have been met. In the absence of such a promise, revenue is recognized when the gift is received. Pledges are recorded at their gross, undiscounted amount. Endowment pledges do not meet eligibility requirements and are not recorded as assets until the related gift is received in accordance with the requirements of GASB Statement No. 33, *Accounting and Financial Reporting for Nonexchange Transactions* (GASB Statement No. 33).

Endowment spending: The Alabama Uniform Prudent Management of Institutional Funds Act (UPMIFA) was enacted by the State Legislature and signed into law effective January 1, 2009. UPMIFA prescribes new guidelines for the expenditure of a donor-restricted endowment funds in the absence of overriding, explicit donor stipulations. Its predecessor, UMIFA, focused on the prudent spending of the net appreciation of the fund. UPMIFA instead focuses on the entirety of a donor-restricted endowment fund, that is, both the original gift amount(s) and net apprecia-

tion. UPMIFA eliminates UMIFA's historic-dollar-value threshold, an amount below which an organization could not spend from the fund, in favor of a more robust set of guidelines about what constitutes prudent spending, explicitly requiring consideration of the duration and preservation of the fund.

UPMIFA permits the Board of Trustees of the University of Alabama (the "Board") to appropriate an amount of realized and unrealized endowment appreciation as the Board determines to be prudent. UAB's policy is to retain the endowment realized and unrealized appreciation within an endowment after the spending rate distributions in a manner consistent with the standards of prudence prescribed by UPMIFA. The Board approved a spending rate for the fiscal years September 30, 2013 and 2012 of 5% of a moving three-year average of the market (unit) value.

Unearned revenue: Unearned revenue consists primarily of student fees related predominantly to future fiscal years and amounts received from grant and contract sponsors that have not yet been earned under the terms of the agreements and, therefore, have not yet been included in the net position.

Federal refundable loans: Certain loans to students are administered by UAB with funding primarily supported by the federal government. UAB's Statement of Net Position includes both the notes receivable and the related federal refundable loan liability representing federal capital contributions owed upon termination of the program.

Compensated absences: UAB accrues annual leave for employees at rates based upon length of service and job classification. UAB accrues compensatory time based upon job classification and hours worked. These amounts are included in accounts payable and accrued liabilities.

Student tuition and fees: Student tuition and residence fees are presented net of scholarships and fellowships applied to student accounts, while stipends and other payments made directly to students are presented as scholarship and fellowship expenses.

Grant and contract revenue: UAB receives grant and contract revenue from governmental and private sources. UAB recognizes revenue associated with the sponsored programs in accordance with GASB Statement No. 33, based on the terms of the individual grant or contract.

Hospital revenue: Net patient service revenue is reported at the Hospital's estimated net realizable amounts from patients, third-party payors, and others for services rendered, included estimated retroactive revenue adjustments due to revenue audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered.

The Hospital provides care to patients who meet certain criteria under its charity care policy without charge or at amounts less than its estimated rates. Because the Hospital does not pursue collection of amounts determined to qualify as charity care, they are not reported as revenue.

Auxiliary enterprise revenue: Auxiliary enterprise revenues primarily represent revenues generated by intercollegiate athletics and parking as well as subscriber premiums.

Other revenue: Other revenue represents primarily revenues generated by UAB for activities such as intellectual property income and HSF revenues.

Equity investments: Investments in affiliated companies where UAB can exercise significant influence and for which UAB's ownership interest is 50% or less are accounted for using the equity method. The investment in the Professional Liability Trust Fund (PLTF) also is accounted for using the equity method. See Notes 5 and 20.

Nonoperating revenues (expenses): Nonoperating revenues and expenses include State educational appropriations, Federal Pell grants, private gifts for other than capital purposes, investment income, net unrealized appreciation or depreciation in the fair value of investments, interest expense, and loss on asset dispositions. Also, during 2013, the Hospital sold a repurchase option for certain dialysis units to a third party for approximately \$24.3 million and recorded a gain on that sale as a component of other nonoperating revenue.

(2) Related Parties

UAB is affiliated with the UABEF, the University of Alabama Health Services Foundation, P.C. (HSF), UAB Health System (UABHS), and the Valley Foundation (VF). UAB is not financially accountable for HSF, VF, UABEF, and UABHS; therefore, they do not constitute component units under the provisions of GASB Statement No. 14. These entities are not required to be presented as component units under GASB Statement No. 39, *Determining Whether Certain Organizations Are Component Units*, or by GASB Statement No. 61, both of which amend GASB 14.

UABEF provides funds and certain facilities to UAB for its educational and scientific functions and provides support for UAB athletic programs. UABEF has 13 board members, including seven outside members not affiliated with UAB. UABEF leases certain facilities to UAB, with annual rental expense of approximately \$2,004,000 and \$1,919,000 for 2013 and 2012, respectively. UABEF made contributions to UAB which totaled approximately \$6,766,000 and \$6,460,000 in 2013 and 2012, respectively. UABEF's total assets were approximately \$56,280,000 and \$56,704,000 at September 30, 2013 and 2012, respectively. UABEF's total liabilities were approximately \$18,445,000 and \$18,563,000 at September 30, 2013 and 2012, respectively.

HSF's primary purpose is to provide a group medical practice for physicians who are members of the regular faculty of the School of Medicine at UAB and serve on the University of Alabama Hospital's medical staff. It is governed by a 19-member board of directors, 16 of whom are not affiliated with UAB. An affiliation agreement (the Agreement) documents the relationship between HSF and UAB. The University's other operating revenues include approximately \$23,807,000 and \$29,238,000 of funding from HSF in 2013 and 2012, respectively, which is used to support the educational and research activities of

UAB. These funds were paid by HSF pursuant to its tax-exempt purpose and in recognition of the mutual benefit derived by the two organizations from the enhancement and continued development of UAB's programs. The funds were negotiated with HSF as part of UAB's budget development process. In the normal course of business, HSF purchases various services from the Hospital, aggregating approximately \$2,493,000 and \$886,000 in 2013 and 2012, respectively, and the Hospital purchases various services from HSF, aggregating approximately \$36.628.000 and \$30.155.000 for the years ended September 30, 2013 and 2012, respectively. As a result of these transactions, the Hospital had a net payable to HSF of approximately \$236,000 and a net receivable from HSF of approximately \$711,000, respectively, at September 30, 2013 and September 30, 2012.

During 2009, the Hospital entered into an operating agreement with HSF whereby HSF began leasing two floors of the UAB Women and Infants' Facility when construction was completed in February 2010. HSF reimbursed the Hospital for construction costs of this space as they were incurred on a square-footage basis. Total reimbursements are being amortized as rent revenue on a straight-line basis over a period equal to the 90 year total lease term, commencing on February 20, 2010 when the building was placed into service. The Hospital had received reimbursements from HSF totaling approximately \$13,908,000 and \$14,071,000, which is included in the accompanying statement of net position as unearned revenue-other for the years ended September 30, 2013 and 2012, respectively. Approximately \$163,000 was recognized as rent revenue during each of the years ended September 30, 2013 and 2012.

The Board and the HSF's board have entered into an agreement under which UAB and HSF have established a common management group, the UAB Health System to provide management for their existing and future health care delivery operations. The UAB Health System Board of Directors is composed of 18 members, of whom nine are appointed by the Board. For the fiscal years ended September 30, 2013 and 2012, respectively, UAB contributed approximately \$8,558,000 and \$8,301,000 to the UAB Health System Board to support Health System administrative functions. In addition, at September 30, 2013 and 2012, respectively, the Hospital had a net payable from the Health System of approximately \$281,000 and \$825,000.

VF's primary purpose is to provide a group medical practice for physicians who are faculty members in the UAB School of Medicine Huntsville program. It is governed by a 17-member board of directors, consisting of three nonvoting members and 14 voting members, of whom seven are affiliated with UAB. VF's total assets were approximately \$9,357,000 (unaudited) and \$8,815,000 (unaudited) and total liabilities were approximately \$1,132,000 (unaudited) and \$1,275,000 (unaudited) at September 30, 2013 and 2012, respectively.

The Hospital received premium revenue (capitation fees) of approximately \$56,903,000 and \$64,068,000 from Triton during the years ended September 30, 2013 and 2012.

The Hospital purchased \$88,473,000 and \$9,384,000 in management, administrative, and staffing services from the LLC during the years ended September 30, 2013 and 2012, respectively.

Effect of Recently Implemented Pronouncements

As a result of UAB's implementation of GASB Statement No. 61, SRI no longer constitutes a blended component unit of UAB for the years ended September 30, 2013 and 2012. GASB Statement No. 61 amends the criteria for reporting component units as if they were part of the primary government (that is, blending) and SRI does not meet the amended criteria. SRI remains a component unit of UAB since the by-laws and corporate charter of SRI allow UAB to appoint a majority of the board of directors and UAB remains financially accountable for SRI. The financial results of SRI are discretely presented in the accompanying financial statements in accordance with GASB Statement No. 61. The effect of the changes from the implementation of GASB Statement No. 61 on UAB's financial statements for

the year ended September 30, 2012 is included in the table below.

In June 2011, the GASB issued Statement No. 63, Financial Reporting of Deferred Outflows of Resources, Deferred Inflows of Resources, and Net Position (GASB Statement No. 63), effective for UAB's fiscal year beginning October 1, 2012. This Statement modifies the presentation of deferred inflows and deferred outflows in the financial statements. In March 2012, the GASB issued Statement No. 65, Items Previously Reported as Assets and Liabilities (GASB Statement No. 65), effective for UAB's fiscal year beginning October 1, 2013; however, UAB early adopted this Statement effective for the fiscal year beginning October 1, 2012. This Statement establishes accounting and financial reporting standards that reclassify, as deferred outflows of resources or deferred inflows of resources, certain items that were previously reported as assets and liabilities and recognizes, as outflows of resources or inflows of resources, certain items that were previously reported as assets and liabilities. The effect of the changes from the implementation of GASB Statements No. 63 and No. 65 on UAB's financial statements for the year ended September 30, 2012 is included in the table below:

| | | PREVIOUSLY REPORTED | AI | GASB 61 DJUSTMENTS | | ASB 63/65 JUSTMENTS | | AS RESTATED |
|---|--------------------|---|-------------------|---|----------|--|----------------|---|
| CONDENSED STATEMENT OF NET POSITION | | | | | | | | |
| Current assets | \$ | 1,004,175,428 | \$ | (93,313,462) | \$ | | \$ | 910,861,966 |
| Non-current assets | | 2,712,661,849 | | (77,245,227) | | | | 2,635,416,622 |
| Total assets | \$ | 3,716,837,277 | \$ | (170,558,689) | \$ | | \$ | 3,546,278,588 |
| DEFERRED OUTFLOW OF RESOURCES | \$ | | \$ | | \$ | 13,019,885 | \$ | 13,019,885 |
| Current liabilities | \$ | 358,846,062 | \$ | (16,832,488) | \$ | | \$ | 342,013,574 |
| Noncurrent liabilities | | 800,694,958 | | (21,270,713) | | 14,225,873 | | 793,650,118 |
| Total liabilities | \$ | 1,159,541,020 | \$ | (38,103,201) | \$ | 14,225,873 | \$ | 1,135,663,692 |
| DEFERRED INFLOW OF RESOURCES | \$ | | \$ | | \$ | 209,886 | \$ | 209,886 |
| Invested in capital | \$ | 741,376,219 | \$ | (53,818,371) | \$ | (1,415,874) | \$ | 686,141,974 |
| Restricted nonexpendable | | 252,844,971 | | | | | | 252,844,97 |
| Restricted expendable | | 221,215,840 | | (9,349,775) | | | | 211,866,065 |
| Unrestricted | | 1,341,859,227 | | (69,287,342) | | | | 1,272,571,885 |
| | | | Φ. | (400 455 400) | \$ | (4.445.054) | _ | 2.423.424.895 |
| Total net position CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANG | \$ GES IN NET P | 2,557,296,257 POSITION | \$ | (132,455,488) | <u> </u> | (1,415,874) | \$ | 2,423,424,033 |
| Total net position CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANG Total operating revenues Total operating expenses | · | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | \$ | (89,767,358) 85,295,129 | \$ | (1,415,874) | \$ | 2,313,144,589 |
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANG Total operating revenues | SES IN NET P | POSITION 2,402,911,947 | · · | (89,767,358) | · · | (1,415,8/4) | _ · | 2,313,144,589 (2,540,375,605 |
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANG Total operating revenues Total operating expenses | GES IN NET P | POSITION 2,402,911,947 (2,625,670,734) | \$ | (89,767,358) 85,295,129 | \$ | (446,297) | \$ | 2,313,144,589 (2,540,375,605 (227,231,016 415,639,575 |
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANG Total operating revenues Total operating expenses Operating loss | GES IN NET P | POSITION 2,402,911,947 (2,625,670,734) (222,758,787) | \$ | (89,767,358) 85,295,129 (4,472,229) | \$ | | \$ | 2,313,144,589 (2,540,375,605 (227,231,016 |
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANG Total operating revenues Total operating expenses Operating loss Nonoperating revenues Income (Loss) before other changes in net position Capital grants and transfers | GES IN NET P | 2,402,911,947 (2,625,670,734) (222,758,787) 415,073,709 192,314,922 25,689,071 | \$ | (89,767,358) 85,295,129 (4,472,229) 1,012,163 (3,460,066) | \$ | (446,297) (446,297) | \$ \$ | 2,313,144,588 (2,540,375,605 (227,231,016 415,639,576 188,408,556 25,689,071 |
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANG Total operating revenues Total operating expenses Operating loss Nonoperating revenues Income (Loss) before other changes in net position Capital grants and transfers Increase in net position | GES IN NET P | 2,402,911,947 (2,625,670,734) (222,758,787) 415,073,709 192,314,922 25,689,071 218,003,993 | \$ | (89,767,358) 85,295,129 (4,472,229) 1,012,163 (3,460,066) | \$ | (446,297) (446,297) | \$ | 2,313,144,588 (2,540,375,605 (227,231,016 415,639,575 188,408,555 25,689,07 214,097,63(|
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANG Total operating revenues Total operating expenses Operating loss Nonoperating revenues Income (Loss) before other changes in net position Capital grants and transfers Increase in net position Net position, beginning of year | S S | 2,402,911,947 (2,625,670,734) (222,758,787) 415,073,709 192,314,922 25,689,071 218,003,993 2,339,292,264 | \$ \$ | (89,767,358) 85,295,129 (4,472,229) 1,012,163 (3,460,066) (3,460,066) (128,995,422) | \$ \$ | (446,297) (446,297) (446,297) (969,577) | \$ \$ | 2,313,144,589 (2,540,375,605 (227,231,016 415,639,576 188,408,555 25,689,071 214,097,630 2,209,327,268 |
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANG Total operating revenues Total operating expenses Operating loss Nonoperating revenues Income (Loss) before other changes in net position Capital grants and transfers Increase in net position | GES IN NET P | 2,402,911,947 (2,625,670,734) (222,758,787) 415,073,709 192,314,922 25,689,071 218,003,993 | \$ | (89,767,358) 85,295,129 (4,472,229) 1,012,163 (3,460,066) | \$ | (446,297) (446,297) | \$ \$ | 2,313,144,588 (2,540,375,605 (227,231,016 415,639,575 188,408,555 25,689,07 214,097,63(|
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANG Total operating revenues Total operating expenses Operating loss Nonoperating revenues Income (Loss) before other changes in net position Capital grants and transfers Increase in net position Net position, beginning of year Net position, end of year | S S | 2,402,911,947 (2,625,670,734) (222,758,787) 415,073,709 192,314,922 25,689,071 218,003,993 2,339,292,264 | \$ \$ | (89,767,358) 85,295,129 (4,472,229) 1,012,163 (3,460,066) (3,460,066) (128,995,422) | \$ \$ | (446,297) (446,297) (446,297) (969,577) | \$ \$ | 2,313,144,589 (2,540,375,605 (227,231,016 415,639,576 188,408,555 25,689,071 214,097,630 2,209,327,268 |
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANG Total operating revenues Total operating expenses Operating loss Nonoperating revenues Income (Loss) before other changes in net position Capital grants and transfers Increase in net position Net position, beginning of year Net position, end of year CONDENSED STATEMENT OF CASH FLOWS Net cash provided (used) by: | SES IN NET P | POSITION 2,402,911,947 (2,625,670,734) (222,758,787) 415,073,709 192,314,922 25,689,071 218,003,993 2,339,292,264 2,557,296,257 | \$ \$ \$ | (89,767,358) 85,295,129 (4,472,229) 1,012,163 (3,460,066) (3,460,066) (128,995,422) (132,455,488) | \$ \$ | (446,297) (446,297) (446,297) (969,577) | \$ \$ \$ \$ \$ | 2,313,144,588 (2,540,375,605 (227,231,016 415,639,578 188,408,558 25,689,07 214,097,630 2,209,327,268 2,423,424,898 |
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANG Total operating revenues Total operating expenses Operating loss Nonoperating revenues Income (Loss) before other changes in net position Capital grants and transfers Increase in net position Net position, beginning of year Net position, end of year CONDENSED STATEMENT OF CASH FLOWS Net cash provided (used) by: Operating activities | S S | POSITION 2,402,911,947 (2,625,670,734) (222,758,787) 415,073,709 192,314,922 25,689,071 218,003,993 2,339,292,264 2,557,296,257 | \$ \$ | (89,767,358) 85,295,129 (4,472,229) 1,012,163 (3,460,066) (128,995,422) (132,455,488) | \$ \$ | (446,297) (446,297) (446,297) (969,577) | \$ \$ | 2,313,144,588 (2,540,375,605 (227,231,016 415,639,575 188,408,555 25,689,07 214,097,630 2,209,327,266 2,423,424,898 |
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANG Total operating revenues Total operating expenses Operating loss Nonoperating revenues Income (Loss) before other changes in net position Capital grants and transfers Increase in net position Net position, beginning of year Net position, end of year CONDENSED STATEMENT OF CASH FLOWS Net cash provided (used) by: | SES IN NET P | POSITION 2,402,911,947 (2,625,670,734) (222,758,787) 415,073,709 192,314,922 25,689,071 218,003,993 2,339,292,264 2,557,296,257 | \$ \$ \$ | (89,767,358) 85,295,129 (4,472,229) 1,012,163 (3,460,066) (3,460,066) (128,995,422) (132,455,488) | \$ \$ | (446,297) (446,297) (446,297) (969,577) | \$ \$ \$ \$ \$ | 2,313,144,588 (2,540,375,605 (227,231,016 415,639,575 188,408,555 25,689,07 214,097,630 2,209,327,266 2,423,424,898 |
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANG Total operating revenues Total operating expenses Operating loss Nonoperating revenues Income (Loss) before other changes in net position Capital grants and transfers Increase in net position Net position, beginning of year Net position, end of year CONDENSED STATEMENT OF CASH FLOWS Net cash provided (used) by: Operating activities | SES IN NET P | POSITION 2,402,911,947 (2,625,670,734) (222,758,787) 415,073,709 192,314,922 25,689,071 218,003,993 2,339,292,264 2,557,296,257 | \$ \$ \$ | (89,767,358) 85,295,129 (4,472,229) 1,012,163 (3,460,066) (128,995,422) (132,455,488) | \$ \$ | (446,297) (446,297) (446,297) (969,577) | \$ \$ \$ \$ \$ | 2,313,144,588 (2,540,375,605 (227,231,016 415,639,575 188,408,555 25,689,07 214,097,630 2,209,327,266 2,423,424,899 (105,779,543 (171,438,508 |
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANG Total operating revenues Total operating expenses Operating loss Nonoperating revenues Income (Loss) before other changes in net position Capital grants and transfers Increase in net position Net position, beginning of year Net position, end of year CONDENSED STATEMENT OF CASH FLOWS Net cash provided (used) by: Operating activities Noncapital financing activities | SES IN NET P | POSITION 2,402,911,947 (2,625,670,734) (222,758,787) 415,073,709 192,314,922 25,689,071 218,003,993 2,339,292,264 2,557,296,257 (97,101,610) (181,985,715) | \$ \$ \$ | (89,767,358) 85,295,129 (4,472,229) 1,012,163 (3,460,066) (128,995,422) (132,455,488) (8,677,933) 10,547,207 | \$ \$ | (446,297) (446,297) (446,297) (969,577) | \$ \$ \$ \$ \$ | 2,313,144,588 (2,540,375,605 (227,231,016 415,639,575 188,408,555 25,689,07 214,097,630 2,209,327,266 2,423,424,895 (105,779,543 (171,438,508 348,365,524 |
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANG Total operating revenues Total operating expenses Operating loss Nonoperating revenues Income (Loss) before other changes in net position Capital grants and transfers Increase in net position Net position, beginning of year Net position, end of year CONDENSED STATEMENT OF CASH FLOWS Net cash provided (used) by: Operating activities Noncapital financing activities Capital and related financing activities Investing activities Net increase (decrease) in cash and cash equivalents | SES IN NET P | POSITION 2,402,911,947 (2,625,670,734) (222,758,787) 415,073,709 192,314,922 25,689,071 218,003,993 2,339,292,264 2,557,296,257 (97,101,610) (181,985,715) 348,775,996 (128,826,360) (59,137,689) | \$ \$ \$ | (89,767,358) 85,295,129 (4,472,229) 1,012,163 (3,460,066) (128,995,422) (132,455,488) (8,677,933) 10,547,207 (410,472) 860,189 2,318,991 | \$ \$ | (446,297) (446,297) (446,297) (969,577) | \$ \$ \$ \$ \$ | 2,313,144,588 (2,540,375,605 (227,231,016 415,639,571 188,408,551 25,689,07 214,097,630 2,209,327,260 2,423,424,899 (105,779,543 (171,438,508 348,365,524 (127,966,171 (56,818,698 |
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANG Total operating revenues Total operating expenses Operating loss Nonoperating revenues Income (Loss) before other changes in net position Capital grants and transfers Increase in net position Net position, beginning of year Net position, end of year CONDENSED STATEMENT OF CASH FLOWS Net cash provided (used) by: Operating activities Noncapital financing activities Capital and related financing activities Investing activities | S S S S S S S | POSITION 2,402,911,947 (2,625,670,734) (222,758,787) 415,073,709 192,314,922 25,689,071 218,003,993 2,339,292,264 2,557,296,257 (97,101,610) (181,985,715) 348,775,996 (128,826,360) | \$ \$ \$ \$ \$ \$ | (89,767,358) 85,295,129 (4,472,229) 1,012,163 (3,460,066) (128,995,422) (132,455,488) (8,677,933) 10,547,207 (410,472) 860,189 | \$ \$ \$ | (446,297) (446,297) (446,297) (969,577) | \$ \$ \$ | 2,313,144,589 (2,540,375,605 (227,231,016 415,639,576 188,408,555 25,689,071 214,097,630 2,209,327,268 |

(4) Cash and Cash Equivalents

The Board approves, by resolution, all banks or other financial institutions utilized as depositories for UAB funds. Prior to approval, each proposed depository must provide evidence of its designation by the Alabama state treasurer as a qualified public depository under the Security for Alabama Funds Enhancement Act (SAFE). From time to time, the Board may request that the depository provide evidence of its continuing designation as a qualified public depository. In the past, the bank pledged collateral directly to each individual public entity. Under the mandatory SAFE program, each qualified public depository (QPD) is required to hold collateral for all its public deposits on a pooled basis in a custody account established for the State Treasurer as SAFE administrator. In the unlikely event a public entity should suffer a deposit loss due to QPD insolvency or default, a claim form would be filed with the state treasurer, who would use the SAFE pool collateral or other means to reimburse the loss.

The System sponsors a short-term investment pool for the System entities to invest operating cash reserves. The Short-Term Fund is invested in a treasury obligation money market fund managed by Federated. As of September 30, 2013, the University, within the Short-Term Fund, had approximately \$118,900,000, all of which was invested in the money market fund. As of September 30, 2012, the University had approximately \$90,100,000 in the Short-Term Fund, all of which was invested in the money market fund. The assets held in the money market fund are presented in cash and cash equivalents and restricted cash and cash equivalents. As of September 30, 2013 and 2012, respectively, UAB had cash and cash equivalents totaling \$339,152,287 and \$268,824,418.

(5) Investments

The Board has the responsibility for the establishment of the investment policy and the oversight of the investments for the System and related entities. In order to facilitate System-wide investment objectives and achieve economies of scale, the Board has established four distinct investment pools based primarily on the projected investment time-horizons for System funds. These investment pools are the Endowment Fund, Prime Fund, Intermediate Fund and the Short-Term Fund (collectively, the "System Pools"). Pursuant to Board investment policies, each System or related entity may include all or a portion of their investments within the System sponsored investment pools. These investment funds are considered 'internal' investment pools under GASB Statement No. 31,

with the assets pooled on a market value basis. Separately managed funds that are resident with each entity are to be invested consistent with the asset mix of the corresponding System investment pool.

UAB applies the same investment policies for separately held investments as those of the System Pools.

The following disclosures relate to both the System Pools, which include the investments of other System entities and other affiliated entities, and the UAB-specific investment portfolio.

Endowment Fund

The purpose of the Endowment Fund is to pool endowment and similar funds to support the System campuses, the Hospital and related entities in carrying out their respective missions over a perpetual time frame. Accordingly, the primary investment objectives of the Endowment Fund are to preserve the purchasing power of the principal and provide a stable source of perpetual financial support to the endowment beneficiaries. To satisfy the longterm rate of return objective, the Endowment Fund relies on a total return strategy in which investment returns are achieved through both capital appreciation and natural income. Asset allocation targets are established to meet return objectives while providing adequate diversification in order to minimize investment volatility. As discussed in Note 1, certain investments within the Endowment Fund are valued at cost, unless impaired. UAB's portion of investments in the Endowment Fund which are measured at cost totaled approximately \$40,600,000 and \$40,100,000 at September 30, 2013 and 2012, respectively.

Prime Fund

The Prime Fund is a longer-term fund used as an investment vehicle to manage operating reserves with a time horizon of seven to ten years. This fund has an investment objective of growth and income and is invested in a diversified asset mix of liquid and semi-liquid securities. This fund is not currently invested in long-term lockup funds with illiquid assets. As discussed in Note 1, certain investments in the Prime Fund are valued at cost, unless impaired. UAB's portion of investments which are measured at cost totaled approximately \$6,600,000 at September 30, 2013 and at September 30, 2012.

Intermediate Fund

The Intermediate Fund serves as an investment vehicle to manage operating reserves with a time horizon of two to six years. This fund is also used to balance the other funds when looking at the System's entire asset allocation of operating reserves relative to its investment objectives. The Intermediate Fund has an investment objective of income with preservation of capital and is invested in intermediate term fixed income securities. System policy states that at least one of the Intermediate Fund investment managers must be a large mutual fund providing daily liquidity.

Short-Term Fund

The Short-Term Fund contains the short-term operating reserves of the various System entities. Because of the different income and disbursement requirements of each entity, consolidation of these funds reduces daily cash fluctuations and minimizes the amount of short-term cash reserves needed. Assets held in the Short-Term Fund are invested with the primary objective of stability of principal and liquidity. Such investments are restricted to high quality, liquid, money market funds and other fixed income obligations with a maturity of one year or less. Refer to Note 4 for additional information related to the Short-Term Fund.

Although the investment philosophy of the Board is to minimize the direct ownership of investment vehicles, preferring ownership in appropriate investment fund groups, there are certain direct investments that are held in the name of the Board. All other investments in the System Pools are classified as commingled funds

The composition of investments, by investment type, for the System Pools at September 30, 2013 is as follows:

| • | END | OWMENT FUND | | PRIME FUND | | INTERMEDIATE FUND | | SHORT TERM FUND |
|---------------------------------------|------|-----------------------|----|--------------|----------|-------------------|----------|-----------------|
| Receivables: | | | | | | | | |
| Accrued Income Receivables | \$ | 1,096,967 | \$ | 651,549 | \$ | 4,056,788 | \$ | |
| TOTAL RECEIVABLES | \$ | 1,096,967 | \$ | 651,549 | \$ | 4,056,788 | \$ | |
| Cash Equivalents: | | | | | | | | |
| Certificates Of Deposit | \$ | | \$ | | \$ | 8,094,239 | \$ | |
| Commercial Paper | | | | | | 2,599,751 | | |
| Money Market Funds | | 56,519,604 | | 50,827,901 | | 69,728,143 | | 201,099,030 |
| TOTAL CASH EQUIVALENTS | \$ | 56,519,604 | \$ | 50,827,901 | \$ | 80,422,133 | \$ | 201,099,030 |
| Equities: | | | | | | | | |
| U.S. Common Stock | \$ | 74,460,258 | \$ | 53,886,837 | \$ | | \$ | |
| U.S. Preferred Stock | | 1,238,188 | | 1,125,625 | | | | |
| Non-U.S. Stock | | 10,624,062 | | 6,771,037 | | | | |
| TOTAL EQUITIES | \$ | 86,322,508 | \$ | 61,783,499 | \$ | | \$ | |
| Fixed Income Securities: | | | | | | | | |
| U.S. Government Obligations | \$ | 21,850,510 | \$ | 11,213,984 | \$ | 317,145,894 | \$ | |
| Muncipal Government Obligations | | | | | | 217,383 | | |
| Mortgage Backed Securities | | | | | | 120,283,662 | | |
| Collarteralized Mortgage Obligations | | | | | | 50,078,274 | | |
| Corporate Bonds | | 59,987,039 | | 30,751,076 | | 343,033,010 | | |
| Non-U.S. Bonds | | | | | | 1,046,990 | | |
| TOTAL FIXED INCOME SECURITIES | \$\$ | 81,837,549 | \$ | 41,965,060 | \$ | 831,805,213 | \$ | |
| Commingled Funds: | • | 400 770 000 | Φ. | 440,000,070 | Φ. | | Φ. | |
| U.S. Equity Funds | \$ | 102,773,998 | \$ | 110,668,279 | \$ | | \$ | |
| Non-U.S. Equity Funds | | 280,637,986 | | 259,399,547 | | 70.077.004 | | |
| U.S. Bond Funds | | 31,464,754 | | 59,945,698 | | 78,977,321 | | |
| Non-U.S. Bond Funds | | 61,765,298 | | 56,698,721 | | | | |
| Hedge Funds | | 153,064,178 | | 120,473,011 | | | | |
| Private Equity Funds Timberland Funds | | 62,791,546 | | | | | | |
| Real Estate Funds | | 16,960 131,161,560 | | 104,551,847 | | | | |
| TOTAL COMMINGLED FUNDS | 6 | | | | <u>_</u> | 70.077201 | <u> </u> | |
| | \$ | 823,676,280 | \$ | 711,737,103 | \$ | 78,977,321 | \$ | 004 6 |
| TOTAL FUND INVESTMENTS | \$ | 1,048,355,941 | \$ | 866,313,563 | \$ | 991,204,667 | \$ | 201,099,030 |
| TOTAL FUND ASSETS | \$ | 1,049,452,908 | \$ | 866,965,112 | \$ | 995,261,455 | \$ | 201,099,030 |
| TOTAL FUND LIABILITIES | \$ | (122,926) | \$ | (85,447) | \$ | (584,144) | \$ | |
| AFFILIATED ENTITY INVESTMENT IN FUNDS | \$ | (138,865,562) | \$ | (53,288,957) | \$ | (88,296,301) | \$ | |
| TOTAL NET ASSET VALUE | \$ | 910,464,420 | \$ | 813,590,708 | \$ | 906,381,010 | \$ | 201,099,030 |

The composition of investments, by investment type, for the System Pools at September 30, 2012 is as follows:

| , | END | OWMENT FUND | PRIME FUND | II | NTERMEDIATE FUND | SHORT TERM FUND |
|---------------------------------------|-----|---------------|--------------------|----|---|-------------------|
| Receivables: | | | | | | |
| Accrued Income Receivables | \$ | 1,007,252 | \$ 610,059 | \$ | 4,047,259 | \$ |
| TOTAL RECEIVABLES | \$ | 1.007.252 | \$ 610.059 | \$ | 4,047,259 | \$ |
| Cash Equivalents: | *. | / / | , | | , | |
| Certificates Of Deposit | \$ | | \$ | \$ | 6,095,374 | \$ |
| Money Market Funds | | 37,622,530 | 25,012,340 | | 117,007,185 | 165,309,391 |
| TOTAL CASH EQUIVALENTS | \$ | 37,622,530 | \$ 25,012,340 | \$ | 123,102,559 | \$ 165,309,391 |
| Equities: | | | , , | | , , | , , |
| U.S. Common Stock | \$ | 71.093.168 | \$ 49,927,229 | \$ | | \$ |
| U.S. Preferred Stock | | 1,031,250 | 937,500 | | | |
| Non-U.S. Stock | | 9,012,235 | 7,038,544 | | | |
| TOTAL EQUITIES | \$ | 81.136.653 | \$ 57,903,273 | \$ | | \$ |
| Fixed Income Securities: | *. | - ,, | - ,, | | | |
| U.S. Government Obligations | \$ | 28,152,015 | \$ 12,728,703 | \$ | 363,188,133 | \$ |
| Muncipal Government Obligations | | , , | | | 6.423.894 | |
| Mortgage Backed Securities | | | | | 50,978,064 | |
| Collarteralized Mortgage Obligations | | 428,837 | 176,195 | | 57,695,598 | |
| Corporate Bonds | | 48,420,651 | 25,691,441 | | 324,568,847 | |
| Non-U.S. Bonds | | -, -, | -, , | | 8,953,326 | |
| TOTAL FIXED INCOME SECURITIES | \$ | 77,001,503 | \$ 38,596,339 | \$ | 811,807,862 | \$ |
| Commingled Funds: | | | | | | |
| U.S. Equity Funds | \$ | 102,545,643 | \$ 99,826,894 | \$ | | \$ |
| Non-U.S. Equity Funds | | 250,230,913 | 220,690,653 | | | |
| U.S. Bond Funds | | 29,518,564 | 55,590,858 | | 118,258,903 | |
| Non-U.S. Bond Funds | | 57,589,079 | 54,429,629 | | | |
| Hedge Funds | | 148,184,664 | 115,874,279 | | | |
| Private Equity Funds | | 61,912,960 | | | | |
| Timberland Funds | | 5,624,452 | | | | |
| Real Estate Funds | | 128,235,796 | 102,617,303 | | | |
| TOTAL COMMINGLED FUNDS | \$ | 783,842,071 | \$ 649,029,616 | \$ | 118,258,903 | \$ |
| TOTAL FUND INVESTMENTS | \$ | 979,602,757 | \$ 770,541,568 | \$ | 1,053,169,324 | \$ 165,309,391 |
| TOTAL FUND ASSETS | \$ | 980,610,009 | \$ 771,151,627 | \$ | 1,057,216,583 | \$ 165,309,391 |
| TOTAL FUND LIABILITIES | \$ | (126,133) | \$ (88,592) | \$ | (481,793) | \$ |
| AFFILIATED ENTITY INVESTMENT IN FUNDS | \$ | (124,786,897) | \$ (51,504,726) | \$ | (77,940,650) | \$ |
| TOTAL NET ASSET VALUE | \$ | 855,696,979 | \$ 719,558,309 | \$ | 978,794,140 | \$ 165,309,391 |

The composition of investments, by investment type, of UAB's separately held investments, and UAB's interest in the System Pools, at September 30, 2013 and 2012 is as follows:

| | | 2013 | | 2012 (Restated) |
|--|--------------|---------------|----|-----------------------|
| Cash and equivalents: | | | | ` , |
| Commercial paper | \$ | 100,000 | \$ | 100,000 |
| Money market funds | | 1,064,724 | | 1,065,477 |
| TOTAL CASH AND EQUIVALENTS | \$ | 1,164,724 | \$ | 1,165,477 |
| E. all | | | | |
| Equities: Common stock | \$ | 1,042 | \$ | 151 700 |
| Equity investment in partnerships | φ | 50,449,513 | Φ | 151,733 38,912,815 |
| TOTAL EQUITIES | \$ | | \$ | |
| TOTAL EQUITIES | <u> </u> | 50,450,555 | \$ | 39,064,548 |
| Fixed Income Securities: | | | | |
| U.S. government obligations | \$ | 71,317,706 | \$ | 50,000,000 |
| Corporate bonds | Ť | 13,831,683 | • | 14,311,980 |
| TOTAL FIXED INCOME SECURITIES | \$ | 85,149,389 | \$ | 64,311,980 |
| | | , , | | |
| Commingled Funds: | | | | |
| U.S. equity funds | \$ | 8,927,430 | \$ | 10,083,093 |
| Non-U.S. equity funds | | 10,285,795 | | 6,955,750 |
| U.S. bond funds | | 3,938,397 | | 4,061,312 |
| Non-U.S. bond funds | | 1,339,360 | | 1,382,863 |
| Liquid alternatives | | 5,244,507 | | 5,130,076 |
| Private equity funds | | 2,517,501 | | 2,510,930 |
| Real estate funds | | 3,839,144 | | 3,804,033 |
| TOTAL COMMINGLED FUNDS | \$ | 36,092,134 | \$ | 33,928,057 |
| REAL ESTATE | \$ | 159,600 | \$ | 259,600 |
| Portion of System Pooled Investments: | - | 159,600 | φ | 259,000 |
| Endowment Fund | \$ | 357,779,788 | \$ | 334,118,822 |
| Prime Fund | Ψ | 561,617,285 | Ψ | 507,361,293 |
| Intermediate Fund | | 610,141,003 | | 574,877,374 |
| Short-Term Fund | | 118,864,217 | | 90,063,756 |
| Total Portion of System Pooled Investments | \$ | 1,648,402,293 | \$ | 1,506,421,245 |
| Total Cash and Investments | \$ | 1,821,418,695 | \$ | 1,645,150,907 |
| Less Short-Term Fund | \$ | 118,864,217 | \$ | 90,063,756 |
| TOTAL INVESTMENTS | \$ | 1,702,554,478 | \$ | 1,555,087,151 |

Investment Risk Factors

There are many factors that can affect the value of investments. Some, such as custodial credit risk, concentration of credit risk and foreign currency risk, may affect both equity and fixed income securities. Equity securities respond to such factors as economic conditions, individual company earnings performance and market liquidity, while fixed income securities are particularly sensitive to credit risks and changes in interest rates.

Credit Risk

Fixed income securities are subject to credit risk, which is the chance that a bond issuer will fail to pay interest or principal in a timely manner, or that negative perceptions of the issuer's ability to make these payments will cause security prices to decline. These circumstances may arise due to a variety of factors such as financial weakness, bankruptcy, litigation, and/or adverse political developments. Certain fixed income securities, primarily obligations of the U.S.

government or those explicitly guaranteed by the U.S. government, are not considered to have significant credit risk.

A bond's credit quality is an assessment of the issuer's ability to pay interest on the bond, and ultimately, to pay the principal. Credit quality is evaluated by one of the independent bond-rating agencies, for example Moody's Investors Service (Moody's) or Standard and Poor's (S&P). The lower the rating, the greater the chance—in the rating agency's opinion—that the bond issuer will default, or fail to meet its payment obligations. Generally, the lower a bond's credit rating, the higher its yield should be to compensate for the additional risk.

Board policy recognizes that a limited amount of credit risk, properly managed and monitored, is prudent and provides incremental risk adjusted return over its benchmark. Credit risk in each investment pool is managed primarily by diversifying across issuers and limiting the amount of portfolio assets that can be invested in non-investment grade securities. Fixed

income holdings in a single entity (excluding obligations of the U.S. government and its agencies) may not exceed 5% of a manager's portfolio measured at market value. At least 95% of these fixed income investments must be in investment grade securities (securities with ratings of BBB- or Baa3) or higher. However, multi-strategy fixed income managers may have up to 20% of their investments in non-investment grade securities. Securities of foreign entities denominated in U.S. dollars are limited to 10% of a manager's portfolio. Securities denominated in currencies other than U.S. dollars are not permissible unless part of a multi-strategy fixed income account where the limitation is 20% of the manager's portfolio.

The investment policy recognizes that credit risk is appropriate in balanced investment pools such as the Endowment and Prime Funds, which are tracked against the Barclays Government Credit Index for U.S. investments and the Citigroup WGBI Index for international investments benchmarks for the fixed income portion of these pools. Fixed income investments within the Endowment and Prime Funds include corporate and U.S. treasury and/or agency bonds with a minimum BBB- rating and an average duration of four years. In addition, approximately \$20,000 in the Endowment Fund at September 30, 2012, is invested in unrated fixed income securities, excluding fixed income commingled funds. Fixed income commingled funds were approximately \$317,200,000 and \$259,800,000 in the Endowment and Prime Funds, at September 30, 2013 and 2012, respectively.

The Intermediate Fund is benchmarked against the 1-3 Year Barclays Government Credit Index with funds invested with four separate fund managers. Fixed income investments include corporate, mortgage backed, asset backed, collateralized mortgage and U.S. treasury and/or agency bonds with an average minimum rating of BB or higher. For September 30, 2013 and 2012, approximately \$135,800,000 and \$63,200,000, respectively, was invested by the Intermediate Fund in unrated fixed income securities, excluding commingled bond funds, money market funds and commercial paper. Fixed income commingled funds and commercial paper totaled approximately \$151,300,000 and \$235,200,000 at September 30, 2013 and 2012, respectively. For September 30, 2013 and 2012, \$8,100,000 and \$6,100,000, respectively, was invested by the Intermediate Fund in certificates of deposit.

The Short-Term Fund is committed to immediate liquidity to meet the operating needs of the System campuses and the Hospital. The Short-Term Fund is invested in a money market fund, which in turn invests mostly in U.S. Treasury Securities and repurchase agreements that are collateralized by U.S. Treasury Securities. These funds are all commingled with funds of other investors. Refer to Note 4 for additional information related to the Short-Term Fund.

The credit risk for fixed and variable income securities, for the System Pools, at September 30, 2013 and 2012 is as follows:

| September | 30, 201 | 3 and | 2012 |
|-----------|---------|-------|------|
| | | | |

| | ENDOWMEN | T FUND | PRIME FU | IND | INTERMEDIAT | ΓE FUND | SHORT TER | M FUND |
|--------------------------------------|----------------|----------------|----------------|----------------|----------------|------------------|----------------|------------|
| | 2013 | 2012 | 2013 | 2012 | 2013 | 2012 | 2013 | 2012 |
| Fixed or Variable Income Securities | | | | | | | | |
| U.S. Government Obligations \$ | 21,850,510 \$ | 28,152,015 \$ | 11,213,984 \$ | 12,728,703 \$ | 317,145,893 \$ | 363,188,133 \$ | \$ | |
| Municipal Government Obligations | | | | | 217,383 | 6,423,894 | | |
| Other U.S. and Non-U.S. Denominated: | | | | | | | | |
| AAA | 1,254,938 | 1,586,686 | 642,291 | 749,786 | 18,861,309 | 30,554,363 | | |
| AA | 11,441,938 | 8,698,140 | 5,792,481 | 4,205,006 | 85,433,796 | 77,971,612 | | |
| A | 27,814,947 | 23,416,600 | 14,242,504 | 12,943,728 | 182,513,978 | 195,302,384 | | |
| BBB | 19,475,216 | 15,128,540 | 10,073,800 | 7,969,116 | 78,670,892 | 61,721,408 | | |
| BB | | | | | 6,740,499 | 9,130,213 | | |
| В | | | | | 3,613,132 | 1,351,313 | | |
| C and < C | | | | | 2,818,596 | 2,939,022 | | |
| Unrated | | 19,522 | | | 135,789,735 | 63,225,520 | | |
| Commingled Funds: | | | | | | | | |
| U.S. Bond Funds: Unrated | 31,464,754 | 29,518,564 | 59,945,698 | 55,590,858 | 78,977,321 | 118,258,903 | | |
| Non-U.S. Bond Funds: Unrated | 61,765,298 | 57,589,079 | 56,698,721 | 54,429,629 | | | | |
| Money Market Funds: Unrated | 56,519,604 | 37,622,530 | 50,827,901 | 25,012,340 | 69,728,143 | 117,007,185 | 201,099,030 | 165,309,39 |
| Commercial Paper: Unrated | | | | | 2,599,751 | | | |
| Certificate of Deposits | | | | | 8,094,239 | 6,095,374 | | |
| TOTAL \$ | 231,587,205 \$ | 201,731,676 \$ | 209,437,380 \$ | 173,629,166 \$ | 991,204,667 \$ | 1,053,169,324 \$ | 201,099,030 \$ | 165,309,39 |

The credit risk for fixed and variable income securities of UAB's separately held investments at September 30, 2013 and 2012 is as follows:

(Restated) Fixed or Variable Income Securities U.S. Government Obligations 71,317,706 \$ 50,000,000 Other U.S. and Non U.S. Denominated: 13,831,683 14,311,980 AAA AA BBB ВВ В CCC CC Unrated Commingled Funds: U.S. Bond Funds: Unrated 3.938.397 4,061,312 Non-U.S. Bond Funds: Unrated 1.339.360 1.382.863

1.064.724

100,000

91,591,870 \$

1.065.477

70,921,632

100.000

Money Market Funds: Unrated

TOTAL

Commercial Paper: Unrated

September 30, 2013 and 2012

Custodial Credit Risk

Custodial credit risk is the risk that in the event of the corporate failure of the custodian, the investment securities may not be returned.

Investment securities in the System Pools and UAB's separately held investments are registered in the Board's name by the custodial bank as an agent for the System. Other types of investments (e.g. openended mutual funds, money market funds) represent ownership interests that do not exist in physical or book-entry form. As a result, custodial credit risk is remote.

Concentration of Credit Risk

Concentration of credit risk is the risk associated with a lack of diversification, such as having substantial investments in a few individual issuers, thereby exposing the organization to greater risks resulting from adverse economic, political, regulatory, geographic, or credit developments.

As previously mentioned, credit risk in each investment pool and UAB's separately held portfolio is managed primarily by diversifying across issuers and limiting the amount of portfolio assets that can be invested in non-investment grade securities. As of September 30, 2013 and 2012, there was no investment in a single issuer that represents 5% or more of

total investments held by any single investment manager of the System Pools or UAB's separately held investment portfolio except for investments issued by the U.S. government and money market investments held by the Short Term Fund.

Interest Rate Risk

Interest rate risk is the risk that the value of fixed income securities will decline because of changing interest rates. The prices of fixed income securities with a longer time to maturity, measured by effective duration, tend to be more sensitive to changes in interest rates and, therefore, more volatile than those with shorter durations. Effective duration is the approximate change in price of a security resulting from a 100 basis point (1 percentage point) change in the level of interest rates. It is not a measure of time. The Board does not have a specific policy relative to interest rate risk. As such, there are no restrictions on weighted average maturity for each portfolio as they are managed relative to the investment objectives and liquidity demands of the investors.

The information presented does not take into account the relative weighting of the portfolio components to the total portfolio. The effective durations for fixed or variable income securities, for the System Pools at September 30, 2013 and 2012 are as follows:

| September 30, 2013 and 2012 | ENDOWM | ENT FUND | PRIME | FUND | INTERMED | IATE FUND |
|----------------------------------|--------|----------|-------|------|----------|-----------|
| | 2013 | 2012 | 2013 | 2012 | 2013 | 2012 |
| U.S. Government Obligations | 5.6 | 5.0 | 5.4 | 5.5 | 1.8 | 1.9 |
| Corporate Bonds | 4.2 | 5.4 | 4.2 | 5.2 | 1.5 | 1.7 |
| Commingled Bond Funds | 1.5 | 0.6 | 2.3 | 1.5 | 2.3 | 2.3 |
| Municipal Government Obligations | | | | | 0.2 | 1.8 |
| Non-U.S. Bonds | | | | | 1.5 | 1.7 |

There are no fixed or variable income securities in the Short-Term Fund at September 30, 2013 and 2012.

While the Board does not have a specific policy relative to interest rate risk, UAB has historically invested funds outside of the investment pools in fixed income and variable income securities with short maturity terms.

The effective durations for fixed or variable income securities for UAB's separately held investments at September 30, 2013 and 2012 are as follows:

| September 30, 2013 and 2012 | | | | | | | | | |
|-----------------------------|------|------|--|--|--|--|--|--|--|
| | 2013 | 2012 | | | | | | | |
| Commingled Bond Funds | 3.0 | 2.2 | | | | | | | |
| U.S. Government Obligations | 1.1 | | | | | | | | |
| | | | | | | | | | |

Investments may also include mortgage pass through securities and collateralized mortgage obligations that may be considered to be highly sensitive to changes in interest rates due to the existence of prepayment or conversion features. At September 30, 2013 and 2012, the fair market values of these investments in the System Pools are as follows:

| September 30, 2013 | ar | nd 2012 | | | | | | | |
|---------------------------------------|----|-----------|---------|------|--------|---------|-------------------|-----|-------------|
| · · · · · · · · · · · · · · · · · · · | | ENDOWMENT | FUND | PRIM | IE FUN | D | INTERMEDI | ATE | FUND |
| | | 2013 | 2012 | 2013 | | 2012 | 2013 | | 2012 |
| Mortgage Backed Securities | \$ | \$ | | \$ | \$ | | \$ 120,283,662 | \$ | 50,978,064 |
| Collateralized Mortgage Obligations | | | 428,837 | | | 176,195 | 50,078,274 | | 57,695,598 |
| TOTAL | \$ | \$ | 428,837 | \$ | \$ | 176,195 | \$ 170,361,936 | \$ | 108,673,662 |

Mortgage Backed Securities. These securities are issued by the Federal National Mortgage Association (Fannie Mae), Government National Mortgage Association (Ginnie Mae) and Federal Home Loan Mortgage Association (Freddie Mac) and include short embedded prepayment options. Unanticipated prepayments by the obligees of the underlying asset reduce the total expected rate of return.

Collateralized Mortgage Obligations. Collateralized mortgage obligations (CMOs) generate a return based upon either the payment of interest or principal on

mortgages in an underlying pool. The relationship between interest rates and prepayments makes the fair value highly sensitive to changes in interest rates. In falling interest rate environments, the underlying mortgages are subject to a higher propensity of prepayments. In a rising interest rate environment, the opposite is true.

At September 30, 2013 and 2012, the effective durations for these securities held in the System Pools are as follows:

| September 30, 2013 and 2012 | ENDOWM | ENT FUND | PRIME | FUND | INTERMED | IATE FUND |
|-------------------------------------|--------|----------|-------|------|----------|-----------|
| | 2013 | 2012 | 2013 | 2012 | 2013 | 2012 |
| Mortgage backed securities | | | | | 0.7 | 1.7 |
| Collateralized mortgage obligations | | 2.6 | | 2.7 | 1.0 | 1.1 |

There are no mortgage backed securities or CMOs in the Short Term Fund at September 30, 2013 and 2012.

There are no mortgage backed securities or CMOs in UAB's separately held investments at September 30, 2013 and 2012.

Foreign Currency Risk

The strategic asset allocation policy for the Endowment Fund, the Prime Fund, and UAB's separately held investments includes an allocation to non-United States equity and fixed income securities. Each international equity manager must hold a minimum of 30 individual stocks with equity holdings in a single company remaining below 8% of the investment manager's portfolio, measured at market value. Currency hedging of foreign bonds and stocks is allowed under System policy. As of September 30, 2013 and 2012, all foreign investments in the System Pools and UAB's separately held investments are denominated in U.S. dollars and are in international commingled funds, which in turn invest in equity securities and bonds of foreign issuers except for approximately \$1.0 and \$8.9 million of foreign bonds denominated in U.S. dollars and held by the Intermediate Fund at September 30, 2013 and 2012, respectively.

Securities Lending

Board policies permit security lending as a mechanism to augment income. Loans of the securities are required to be collateralized by cash, letters of credit or securities issued or guaranteed by the U.S. Government or its agencies. The collateral must equal at least 102% of the current market value of the loaned securities. Securities lending contracts must state acceptable collateral for securities loaned, duties of the borrower, delivery of loaned securities and acceptable investment of the collateral.

At September 30, 2013 and 2012, there were no securities on loan from the investment pools.

Joint Ventures

UAB accounts for its ownership of the PLTF as a joint venture, using the equity method in the amount of approximately \$50,450,000 and \$38,913,000 at September 30, 2013 and 2012, respectively. See note 20 for further discussion of the PLTF.

(6) Accounts Receivable

The composition of accounts receivable at September 30, 2013 and 2012 is summarized as follows:

| | ; | 2013 | 2012 (RESTATED) |
|---|----|-------------|--------------------|
| Patient care | \$ | 316,232,867 | \$ 275,701,352 |
| Receivables from sponsoring agencies | | 59,222,421 | 57,633,120 |
| Student accounts | | 21,573,744 | 12,621,641 |
| Other | | 26,063,161 | 21,157,202 |
| | \$ | 423,092,193 | \$ 367,113,315 |
| Less: Provision for doubtful acocunts from patient care | | 159,237,478 | 149,925,173 |
| Less: Provision for doubtful accounts from student accounts | | 1,556,559 | 1,537,193 |
| Less: Provision for doubtful accounts other | | 1,546,472 | 1,513,680 |
| Total accounts receivable | \$ | 260,751,683 | \$ 214,137,269 |



The composition of loans and pledges receivable at September 30, 2013 and 2012, is summarized in the table.

The principal repayment and interest rate terms of federal and university loans vary considerably. The allowance for doubtful accounts only applies to University-funded notes and the University portion of federal student loans, since the University is not ob-

ligated to fund the federal portion of uncollected student loans. Federal loan programs are funded principally with federal advances to UAB under the Perkins and various health professions loan programs.

Pledges for permanent endowments do not meet eligibility requirements, as defined by GASB Statement No. 33, until the related gift is received. Due to uncertainties with regard to their realization and valuation, bequest intentions and other conditional promises are not recognized as assets until the specified conditions are met.

| LOANS RECEIVABLE: | | 2013 | 2012 |
|--|----|------------|------------------|
| Federal loan program | \$ | 17,367,247 | \$ 17,802,292 |
| University loan funds | | 1,999,468 | 1,941,183 |
| Other | | 992,312 | 1,254,042 |
| Total loans receivable | \$ | 20,359,027 | \$ 20,997,517 |
| Less allowance for doubtful accounts | | 2,460,058 | 2,300,116 |
| Total loans receivable, net | \$ | 17,898,969 | \$ 18,697,401 |
| Less: current portion | | 2,312,259 | 2,403,659 |
| Total loans receivable outstanding, noncurrent | \$ | 15,586,710 | \$ 16,293,742 |
| GIFT PLEDGES OUTSTANDING: | | | |
| Operations | \$ | 12,344,563 | \$ 12,120,132 |
| Capital | | 7,308,139 | 7,431,019 |
| Total gift pledges | \$ | 19,652,702 | \$ 19,551,151 |
| Less: current portion | | 8,315,206 | 7,429,210 |
| Total gift pledges, noncurrent | • | 11,337,496 | \$ 12.121.941 |

(8) Capital Assets

Capital assets activity for the years ended September 30, 2013 and 2012 is summarized on the following 2 tables:

Net interest costs capitalized for the University and Component Units in 2013 and 2012, respectively, were approximately \$2,717,000 and \$3,049,000 (net of \$1,240,000 and \$912,000 investment earnings in 2013 and 2012, respectively). There were no net interest costs capitalized in 2013 or 2012 for the Hospital.

| , , , , , , , , , , , , , , , , , , , | BEG | INNING BALANCE | | ADDITIONS | | SALES/RETIREMENTS/ | | ENDING BALANCE |
|--|-------|----------------|----|-------------|----|---|----|---------------------------------------|
| UNIVERSITY AND COMPONENT UNITS | | (RESTATED) | | | | TRANSFERS | | |
| Capital assets not being depreciated | | | | | | | | |
| Land | \$ | 57.225.762 | \$ | 17,866,026 | \$ | | \$ | 75.091.788 |
| Construction in progress | • | 91.610.079 | Ÿ | 15,266,892 | Ψ. | 85,418,242 | Ψ | 21,458,729 |
| Concudation in progress | s | 148,835,841 | \$ | 33,132,918 | \$ | 85,418,242 | s | 96,550,517 |
| Capital assets being depreciated | Ť | , | | ,, | _ | ,, | • | ,, |
| Land Improvements | \$ | 24.183.330 | \$ | 1,594,491 | \$ | | \$ | 25,777.82 |
| Buildings | Ť | 1,120,451,449 | • | 176,702,373 | _ | 12,946,398 | • | 1,284,207,42 |
| Fixed Equipment Systems | | 48,043,336 | | 1,316,420 | | 6,928,391 | | 42,431,36 |
| Equipment | | 375,058,133 | | 17,370,182 | | 1,307,505 | | 391,120,81 |
| Library Materials | | 93,442,514 | | 3,297,826 | | 1,201,000 | | 96,740,34 |
| | \$ | 1,661,178,762 | \$ | 200,281,292 | \$ | 21,182,294 | \$ | 1,840,277,76 |
| Total Capital Assets | \$ | 1,810,014,603 | \$ | 233,414,210 | _ | 106,600,536 | \$ | 1,936,828,27 |
| Less: Accumulated Depreciation | | 1,007,432,609 | | 40,459,249 | | 15,981,839 | | 1,031,910,01 |
| Total Net Capital Assets | \$ | 802,581,994 | \$ | 192,954,961 | \$ | 90,618,697 | \$ | 904,918,25 |
| HOSPITAL | • | | | | | | | , , , , , , , , , , , , , , , , , , , |
| Capital assets not being depreciated | | | | | | | | |
| Land | \$ | 19,044,954 | \$ | | \$ | | \$ | 19,044,95 |
| Construction in progress | | 7,446,251 | | 7,845,385 | | 1,371,288 | | 13,920,34 |
| | s | 26,491,205 | \$ | 7,845,385 | \$ | 1,371,288 | \$ | 32,965,30 |
| Capital assets being depreciated | · | -, - , | | ,, | · | , | · | ,,,,,, |
| Land Improvements | \$ | 537,526 | \$ | 87,203 | \$ | | \$ | 624,72 |
| Buildings | · | 835,208,553 | • | 7,692,056 | · | | · | 842,900,60 |
| Fixed Equipment Systems | | 10,002,839 | | , , | | | | 10,002,83 |
| Equipment | | 354,745,244 | | 32,508,036 | | 2,768,320 | | 384,484,96 |
| The Property of the Control of the C | \$ | 1,200,494,162 | \$ | 40,287,295 | \$ | 2.768.320 | \$ | 1,238,013,13 |
| Total Capital Assets | \$ | 1,226,985,367 | \$ | 48,132,680 | \$ | 4.139.608 | \$ | 1,270,978,43 |
| Less: Accumulated Depreciation | · | 595,885,983 | • | 57,843,816 | · | 2,717,026 | · | 651,012,77 |
| Total Net Capital Assets | s | 631,099,384 | \$ | (9,711,136) | \$ | 1,422,582 | \$ | 619,965,66 |
| TOTAL UAB | · · · | | | (3)) = 3/ | Ė | , | | |
| Capital assets not being depreciated | | | | | | | | |
| Land | \$ | 76,270,716 | \$ | 17,866,026 | \$ | | \$ | 94,136,74 |
| Construction in progress | | 99,056,330 | | 23,112,277 | | 86,789,530 | | 35,379,07 |
| | \$ | 175,327,046 | \$ | 40,978,303 | \$ | 86,789,530 | \$ | 129,515,81 |
| Capital assets being depreciated | | .,,. | | .,, | | , ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | | .,,. |
| Land Improvements | \$ | 24.720.856 | \$ | 1.681.694 | \$ | | \$ | 26.402.55 |
| Buildings | · | 1.955.660.002 | • | 184,394,429 | · | 12.946.398 | · | 2.127.108.03 |
| Fixed Equipment Systems | | 58.046.175 | | 1,316,420 | | 6.928.391 | | 52,434,20 |
| Equipment | | 729.803.377 | | 49,878,218 | | 4.075.825 | | 775,605,77 |
| Library Materials | | 93,442,514 | | 3,297,826 | | .,,0,020 | | 96,740,34 |
| | \$ | 2,861,672,924 | \$ | 240,568,587 | \$ | 23,950,614 | \$ | 3,078,290,89 |
| Total Capital Assets | \$ | 3,036,999,970 | \$ | 281,546,890 | \$ | 110,740,144 | \$ | 3,207,806,71 |
| Less: Accumulated Depreciation | • | 1,603,318,592 | Ť | 98,303,065 | Ψ. | 18,698,865 | ~ | 1,682,922,79 |
| Total Net Capital Assets | \$ | 1,433,681,378 | \$ | 183,243,825 | \$ | 92,041,279 | \$ | 1,524,883,92 |

| UNIVERSITY AND COMPONENT UNITS | | (RESTATED) | (RESTATED) | SALES/RETIREMENTS/ TRANSFERS (RESTATED) | | | (RESTATED) |
|--|----|--------------------------------|---------------------------------|---|---------------------------------|----|--------------------------------|
| | | | | | , | | |
| Capital assets not being depreciated | | | | | | | |
| Land | \$ | 47,722,663 | \$ 10,163,099 | \$ | 660,000 | \$ | 57,225,762 |
| Construction in progress | | 36,549,097 | 67,964,923 | | 12,903,941 | | 91,610,079 |
| | \$ | 84,271,760 | \$ 78,128,022 | \$ | 13,563,941 | \$ | 148,835,841 |
| Capital assets being depreciated | | | | | | | |
| Land Improvements | \$ | 22,132,510 | \$ 2,050,820 | \$ | | \$ | 24,183,330 |
| Buildings | | 1,105,433,812 | 18,963,223 | | 3,945,586 | | 1,120,451,449 |
| Fixed Equipment Systems | | 46,068,563 | 1,974,773 | | | | 48,043,336 |
| Equipment | | 377,874,390 | 14,745,014 | | 17,561,271 | | 375,058,133 |
| Library Materials | | 90,131,630 | 3,310,884 | | | | 93,442,514 |
| | \$ | 1,641,640,905 | \$ 41,044,714 | \$ | 21,506,857 | \$ | 1,661,178,762 |
| Total Capital Assets | \$ | 1,725,912,665 | \$ 119,172,736 | \$ | 35,070,798 | \$ | 1,810,014,603 |
| Less: Accumulated Depreciation | | 958,142,343 | 67,505,834 | | 18,215,568 | | 1,007,432,609 |
| Total Net Capital Assets | \$ | 767,770,322 | \$ 51,666,902 | \$ | 16,855,230 | \$ | 802,581,994 |
| HOSPITAL | | | | | | | |
| Capital assets not being depreciated | | | | | | | |
| Land | \$ | -, -, | \$ | \$ | 425,532 | \$ | 19,044,954 |
| Construction in progress | | 9,152,554 | 5,378,341 | | 7,084,644 | | 7,446,25 |
| | \$ | 28,623,040 | \$ 5,378,341 | \$ | 7,510,176 | \$ | 26,491,205 |
| Capital assets being depreciated | | | | | | | |
| Land Improvements | \$ | 340,061 | \$ \$197,465 | \$ | | \$ | 537,526 |
| Buildings | | 823,167,504 | 12,041,049 | | | | 835,208,550 |
| Fixed Equipment Systems | | 10,002,839 | | | | | 10,002,839 |
| Equipment | | 334,595,514 | 22,138,603 | | 1,988,873 | | 354,745,244 |
| | \$ | 1,168,105,918 | \$ 34,377,117 | | 1,988,873 | \$ | 1,200,494,162 |
| Total Capital Assets | \$ | 1,196,728,958 | \$ 39,755,458 | \$ | 9,499,049 | \$ | 1,226,985,367 |
| Less: Accumulated Depreciation | | 542,513,377 | 55,542,120 | | 2,169,514 | | 595,885,983 |
| Total Net Capital Assets | \$ | 654,215,581 | \$ (15,786,662) | \$ | 7,329,535 | \$ | 631,099,384 |
| TOTAL UAB | | | | | | | |
| Capital assets not being depreciated | | | | | | | |
| Land | \$ | - , , - | \$ -,, | \$ | 1,085,532 | \$ | 76,270,71 |
| Construction in progress | | 45,701,651 | 73,343,264 | | 19,988,585 | | 99,056,33 |
| | \$ | 112,894,800 | \$ 83,506,363 | \$ | 21,074,117 | \$ | 175,327,040 |
| Capital assets being depreciated | _ | | | | | | |
| Land Improvements | \$ | 22,472,571 | \$ \$2,248,285 | \$ | | \$ | 24,720,856 |
| Buildings | | 1,928,601,316 | 31,004,272 | | 3,945,586 | | 1,955,660,002 |
| Fixed Equipment Systems | | 56,071,402 | 1,974,773 | | | | 58,046,175 |
| Equipment | | 712,469,904 | 36,883,617 | | 19,550,144 | | 729,803,377 |
| Library Materials | | 90,131,630 | 3,310,884 | | | _ | 93,442,514 |
| T. 1.10. 11.14 | \$ | 2,809,746,823 | \$ 75,421,831 | \$ | 23,495,730 | \$ | 2,861,672,924 |
| Total Capital Assets | \$ | 2,922,641,623 | \$ 158,928,194 | \$ | 44,569,847 | \$ | 3,036,999,970 |
| Less: Accumulated Depreciation Total Net Capital Assets | | 1,500,655,720 1,421,985,903 | \$ 123,047,954 35,880,240 | \$ | 20,385,082 24,184,765 | \$ | 1,603,318,592 1,433,681,378 |

(9) Long-Term Debt

Long-term debt activity for the years ended September 30, 2013 and 2012 is summarized as follows:

A portion of UAB's long term debt has been issued with variable interest rates. The interest rates are determined in accordance with the individual related indenture of the related outstanding debt. UAB's bonds are collateralized by pledged revenues as defined in the applicable indentures.

September 30, 2013

| UNIVERSITY | BEGINNING BALANCE (RESTATED) | | NEW DEBT | | PRINCIPAL EPAYMENT | | ENDING BALANCE |
|---|------------------------------------|----|-------------|----|-----------------------|----|-------------------|
| Leases Payable for purchase of equipment, 4.55% to 5.04%, due various dates through 2013 | \$ 41,805 | \$ | | \$ | 41,805 | \$ | |
| Birmingham General Revenue Bonds Series 1993B, variable rate interest(0.2% at September 30, 2013), due annually through 2014 | 2,200,000 | | | | 1,100,000 | | 1,100,000 |
| Birmingham General Revenue Bonds Series 2002, 3.0% to 3.8%, due annually through 2014 | 2,370,000 | | | | 1,165,000 | | 1,205,000 |
| Birmingham General Revenue Bonds Series 2003A, 3.4% to 4.5% due annually through 2030 | 52,600,000 | | | | 49,840,000 | | 2,760,000 |
| Birmingham General Revenue Bonds Series 2005A, 4.0% to 5.0% due annually from 2007 through 2021 | 35,555,000 | | | | 4,685,000 | | 30,870,000 |
| Birmingham General Revenue Bonds Series 2005B, 4.0% to 4.5% due annually through 2028 | 44,505,000 | | | | 2,250,000 | | 42,255,000 |
| Birmingham General Revenue Bonds Series 2010A, 2.0% to 4.5% due annually through 2041 | 53,930,000 | | | | 660,000 | | 53,270,000 |
| Birmingham General Revenue Bonds Series 2010B, 1.0% to 5.8% due annually through 2041 | 52,785,000 | | | | 180,000 | | 52,605,000 |
| Birmingham General Revenue Bonds Series 2010C, 2.0% to 4.0% due annually through 2028 | 30,068,209 | | | | 2,765,045 | | 27,303,164 |
| Birmingham General Revenue Bonds Series 2013A1, 1.1.% due annually through 2020 | | | 19,195,000 | | | | 19,195,000 |
| Birmingham General Revenue Bonds Series 2013A2, 2.25% to 5.0% due annually through 2044 | | | 72,595,000 | | | | 72,595,000 |
| Birmingham General Revenue Bonds Series 2013B, 1.99% due annually through 2029 | | | 45,190,000 | | | | 45,190,000 |
| Birmingham General Revenue Bonds Series 2013C, 1.0% to 1.45% due annually through 2019 | | | 3,095,000 | | | | 3,095,000 |
| Birmingham General Revenue Bonds Series 2013D1, 1.97% due annually through 2023 | | | 20,425,000 | | | | 20,425,000 |
| Birmingham General Revenue Bonds Series 2013D2, 4.0% to 5.0% due annually through 2044 | | | 78,325,000 | | | | 78,325,000 |
| | \$ 274,055,014 | \$ | 238,825,000 | \$ | 62,686,850 | \$ | 450,193,164 |
| Less (Plus): unamortized bond discount (premium) | | | | | | | (2,390,311) |
| TOTAL UNIVERSITY DEBT | | | | | | \$ | 452,583,475 |
| Less: current portion | | | | | | | 16,010,937 |
| TOTAL UNIVERSITY DEBT, NONCURRENT | | | | | | \$ | 436,572,538 |
| | | | | | | | |
| | | | | | | | |
| HOSPITAL | | _ | | _ | | _ | |
| Lease Payable, 3.75% due monthly through 2020 | \$ 3,754,143 | \$ | | \$ | 590,801 | \$ | 3,163,342 |
| Birmingham Hospital Revenue Bonds Series 2004A, 5.0% due annually through 2014 | 10,155,000 | | | | 4,955,000 | | 5,200,000 |
| Birmingham Hospital Revenue Bonds Series 2006A, 4.% due annually through 2041 | 242,045,000 | | | | 865,000 | | 241,180,000 |
| Birmingham Hospital Revenue Bonds Series 2008A, 4% to 5.75% due annually through 2025 | 101,080,000 | | | | 1,955,000 | | 99,125,000 |
| Birmingham General Revenue Bonds Series 2010C, 2.0% to 4.0% due annually through 2018 | 1,421,791 | | | | 219,955 | | 1,201,836 |
| Birmingham Hospital Revenue Bonds Series 2012A, 2.57% due annually through 2027 | 20,580,000 | | | | 1,132,000 | | 19,448,000 |
| Birmingham Hospital Revenue Bonds Series 2012B, variable interest rate (0.06% at September 30, 2013), due annually through 2042 | 65,000,000 | | | | | | 65,000,000 |
| Birmingham Hospital Revenue Bonds Series 2012C, variable interest rate (0.07% at September 30, 2013), due annually through 2042 | 65,000,000 | | | | | | 65,000,000 |
| | \$ 509,035,934 | \$ | | \$ | 9,717,756 | \$ | 499,318,178 |
| Less (Plus): unamortized bond discount (premium) | | | | | | | (4,203,746) |
| TOTAL HOSPITAL DEBT | | | | | | | 503,521,924 |
| Less: current portion | | | | | | | 10,147,512 |
| TOTAL HOSPITAL DEBT, NONCURRENT | | | | | | \$ | 493,374,412 |
| | | | | | | | |
| | | | | | | | |
| TOTAL UAB | \$ 783,090,948 | \$ | 238,825,000 | \$ | 72,404,606 | \$ | 949,511,342 |
| Less (Plus): unamortized bond discount (premium) | | | | | | | (6,594,057) |
| TOTAL UAB DEBT | | | | | | | 956,105,399 |
| Less: current portion | | | | | | | 26,158,449 |
| TOTAL UAB DEBT, NONCURRENT | | | | | | \$ | 929,946,950 |

| Lasse Payable for purchase of equipment, 45% is 0.04%, due various dashe Prough 2013 \$ 1.42,462 \$ 1.00,507 \$ 1.00,000 2.200 | | | | | | |
|---|---|---|----------------|--|--------------------------------------|--|
| UNIVERSITY Leases Playable for purchase of equipment, 4.55% to 5.04%, due various dates through 2013 Eleminghan General Revenue Bonds Series 1993B, variable rate interset(0.375% at September 90, 2012), due annually through 2014 Eleminghan General Revenue Bonds Series 1993B, variable rate interset(0.375% at September 90, 2012), due annually through 2014 Eleminghan General Revenue Bonds Series 1993B, variable rate interset(0.375% at September 90, 2012), due annually through 2014 Eleminghan General Revenue Bonds Series 1993B, variable rate interset(0.375% at September 90, 2012), due annually through 2019 Eleminghan General Revenue Bonds Series 1993B, variable rate interset(0.375% at September 90, 2012), due annually through 2019 Eleminghan General Revenue Bonds Series 2010A, 476 to 5.05% due annually through 2029 Eleminghan General Revenue Bonds Series 2010B, 476 to 5.05% due annually through 2029 Eleminghan General Revenue Bonds Series 2010B, 476 to 4.55% due annually through 2029 Eleminghan General Revenue Bonds Series 2010B, 476 to 4.55% due annually through 2029 Eleminghan General Revenue Bonds Series 2010B, 476 to 4.55% due annually through 2029 Eleminghan General Revenue Bonds Series 2010B, 476 to 4.55% due annually through 2029 Eleminghan General Revenue Bonds Series 2010B, 476 to 4.55% due annually through 2028 Eleminghan General Revenue Bonds Series 2010B, 476 to 4.55% due annually through 2029 Eleminghan General Revenue Bonds Series 2010B, 476 to 4.55% due annually through 2029 Eleminghan General Revenue Bonds Series 2010B, 476 to 4.55% due annually through 2029 Eleminghan General Revenue Bonds Series 2010B, 476 to 4.55% due annually through 2014 Eleminghan Hospital Revenue Bonds Series 2010B, 476 to 4.55% due annually through 2014 Eleminghan Hospital Revenue Bonds Series 2010B, 476 to 4.55% due annually through 2014 Eleminghan Hospital Revenue Bonds Series 2010B, 476 to 4.55% due annually through 2015 Eleminghan Hospital Revenue Bonds Series 2010B, 476 to 4.55% due annually through | September 30, 2012 | | | | | |
| MINURE PRY | | | | | | ENDING |
| NUMERSTY Concess Physible for prochase of equipment, 4.55% to 5.01%, due various dates through 2013 \$1.02.462 \$1.00.000 \$1.00.000 \$2.00 | | | | | | |
| Lasse Psyable for purchase of quipment, 45% is 0.04%, due various distelle mirrogin 2015 | | | | | | |
| Bimingham General Revenue Ponds Series 19381, windshe met Interestin 32, and 1, 200, 200 1,000, 200, 200, 200, 200, 200, 200, 20 | | ` , | ` , | • | , | (RESTATED) |
| Birmingham General Revenue Bonds Series 2002, 3.9% to 3.8%, due annually through 2019 5.9.85 to 0.0% 5.2.80 to 0.0% 5 | | \$ | \$ | | | |
| Brimingham General Revenue Bonds Series 2005A, 34% to 45% due annually mrough 2021 | | | | | | 2,200,000 |
| Brindingtam General Revenue Bonds Series 2008.4, 47% to 50% due annually through 2026 | | | | | | 2,370,000 |
| Birmingham General Reverue Bonds Series 2008.4, 20% to 4.5% due annually through 2041 | | | | | | 52,600,000 |
| Brindingsian General Revenue Bonds Series 2010A, 20% in 45% due annually through 2041 | · · · · · · · · · · · · · · · · · · · | | | ,, | | 44,505,000 |
| Birmingham General Revenue Bonds Series 20106, 10% to 5.8% due annually through 2021 2.89,280,404 1.90,000 52,78 1.90 | | | | | | 53,930,000 |
| Pemingham General Reverue Bonds Series 2010C. 2 0% to 4.0% due annually through 2028 \$28,080,404 \$15,25,309 \$274,055 \$28,005 | | | | | | 52,785,000 |
| Sab 280,804 \$ \$ \$ \$ \$ \$ \$ \$ \$ | | | | | | 30,068,209 |
| TOTAL UNIVERSITY DEBT | | \$ | \$ | | | |
| PROSPITAL | Less (Plus): unamortized bond discount (premium) | | | | | (2,046,918) |
| HOSPITAL Lease Payable, 3.75% due monthly through 2020 \$ 4.334,690 \$ \$ \$580,547 \$ \$ 3.75 Birmingham Hospital Revenue Bonds Series 2006A, 4.% due annually through 2014 14.875,000 4.720,000 10.15 Birmingham Hospital Revenue Bonds Series 2008A, 4.% due annually through 2014 242,975,000 40,000,000 Birmingham Hospital Revenue Bonds Series 2008A, 4.% due annually through 2013 40,000,000 40,000,000 Birmingham Hospital Revenue Bonds Series 2008A, 4.% to 5.75% due annually through 2025 102,830,000 1,750,000 Birmingham Hospital Revenue Bonds Series 2008A, 4.% to 5.75% due annually through 2025 102,830,000 109,930,000 Birmingham Hospital Revenue Bonds Series 2012A, 2.57% due annually through 2025 102,830,000 109,930,000 Birmingham Hospital Revenue Bonds Series 2012A, 2.57% due annually through 2028 1,647,058 225,267 1,42 Birmingham Hospital Revenue Bonds Series 2012A, 2.57% due annually through 2027 20,580,000 25,588 Birmingham Hospital Revenue Bonds Series 2012A, 2.57% due annually through 2027 20,580,000 65,000 Birmingham Hospital Revenue Bonds Series 2012C, variable interest rate (0.17% at September 30, 2012), due annually through 2042 65,000,000 65,000 Birmingham Hospital Revenue Bonds Series 2012C, variable interest rate (0.17% at September 30, 2012), due annually through 2042 65,000,000 65,000 Birmingham Hospital Revenue Bonds Series 2012C, variable interest rate (0.17% at September 30, 2012), due annually through 2042 65,000,000 65,000 Birmingham Hospital Revenue Bonds Series 2012C, variable interest rate (0.17% at September 30, 2012), due annually through 2042 65,000,000 65,000 Birmingham Hospital Revenue Bonds Series 2012C, variable interest rate (0.17% at September 30, 2012), due annually through 2042 65,000,000 65,000 Birmingham Hospital Revenue Bonds Series 2012C, variable interest rate (0.17% at September 30, 2012), due annually through 2042 65,000,000 65,000 65,000 Birmingha | TOTAL UNIVERSITY DEBT | | | | \$ | 276,101,932 |
| HOSPITAL Lease Payable, 3.75% due monthly through 2020 \$ 4.334,690 \$ \$ 580,547 \$ 3.75 Birmingham Hospital Revenue Bonds Series 2004A, 5.0% due annually through 2014 \$ 14,875,000 \$ 4,720,000 \$ 10,15 Birmingham Hospital Revenue Bonds Series 2006A, 4.% due annually through 2014 \$ 40,000,000 \$ 40,000,000 \$ 40,000,000 \$ 10,15 Birmingham Hospital Revenue Bonds Series 2008A, 4% due annually through 2019 \$ 40,000,000 \$ 10,2830,000 \$ 1,755,000 \$ 10,108 Birmingham Hospital Revenue Bonds Series 2008A, 4% to 5.75% due annually through 2025 \$ 102,830,000 \$ 109,930,000 | Less: current portion | | | | | 15,516,849 |
| Lease Payable, 3.75% due monthly through 2020 \$ 4,334,690 \$ 580,547 \$ 3,755 Birmingham Hospital Revenue Bonds Series 2004A, 5.0% due annually through 2014 14,875,000 4,720,000 10,155 Birmingham Hospital Revenue Bonds Series 2006A, 4.% due annually through 2013 40,000,000 40,000,000 Birmingham Hospital Revenue Bonds Series 2008A, 4% to 5.75% due annually through 2025 102,830,000 109,930,000 Birmingham Hospital Revenue Bonds Series 2008B, variable interest due annually through 2025 109,930,000 109,930,000 Birmingham Hospital Revenue Bonds Series 2008B, variable interest rate, due annually through 2025 1,750,000 109,930,000 Birmingham Hospital Revenue Bonds Series 2008B, variable interest rate, due annually through 2028 1,647,058 22,580,000 Birmingham Hospital Revenue Bonds Series 2012A, 2.57% due annually through 2027 20,580,000 225,267 1,42 Birmingham Hospital Revenue Bonds Series 2012B, variable interest rate (0.17% at September 30, 2012), due annually through 2042 65,000,000 65,000 Birmingham Hospital Revenue Bonds Series 2012B, variable interest rate (0.17% at September 30, 2012), due annually through 2042 65,000,000 65,000 Birmingham Hospital Revenue Bonds Series 2012B, variable interest rate (0.17% at September 30, 2012), due annually through 2042 516,591,748 510,580,000 518,135,814 509,038 Birmingham Hospital Revenue Bonds Series 2012B, variable interest rate (0.17% at September 30, 2012), due annually through 2042 516,591,748 510,580,000 518,135,814 509,038 Birmingham Hospital Revenue Bonds Series 2012B, variable interest rate (0.17% at September 30, 2012), due annually through 2042 516,591,748 510,580,000 518,135,814 509,038 Birmingham Hospital Revenue Bonds Series 2012B, variable interest rate (0.17% at September 30, 2012), due annually through 2042 516,591,748 510,580,000 518,135,814 519,300 Birmingham Hospital Revenue Bonds Series 2012B, variable interest rate (0.17% | TOTAL UNIVERSITY DEBT, NONCURRENT | | | | \$ | 260,585,083 |
| Birmingham Hospital Revenue Bonds Series 2012B, variable interest rate (0.17% at September 30, 2012), due annually through 2042 65,000,000 65,000 Birmingham Hospital Revenue Bonds Series 2012C, variable interest rate (0.17% at September 30, 2012), due annually through 2042 \$ 516,591,748 \$ 150,580,000 \$ 158,135,814 \$ 509,033 Less (Plus): unamortized bond discount (premium) 5 16,591,748 \$ 150,580,000 \$ 158,135,814 \$ 509,033 Less: current portion 5 516,591,748 \$ 150,580,000 \$ 158,135,814 \$ 509,033 Less: current portion 5 516,591,748 \$ 150,580,000 \$ 783,091 TOTAL HOSPITAL DEBT, NONCURRENT \$ 805,872,152 \$ 150,580,000 \$ 173,361,204 \$ 783,091 Less (Plus): unamortized bond discount (premium) \$ 805,872,152 \$ 150,580,000 \$ 173,361,204 \$ 783,091 Less (Plus): unamortized bond discount (premium) \$ 805,872,152 \$ 150,580,000 \$ 173,361,204 \$ 783,091 Less: current portion \$ 805,872,152 \$ 150,580,000 \$ 173,361,204 \$ 783,091 Less: current portion \$ 805,872,152 \$ 150,580,000 \$ 173,361,204 \$ 783,091 Less: current portion \$ | Birmingham Hospital Revenue Bonds Series 2004A, 5.0% due annually through 2014 Birmingham Hospital Revenue Bonds Series 2006A, 4.% due annually through 2041 Highlands Bonds Series 2007A, variable rate interest due annually through 2013 Birmingham Hospital Revenue Bonds Series 2008A, 4% to 5.75% due annually through 2025 Birmingham Hospital Revenue Bonds Series 2008B, variable interest rate, due annually through 2031 | \$ 14,875,000 242,975,000 40,000,000 102,830,000 109,930,000 | | 4,720 930 40,000 1,750 109,930 | ,000 ,000 ,000 ,000 ,000 | 3,754,143 10,155,000 242,045,000 101,080,000 1,421,791 |
| Birmingham Hospital Revenue Bonds Series 2012C, variable interest rate (0.17% at September 30, 2012), due annually through 2042 65,000,000 65,000 Less (Plus): unamortized bond discount (premium) \$ 16,591,748 \$ 150,580,000 \$ 158,135,814 \$ 509,038 TOTAL HOSPITAL DEBT \$ 25,000 \$ 25,0 | | | -,, | | | 20,580,000 |
| S 15,591,748 150,580,000 158,135,814 509,032 | | | | | | 65,000,000 |
| Less (Plus): unamortized bond discount (premium) (4,470 TOTAL HOSPITAL DEBT 513,50 Less: current portion 9,71 TOTAL HOSPITAL DEBT, NONCURRENT \$805,872,152 \$150,580,000 \$173,361,204 \$783,091 Less (Plus): unamortized bond discount (premium) (6,517 (6,517 (6,517 (707AL UAB DEBT 789,601 (5,23 | Birmingnam Hospital Revenue Bonds Series 2012C, variable interest rate (0.17% at September 30, 2012), due annually through 2042 | F40 F04 F40 | | 0 450 605 | 044 ^ | 65,000,000 |
| TOTAL HOSPITAL DEBT 513,501 Less: current portion 9,71 TOTAL HOSPITAL DEBT, NONCURRENT \$ 503,78 TOTAL UAB \$ 805,872,152 \$ 150,580,000 \$ 173,361,204 \$ 783,099 Less (Plus): unamortized bond discount (premium) (6,517 789,601 TOTAL UAB DEBT 25,233 Less: current portion 25,233 | Loca (Dlun), unamortized hand discount (aramium) | \$ 516,591,748 | \$ 150,580,000 | \$ 158,135, | 814 \$ | |
| Eess: current portion 9,71 | | | - | | | (4,470,636) 513,506,570 |
| TOTAL HOSPITAL DEBT, NONCURRENT \$ 503,78. TOTAL UAB \$ 805,872,152 \$ 150,580,000 \$ 173,361,204 \$ 783,099 Less (Plus): unamortized bond discount (premium) (6,517) TOTAL UAB DEBT | · · · · · · · · · · · · · · · · · · · | | | | | 9,717,757 |
| TOTAL UAB \$ 805,872,152 \$ 150,580,000 \$ 173,361,204 \$ 783,091 Less (Plus): unamortized bond discount (premium) (6,517 TOTAL UAB DEBT 789,601 Less: current portion 25,233 | <u> </u> | | | | ¢ | |
| Less (Plus): unamortized bond discount (premium) (6,517 TOTAL UAB DEBT 789,601 Less: current portion 25,231 | TOTAL HOOF HAL DEDT, NOROUNNENT | | | | 4 | 303,700,013 |
| Less (Plus): unamortized bond discount (premium) (6,517 TOTAL UAB DEBT 789,601 Less: current portion 25,231 | | | | | | |
| Less (Plus): unamortized bond discount (premium) (6,517 TOTAL UAB DEBT 789,601 Less: current portion 25,231 | TOTAL HAD | 005.070.450 | 0 450 500 000 | 0 470 001 | 004 | 700 000 010 |
| TOTAL UAB DEBT 789,60° Less: current portion 25,23° | | \$ 805,872,152 | \$ 150,580,000 | \$ 1/3,361 | ,204 \$ | |
| Less: current portion 25,23 | | | | | | (6,517,554) |
| | | | | | | 789,608,502 25.234.606 |
| TOTAL UAD DEDT, NUNCURRENT | | | | | | -, - , |
| | IOIAL UAD DEDI, NONCUKKENI | | | | \$ | 764,373,896 |

Maturities and interest on notes, leases, and bonds payable for the next five years and in the subsequent five-year incremental periods are presented in the table below. Future interest payments for variable rate debt are computed by applying the rate in effect at September 30, 2013.

| UNIVERSITY | | | | | | | |
|------------------|-----------|----|-------------|----|-------------|----|-------------|
| | YEAR | | PRINCIPAL | | INTEREST | | TOTAL |
| | 2014 | \$ | 16,010,937 | \$ | 14,621,176 | \$ | 30,632,113 |
| | 2015 | | 19,291,216 | | 15,887,569 | | 35,178,78 |
| | 2016 | | 20,147,454 | | 15,211,653 | | 35,359,10 |
| | 2017 | | 20,335,661 | | 14,525,848 | | 34,861,509 |
| | 2018 | | 21,037,896 | | 13,842,554 | | 34,880,450 |
| | 2019-2023 | | 96,375,000 | | 59,689,664 | | 156,064,66 |
| | 2024-2028 | | 83,965,000 | | 44,306,365 | | 128,271,36 |
| | 2029-2033 | | 64,200,000 | | 30,262,312 | | 94,462,31 |
| | 2034-2038 | | 54,585,000 | | 18,252,296 | | 72,837,29 |
| | 2039-2043 | | 46,870,000 | | 5,846,006 | | 52,716,00 |
| | 2044 | | 7,375,000 | | 157,888 | | 7,532,88 |
| TOTAL UNIVERSITY | | \$ | 450,193,164 | \$ | 232,603,331 | \$ | 682,796,49 |
| HOSPITAL | | | | | | | |
| HOOFTIAL | VEAD | | PRINCIPAL | | INTEREST | | TOTAL |
| | YEAR | \$ | | ф | | ¢. | |
| | 2014 | \$ | 10,147,512 | \$ | 18,338,867 | \$ | 28,486,37 |
| | 2015 | | 10,590,281 | | 17,897,843 | | 28,488,12 |
| | 2016 | | 11,065,520 | | 17,419,576 | | 28,485,09 |
| | 2017 | | 11,538,244 | | 16,924,973 | | 28,463,21 |
| | 2018 | | 11,825,224 | | 16,385,781 | | 28,211,00 |
| | 2019-2023 | | 66,758,397 | | 72,453,088 | | 139,211,48 |
| | 2024-2028 | | 77,583,000 | | 57,645,598 | | 135,228,59 |
| | 2029-2033 | | 86,230,000 | | 54,594,403 | | 140,824,40 |
| | 2034-2038 | | 107,115,000 | | 36,180,778 | | 143,295,77 |
| | 2039-2041 | | 106,465,000 | | 7,981,767 | | 114,446,76 |
| TOTAL HOSPITAL | | \$ | 499,318,178 | \$ | 315,822,674 | \$ | 815,140,852 |
| TOTAL UAB | | | | | | | |
| | YEAR | | PRINCIPAL | _ | INTEREST | _ | TOTAL |
| | 2014 | \$ | 26,158,449 | \$ | 32,960,043 | \$ | 59,118,492 |
| | 2015 | | 29,881,497 | | 33,785,412 | | 63,666,90 |
| | 2016 | | 31,212,974 | | 32,631,229 | | 63,844,20 |
| | 2017 | | 31,873,905 | | 31,450,821 | | 63,324,72 |
| | 2018 | | 32,863,120 | | 30,228,335 | | 63,091,45 |
| | 2019-2023 | | 163,133,397 | | 132,142,752 | | 295,276,14 |
| | 2024-2028 | | 161,548,000 | | 101,951,963 | | 263,499,96 |
| | 2029-2033 | | 150,430,000 | | 84,856,715 | | 235,286,71 |
| | 2034-2038 | | 161,700,000 | | 54,433,074 | | 216,133,07 |
| | 2039-2043 | | 153,335,000 | | 13,827,773 | | 167,162,77 |
| | 2044 | | 7,375,000 | | 157,888 | | 7,532,88 |
| TOTAL HAD | 2017 | _ | | _ | | _ | |
| TOTAL UAB | | \$ | 949,511,342 | \$ | 548,426,005 | \$ | 1,497,937,3 |

See Note 11 for information regarding the pledged revenues, which collateralize certain outstanding debt.

The University defeased certain indebtedness by depositing funds in escrow trust accounts sufficient to provide for the subsequent payment of principal and interest on the defeased indebtedness. Under the trust agreements, all funds deposited in the trust accounts are invested in obligations of the U.S. government. Neither the assets of the trust accounts nor the defeased indebtedness are included in the accompanying statement of net assets as of September 30, 2013 and 2012. The principal outstanding on the defeased indebtedness at September 30, 2013 and 2012, respectively, was \$49,840,000 and \$0, which all related to the University.

In July 2012, the Hospital refinanced two series of its hospital revenue bonds: the Series 2008B Bonds,

which were variable rate demand bonds (VRDOs) with a principal balance of \$109,930,000 collateralized by a letter of credit from Bank of America (BA); and the Series 2007A Bonds, which were variable rate obligations with a principal balance of \$40,000,000. The Series 2008B Bonds refunded obligations that provided funding for the North Pavilion project. The Series 2007A Bonds provided interim financing for the Highlands acquisition. The Series 2007A Bonds had an original maturity of October 1, 2012 if the debt was not refinanced. To accomplish this refinancing, the Hospital issued its 2012A, 2012B, and 2012C hospital revenue bonds in the amounts of \$20,580,000, \$65,000,000, and \$65,000,000, respectively. The issuance of the 2012 bonds allowed the Hospital to reduce its borrowing costs and refinance certain obligations on a long-term basis. These bonds were issued at a discount of \$215,378 resulting in total cash received of \$150,364,622.

The 2012B and 2012C bonds include a demand obligation feature that allows the bondholder to tender the bonds back to the Hospital at any date. The Hospital has obtained a letter of credit ("LOC") in the aggregate amount of the bonds to repay any tendered amounts in the event the remarketing agent is unable to resell the bonds in the allotted time (7 days from the notice of intent to tender). The LOC for 2012B bond expires on July 31, 2015 and the LOC for the 2012C bonds expire on July 31, 2017. Under the terms of the 2012B LOC, no principal amounts are due during the remarketing period, which is 367 days following the date of any draw on the LOC. Thereafter, any amount drawn is payable in quarterly installments over a two-year period. Under the terms of the 2012C LOC, no principal amounts are due for one year subsequent to the date of any draw on the LOC. Thereafter, any amount drawn converts to a term loan that is payable in quarterly installments over a two-year period.

Similarly, the Series 2008B bonds, which were repaid during 2012 with proceeds from the 2012 offering, included a demand obligation feature that allowed the bondholder to tender the bonds back to the Hospital at any date. The Hospital obtained a letter of credit (LOC) in the aggregate amount of the bonds to repay any tendered amounts in the event the remarketing agent is unable to resell the bonds in the allotted time (7 days from the notice of intent to tender).

In March 2013, the University issued \$19,195,000 in Series 2013A-1 General Revenue Bonds. The bonds pay interest at a rate of 1.1% with principal due annually through October 1, 2020. The proceeds of this offering are being used for the purposes of constructing facilities, additions, and improvements at UAB; funding capitalized interest on a portion of the Series 2013A-1 Bonds through October 1, 2015; and paying costs and expenses associated with this issue. In March 2013, the University issued \$72,595,000 in Series 2013A-2 General Revenue Bonds. The bonds pay interest at varying rates of 2.25% to 5.0% with principal due annually through October 1, 2043. The proceeds of this offering are being used for the purposes of constructing facilities, additions, and improvements at UAB; funding capitalized interest on a portion of the Series 2013A-2 Bonds through October 1, 2015; and paying costs and expenses associated with this issue. In March 2013, the University issued \$45,190,000 in Series 2013B General Revenue Bonds. The bonds pay interest at a rate of 1.99% with principal due annually through October 1, 2029. The proceeds of this offering are being used for the purposes of advance refunding Series 2003A General Revenue Bonds; and paying costs and expenses associated with this issue. In March 2013, the University issued \$3,095,000 in Series 2013C General Revenue Bonds. The bonds pay interest at varying rates of 1.0% to 1.45% with principal due annually through October 1, 2019. The proceeds of this offering are being used for the purposes of advance refunding Series 2003A General Revenue Bonds; and paying costs and expenses associated with this issue. These bonds were issued at a premium of \$2,104,514 resulting in total cash received of \$142,179,514.

In August 2013, the University issued \$20,425,000 in Series 2013D-1 General Revenue Bonds. The bonds pay interest at a rate of 1.97% with principal due annually through October 1, 2023. The proceeds of this offering are being used for the purposes of constructing housing facilities, as well as purchasing two existing housing facilities; funding capitalized interest on a portion of the Series 2013D-1 Bonds through October 1, 2015; and paying costs and expenses associated with this issue. In August 2013, the University issued \$78,325,000 in Series 2013D-2 General Revenue Bonds. The bonds pay interest at varying rates of 4.0% to 5.0% with principal due annually through October 1, 2043. The proceeds of this offering are being used for the purposes of constructing housing facilities, as well as purchasing two existing housing facilities; funding capitalized interest on a portion of the Series 2013D-2 Bonds through October 1, 2015; and paying costs and expenses associated with this issue. These bonds were issued at a premium of \$1,141,688 resulting in total cash received of \$99,891,688.

UAB's general revenue bonds and the Hospital Series 2004A, 2006A, 2008A, 2012A, 2012B, and 2012C Revenue Trust Indentures contain certain restrictive financial covenants. UAB's management believes that it was in compliance with respect to these covenants at September 30, 2013 and 2012.

Other Noncurrent Liabilities

The activity with respect to other noncurrent liabilities for the year ended September 30, 2013 and 2012, is as follows for UAB:

| September 30, 2013 | | | | | | | |
|---|----|---------------------------------|----|-----------|-----|-----------|---------------------|
| | В | EGINNING BALANCE ESTATED) | AD | DITIONS | DED | UCTIONS | NDING ALANCE |
| Federal Advances - Ioan funds | \$ | 14,925,390 | \$ | 161,028 | \$ | (358,941) | \$ 14,727,477 |
| Unearned revenue | | 14,349,359 | | | | (228,427) | 14,120,932 |
| Other noncurrent liabilities | | 1,473 | | 2,301,066 | | (588) | 2,301,951 |
| Total advances federal loans and other noncurrent liabilities | \$ | 29,276,222 | \$ | 2,462,094 | \$ | (587,956) | \$ 31,150,360 |

| | E | EGINNING BALANCE RESTATED) | DITIONS STATED) | DUCTIONS ESTATED) | В | ENDING ALANCE ESTATED) |
|---|----|----------------------------------|------------------------|--------------------------|----|------------------------------|
| Federal Advances - Ioan funds | \$ | 15,425,453 | \$ 240,406 | \$ (740,469) | \$ | 14,925,390 |
| Unearned revenue | | 14,577,781 | 147,726 | (376, 148) | | 14,349,359 |
| Other noncurrent liabilities | | 289,010 | | (287,537) | | 1,473 |
| Total advances federal loans and other noncurrent liabilities | \$ | 30,292,244 | \$ 388,132 | \$ (1,404,154) | \$ | 29,276,222 |

(11) Pledged Revenues

Pledged revenues for 2013 and 2012, as defined by the Series 2004A, 2006A, 2008A, 2012A, 2012B and 2012C Hospital Revenue Trust Indentures, are as follows:

| HOSPITAL BONDS | 2013 | 2012 |
|------------------------|---------------------|---------------------|
| Total pledged revenues | \$ 1,295,916,857 | \$ 1,211,793,337 |

Pledged revenues for 2013 and 2012, as defined by the Series 1993B, 2002, 2003A, 2005A, 2005B, 2010A, 2010B, 2010C, 2013A, 2013B, 2013C and 2013D General Revenue Trust Indentures, are as follows:

| UNIVERSITY BONDS | 2013 | 2012 |
|---|----------------------|-------------|
| Tuition and fees | \$ 193,958,793 \$ | 175,184,111 |
| Indirect cost recovery | 76,305,429 | 80,901,702 |
| Sales and service of educational activities | 58,133,856 | 55,906,284 |
| Auxiliary sales and services | 23,792,255 | 21,281,904 |
| Endowment and investment income | 29,808,601 | 27,096,839 |
| Other sources | 35,458,475 | 39,442,801 |
| TOTAL PLEDGED REVENUES | \$ 417,457,409 \$ | 399,813,641 |

(12) Employee Benefits

Retirement and Pension Plans

Most employees of the University, the Hospital, and UABRF participate in the Teachers' Retirement System of Alabama (TRS), a cost-sharing, multiple-employer public retirement system. Certain employees also participate in an optional 403(b) plan (403(b) Plan). TRS is a defined benefit plan and the 403(b) Plan is a defined contribution plan. The TRS was established as of September 15, 1939, under the provisions of Act 419 of the Legislature of 1939 for the purpose of providing retirement allowances and other specified benefits for qualified persons employed by State-supported educational institutions. The responsibility for the general administration and operation of the TRS is vested in its Board of Control.

Participants in TRS who retire at age 60 with 10 years of credited service, or after completing 25 years of credited service, regardless of age, are entitled to an annual benefit, payable monthly for life. Service retirement benefits are calculated by three methods, with the participants receiving payments under the method which yields the highest monthly benefit. These methods include (1) minimum guaranteed, (2) money purchase, or (3) formula. Under the formula method, participants are allowed 2.0125% of their final average salary (average of three highest years of annual compensation during the last 10 years of service) for each year of service. A participant terminating before reaching retirement age, but after completing 10 years of credited service, is eligible for a vested allowance at age 60 provided accumulated employee contributions are not withdrawn. TRS also provides death and disability benefits.

During 2013, TRS created a Tier 2 Defined Benefit plan for all participants hired on or after January 1, 2013. New participants pay lower contribution rates, but will not be able to draw a retirement benefit until they reach age 62. Upon the creation of the Tier 2 Defined Benefit plan, all existing TRS participants became Tier 1 participants keeping the same benefits as before the creation of Tier 2.

Covered employees are required by statute to contribute to TRS. UAB, as the employer, contributes to TRS. The contribution requirements for fiscal years 2013, 2012, and 2011, respectively, were approximately \$138,146,000, \$137,065,000, and \$134,826,000, which consisted of \$79,253,000, \$79,548,000, and \$96,297,000 from UAB and \$58,893,000, \$57,607,000, and \$38,529,000 from employees. UAB's contribution rate for the year ended September 30, 2013 was 10.08% for Tier 1 covered employees and 9.44% for Tier 2 employees. UAB's contribution was 10% of salaries and wages for covered employees in 2012 and 12.51% in 2011. Tier 1 covered employees (except for law enforce-

ment employees) were required by statute to contribute 7.5% in 2013 and 7.25% in 2012 of earned compensation to TRS. The contribution by Tier 1 law enforcement employees was 8.5% in 2013 and 8.25% in 2012 of earned compensation. Tier 2 covered employees (except for law enforcement employees) were required by statute to contribute 6.0% of earned compensation to TRS in 2013. The contribution by Tier 2 law enforcement employees was 7.0% of earned compensation in 2013. All regular employees of UAB are members of TRS, with the exception of temporary employees who, by definition, are those employees hired for a predetermined period of employment of less than one year and employees working less than one half of a regular schedule.

The actuarial accrued liability ("AAL"), which is the actuarial present value of credited projected benefits, is a standardized disclosure measure of the present value of pension benefits, adjusted for the effects of projected salary increases and step-rate benefits, estimated to be payable in the future as a result of employee service to date. The actuarial value of assets, which is the actuarial present value of assets, is a standardized disclosure method of the present value of accumulated assets, adjusted for projected investment performance and contributions. TRS does not make separate measurements of assets and the AAL for individual employers. The AAL and the actuarial valuation of assets at September 30, 2012 (the most recent valuation date) for TRS as a whole, determined through actuarial validations performed as of that date, were \$28.3 billion and \$18.8 billion, respectively, resulting in an under-funded AAL of \$9.5 billion. Complete financial presentation and disclosure of the financial position and activities of the TRS are presented in the September 30, 2012 annual financial report of TRS. That report is publicly available and may be obtained by contacting TRS.

As previously noted, some employees participate in the optional 403(b) Plan, which is a defined contribution plan. In defined contribution plans, benefits depend solely on amounts contributed plus investment earnings. All full-time regular monthly employees are eligible to participate from the date of employment. UAB contributes a matching amount of up to 5% of total salaries for participating employees. UAB's contribution is funded as it accrues and, along with that of the employee, is immediately and fully vested. The contributions for 2013 and 2012, respectively, excluding employee amounts not eligible for matching, were approximately \$34,307,000 and \$31,357,000 which included approximately \$17,154,000 and \$15,678,000 each from UAB and its employees.

The University, the Hospital, and UABRF total salaries and wages for fiscal year 2013 and 2012, respectively, were approximately \$967,667,000 and \$921,253,000. Total salaries and wages during fiscal years 2013 and 2012 for covered employees participating in TRS were approximately \$786,243,000

and \$794,579,000, respectively. Total salaries and wages during fiscal years 2013 and 2012 for covered employees participating in the 403(b) Plan were approximately \$360,771,000 and \$327,589,000, respectively.

Triton sponsors a 401(k) plan covering substantially all employees who have completed at least six months of service. Information regarding this benefit is presented in Triton's annual report.

The LLC sponsors a voluntary 403(b) retirement plan for eligible employees. The 403(b) plan is a voluntary, defined-contribution, tax-deferred as well as Roth after tax plan governed by Internal Revenue Code 403(b). Eligible employees can choose between both TIAA and VALIC for investments. Employees are vested after 3 years of employment. Eligibility for matching is for all full-time and part-time regular, twelve-hour shift, and weekend staff employees.

Compensated Absences

Certain UAB employees accumulate vacation and sick leave at varying rates depending upon their years of continuous service and their payroll classification, subject to maximum limitations. Upon termination of employment, employees are paid all unused accrued vacation at their regular rate of pay up to a designated maximum number of days. In accordance with GASB Statement No. 16, Accounting for Compensated Absences, the financial statements include accruals of approximately \$74,064,000 and \$44,705,000 as of September 30, 2013 and 2012, respectively, for accrued vacation pay and salary-related payments associated with vacation pay. There is no such accrual recognized for sick leave benefits because there is no terminal cash benefit available to employees for accumulated sick leave.

(13) Other Postemployment Benefits

UAB offers other postemployment health care benefits (OPEB) to all employees who officially retire from UAB. Health care benefits are offered through the Alabama Retired Education Employees Health Core Trust Plan (PEEHIP) with TRS or certain retired employees may elect to continue to participate in UAB's group health plan until they are eligible for Medicare by paying the full cost of the plan premium. Retired employees age 65 or older who are eligible for Medicare must enroll in the Medicare Coordinated Plan under which Medicare is the primary insurer and UAB's health care plan becomes the secondary insurer. Despite the availability of the UAB plan, most retirees elect to participate in the PEEHIP with TRS, in which case the retirees pay a portion of the PEEHIP premium, with UAB paying an allocation towards the cost of retiree coverage.

Certain retirees may also elect to continue their

basic term life insurance coverage and accidental death and dismemberment insurance up to certain maximum amounts. The retirees pay the full amount of the premiums in such cases. Retirees are not eligible for tuition assistance benefits themselves. However, their unmarried dependent children may qualify in some cases.

PEEHIP is a cost-sharing multiple-employer defined benefit OPEB plan administered by the Public Education Employees Health Insurance Board. PEEHIP offers a basic hospital/medical plan that provides basic medical coverage for up to 365 days of care during each hospital confinement. The basic hospital/medical plan also provides for physicians' benefits, outpatient care, prescription drugs, and mental health benefits. Major medical benefits under the basic hospital/medical plan are subject to a lifetime contract maximum of \$1,000,000 for each covered individual. The financial report for PEEHIP can be obtained by contacting TRS. The Code of Alabama 1975, Section 16-25-A-8 provides authority to set the contribution requirements for retirees and employers. The required contribution rates of retirees are as follows as of September 30, 2013 and 2012, respectively:

Retired Member Rates

- Individual Coverage/Non-Medicare Eligible -\$151
- Family Coverage/Non-Medicare Eligible Retired Member and Non-Medicare Eligible Dependent(s) - \$391
- Family Coverage/Non-Medicare Eligible Retired Member and Dependent Medicare Eligible - \$250
- Individual Coverage/Medicare Eligible Retired Member - \$10
- Family Coverage/Medicare Eligible Retired Member and Non-Medicare Eligible Dependent(s) - \$250
- Family Coverage/Medicare Eligible Retired Member and Dependent Medicare Eligible - \$109

The required contribution rates of the employer were \$336 and \$370 per employee per month in the years ended September 30, 2013 and 2012, respectively. 100% of 2013 and 2012 contributions were paid in 2013 and 2012, respectively. UAB contributed \$16,071,600 and \$16,732,900 to PEEHIP in 2013 and 2012, respectively. The required contribution rate is determined by PEEHIP in accordance with State statute.

The UAB Plan is considered a single-employer plan and consists of hospital benefits, major medical benefits, a prescription drug program and a basic term life insurance up to an established maximum policy limit. The health care benefits cover medical and hospitalization costs for retirees and their

dependents. The portion of the UAB plan related to health care may be amended by the approval of the President of UAB upon recommendation from the Benefits Committee. The portion of the UAB plan related to the life insurance may be amended by the System.

Employees included in the actuarial valuation include active employees, retirees and disabled employees enrolled in the medical plan and retirees not enrolled in the medical plan with retiree life insurance. Expenditures for postretirement health care benefits are paid monthly on a pay-as-you-go basis.

In accordance with GASB Statement No. 45, Accounting and Financial Reporting by Employers for Postemployment Benefits Other Than Pensions, UAB accrued an additional \$4,288,767 and \$7,142,350 in retiree healthcare and benefit expense during the years ended September 30, 2013 and 2012, respectively.

The UAB Plan does not issue a stand-alone financial report.

UAB's annual retiree health and life insurance benefit expense and related information for the years ended September 30, 2013 and 2012 is as follows:

| | 2013 | 2012 | 2011 |
|---|------------------|------------------|-----------------|
| Annual required contribution | \$ 9,194,860 | \$ 10,342,567 | \$ 6,539,591 |
| Interest on obligations for retiree benefits | 1,127,669 | 728,677 | 560,001 |
| Adjustment to annual required contribution | (859,231) | (555,218) | (367,986) |
| Annual retiree benefit costs | 9,463,298 | 10,516,026 | 6,731,606 |
| UAB Contributions | (5,174,531) | (3,373,676) | (4,914,996) |
| Increase in obligations for retiree benefits | 4,288,767 | 7,142,350 | 1,816,610 |
| Obligations for retiree benefits, beginning of year | 16,109,549 | 8,967,199 | 7,150,589 |
| Total obligations for retiree benefits, end of year | \$ 20,398,316 | \$ 16,109,549 | \$ 8,967,199 |

The annual retiree benefit cost, percentage of the annual retiree benefit cost contributed to the retiree benefit plan and the net obligation for retiree benefits for UAB for year ended September 30, 2013 and 2012 are as follows:

| | 2013 | 2012 | 2011 |
|--|------------------|------------------|-----------------|
| Annual retiree benefit cost | \$ 9,463,298 | \$ 10,516,026 | \$ 6,731,606 |
| Percentage of annual cost contributed | 54.68% | 32.08% | 73.01% |
| Net obligation to the retiree benefit plan | \$ 20,398,316 | \$ 16,109,549 | \$ 8,967,199 |

Funded Status

Actuarial valuations represent a long-perspective and involve estimates of the value of report amounts and assumptions about the probability of occurrence of events into the future. Examples include assumptions about future employment, mortality, investment return and health care cost trends. Actuarially determined amounts are subject to peri-

odic revisions as actual rates are compared with past expectations and new estimates are made about the future.

The funded status of the plan as of October 1, 2011 and 2012 was as follows:

| Actuarial accrued liability Actuarial value of plan assets Unfunded actuarial accrued liability | \$ 2013 46,446,404 46,446,404 | \$ 2012 44,358,077 44,358,077 | \$ 2011 52,061,639 52,061,639 |
|---|---|---|---|
| Funded ratio | Zero | Zero | Zero |
| Covered payroll | \$ 967,667,454 | \$ 921,253,387 | \$ 887,356,263 |
| Unfunded actuarial accrued liability as a percentage of covered payroll | 4.80% | 4.81% | 5.87% |

Actuarial Methods and Assumptions

Projections of benefits for financial reporting purposes are based upon the plan as understood by UAB and plan members, and include types of benefits provided at the time of each valuation and the historical cost pattern of sharing of benefit costs between UAB and plan members to that point. The actuarial methods and assumptions used include techniques that are designed to reduce short-term volatility in actuarial accrued liabilities and the actuarial value of assets, consistent with the long-term perspective of the calculations.

Significant actuarial methods and assumptions used in the valuation were:

- actuarial valuation date, October 1, 2011
- actuarial cost method-projected unit cost method
- assumed return on investment of 7% per year, based on the estimated return on UAB's assets expected to be used to finance benefits;
- health care cost trend rate 9.5% and 7.8% for the years ended September 30, 2012 and September 30, 2011, respectively, reduced by increments to an ultimate rate of 5.0% over years through 2018;
- amortization of the initial unfunded actuarial liability over 30 years on a level percent of pay method with payroll growth rate of 3.25%

Federal Direct Student Loan Program

The Federal Direct Student Loan Program (FDSLP) was established under the Higher Education Act of 1965, as amended in the Student Loan Reform Act of 1993. The FDSLP enables an eligible student or parent to obtain a loan to pay for the student's cost of attendance directly through the university rather than through private lenders. UAB began participation in the FDSLP on July 1, 1994. As a university qualified to originate loans, UAB is responsible for handling the complete loan process, including funds management, as well as promissory note functions. UAB is not responsible for collection of these loans. During the years ended September 30, 2013 and 2012, respectively, UAB disbursed approximately \$130,081,000 and \$130,039,000 under the FDSLP.

(15) Grants and Contracts

At September 30, 2013 and 2012, UAB had been awarded approximately \$371,572,000 (unaudited) and \$366,519,000 (unaudited) in grants and contracts which had not been expended. These awards, which represent commitments of sponsors to provide funds for specific research, training, and service projects, have not been reflected in the financial statements.

In addition, during fiscal year 2009, the University began receiving and expending federal funding under the American Recovery and Reinvestment Act (ARRA), primarily in the form of sponsored research grants and State Fiscal Stabilization Funds. At September 30, 2013 and 2012, UAB had been awarded approximately \$7,153,000 (unaudited) and \$12,459,000 (unaudited) in ARRA funding which had not been expended. These awards have not been reflected in the financial statements.

Net Patient Service Revenue

The Hospital has agreements with governmental and other third-party payors that provide for reimbursement to the Hospital at amounts different from its established rates. Contractual adjustments under third-party reimbursement programs represent the difference between the Hospital's billings at established rates for services and amounts reimbursed by third-party payors. A summary of the basis of reimbursement with major third-party payors follows:

Medicare-Substantially all acute-care services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to patient classification systems that are based on clinical, diagnostic, and other factors. Additionally, the Hospital is reimbursed for both its direct and indirect medical education costs (as defined), principally based on per-resident prospective payment amounts and certain adjustments to prospective rate-per-discharge operating reimbursement payments. The Hospital generally is reimbursed for certain retroactively settled items at tentative rates with final settlement determined after submission of annual cost reports by the Hospital and audits by the Medicare fiscal intermediary. The Hospital's cost reports have been audited and settled for all fiscal years through 2006. Revenue from the Medicare program accounted for approximately 26% of the Hospital's net patient service revenue for the years ended September 30, 2013 and 2012.

Blue Cross—Inpatient services rendered to Blue Cross subscribers are paid at a prospectively determined per diem rate. Outpatient services are reimbursed at a prospectively determined rate or under a cost reimbursement methodology. The method of reimbursement is determined by the procedures that are performed. For outpatient services reimbursed under a cost reimbursement methodology, the Hospital is reimbursed at a tentative rate with a final settlement determined after submission of annual cost reports by the Hospital and audits thereof by Blue Cross. The Hospital's Blue Cross cost reports have been audited and settled for all fiscal years through 2009. Revenue from the Blue Cross program accounted for approximately 30% and 31% of the Hospital's net patient service revenue for each of the years ended September 30, 2013 and 2012, respectively.

Medicaid—Inpatient services rendered to Medicaid program beneficiaries are reimbursed at all-inclusive prospectively determined per diem rates. Outpatient services are reimbursed based on an established fee schedule. The Hospital participates in the Alabama Medicaid Plan and therefore, also receives supplemental payments based on formulas established by

the Alabama Medicaid Agency. The net benefit associated with the Hospital's essential provider designation, totaling approximately \$60,558,000 and \$58,907,000 in 2013 and 2012, respectively, is included in net patient service revenue in the accompanying statements of revenues, expenses, and changes in net position. There can be no assurance that the Hospital will continue to qualify for future participation in this program or that the program will not ultimately be discontinued or materially modified.

Revenue from the Medicaid program accounted for approximately 16% and 15% of the Hospital's net patient service revenue for the years ended September 30, 2013 and 2012, respectively.

Other—The Hospital has also entered into payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. The bases for payments to the Hospital under these agreements include discounts from established charges, capitation, and prospectively determined daily and case rates.

The composition of Hospital operating revenue follows:

| | 2013 | 2012 |
|--|---------------------|---------------------|
| Gross Patient Service Revenue | \$ 4,595,650,176 | \$ 4,143,237,574 |
| Less Provision for Contractual and Other Adjustments | (3,206,091,880) | (2,851,491,622) |
| Less Provision Bad Debts | (251,725,723) | (236,995,097) |
| Net Patient Service Revenue | \$ 1,137,832,573 | \$ 1,054,750,855 |
| Capitation Revenue | 56,902,605 | 64,068,261 |
| Other Operating Revenue | 91,832,795 | 83,855,212 |
| TOTAL HOSPITAL SALES REVENUE | \$ 1,286,567,972 | \$ 1,202,674,328 |
| | | |



The Hospital maintains records to identify and monitor the level of charity care it provides. These records include the amount of charges foregone for

services and supplies furnished under its charity care policy, the estimated cost of those services, and supplies and equivalent service statistics. The following information measures the level of charity care provided during the years ended September 30, 2013 and 2012:

| | 2013 | 2012 |
|---|-------------------|------|
| Approximate charges forgone, based on established rates | \$ 256,380,000 | \$ |
| Percentage of charity charges to total charges | 5.6% | 5.2% |

(18) Credit Risk

The Hospital grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. The mix of receivables from patients and third-party payors at September 30, 2013 and 2012 follows:

| | 2013 | 2012 |
|------------|------|------|
| Other | 45% | 43% |
| Medicare | 19 | 20 |
| Blue Cross | 27 | 28 |
| Medicaid | 9 | 9 |
| | 100% | 100% |
| | | |

(19) Construction Commitments and Financing

UAB has contracted for the construction and renovation of several facilities. At September 30, 2013 and 2012, the estimated remaining cost to complete the construction and renovation of these facilities was approximately \$191,823,000 (unaudited) and \$109,756,000 (unaudited), respectively, which is expected to be financed from private gifts, grants, bond proceeds, and UAB reserves.

(20) Risk Management and Self-Insurance

UAB manages risks related to medical malpractice, general liability, and employee health care through a combination of self-insurance, risk pooling arrangements, and commercial insurance coverage.

UAB's medical malpractice liability is managed by PLTF, a professional liability trust fund. PLTF func-

tions as a risk-sharing vehicle for UAB and more than ten nongovernmental organizations. PLTF covers liabilities of the covered parties, including UAB, arising from reported claims, claims that are incurred but not reported, and future costs of handling these claims. The liabilities are generally based on present value actuarial valuations discounted using interest rates from 2% to 5%. The discount rate used in both 2013 and 2012 was 2%. The associated risks of claims are subject to aggregate limits, with excess liability coverage provided by independent insurers to protect participants against losses should a claim arise that exceeds PLTF coverage limits. Although UAB is the sponsor of PLTF, it is not the predominant participant in the fund.

The PLTF's policy committee establishes the premium rate of participants based on recommendations from consulting actuaries and considering the assumption of risk from the PLTF's date of inception. Premiums paid to the PLTF are provided by UAB, HSF, and other participants. In addition, certain legal and administrative services are provided to the PLTF by the University of Alabama System.

The PLTF agreement requires 10% of all PLTF assets to be held in liquid assets. At September 30, 2013 and 2012, the liquid assets of the PLTF, as defined by the agreement, were in compliance with the agreement

General liability is subject to various claims and aggregate limits, with excess liability coverage provided by an independent insurer. General liability and employee health care claims and expenses are reported when it is probable that a loss has occurred and the amount of the loss can be reasonably estimated. Those losses include an estimate of claims that have been incurred but not reported and the future costs of handling claims. The general liability is generally based on actuarial valuations and is reported at present value. The discount rate used for the general liability was 2% in both 2013 and 2012. Changes in the total self-insured liabilities for the years ended September 30, 2013 and 2012 are presented as follows for UAB:

| SELF INSURED LIABILITIES | 2013 | 2012 (RESTATED) |
|--|------------------|------------------|
| Balance, beginning of year | \$ 14,531,084 | \$ 9,360,771 |
| Claims incurred and changes in estimates | 72,076,282 | 75,543,057 |
| Claim payments | (73,929,226) | (70,372,744) |
| BALANCE, END OF YEAR | \$ 12,678,140 | \$ 14,531,084 |

(21) Commitments and Contingencies

UAB has sovereign immunity and is, therefore, in the opinion of UAB counsel, immune to ordinary tort actions including those based on medical malpractice or general injury to patients. Consequently, while UAB is sometimes named as defendant in malpractice actions and other actions for injuries arising in the Hospital, it has consistently been dismissed from those lawsuits on the basis of the sovereign immunity doctrine. That doctrine also protects UAB from vicarious liability arising from the negligence of its employees. To the extent that UAB employees are sued in their individual capacity for action related to their official duties within the line and scope of their employment, UAB has defended those actions and paid for any resulting costs through its self-insured trust fund. While UAB is not aware of any impending threat to this doctrine, UAB is a named insured under the terms of the PLTF and GLTF and excess insurance purchased from commercial companies (Note 19). There are some exceptions to the sovereign immunity doctrine, most notably federal court cases arising under the federal constitution or federal statutes.

UAB is engaged in various legal actions in the ordinary course of business. Management does not believe the ultimate outcome of these actions will have a material adverse effect on the financial statements. However, the settlement of legal actions is subject to inherent uncertainties and it is possible that such outcomes could differ materially from management's current expectations.

Amounts received or receivable from grantor agencies are subject to audit and adjustments by such agencies, principally the United States Government. Any disallowed claims, including amounts already collected, may constitute a liability of UAB. The amount, if any, of expenditures that may be disallowed by the grantor cannot be determined at this time, although UAB expects any such amounts to be immaterial.

The University and UABRF entered into a services agreement in November 2009. The agreement requires UABRF to undertake and manage UAB's interest in a joint venture for the purpose of implementing a drug development program (DDP) through investigation and evaluation of promising proteins and chemical compounds. The agreement was never funded and was terminated effective July 31, 2013.

In addition, in November 2009, UABRF (on behalf of UAB), SRI and Jubilant Organosys, Ltd. (Jubilant) entered into a joint venture to implement a drug development program to discover new pharmaceutical compounds for human and veterinary use (drug development program). The joint venture was terminated effective July 31, 2013.

(22) Operating Expenses by Function

Total operating expenses by functional classification for the years ended September 30, 2013 and 2012 are as follows for UAB:

| September 30, 2013 | RIES, WAGES, D BENEFITS | SUPPLIES AND SERVICES | EPRECIATION AND AMORTIZATION | SCHOLARSHIPS ID FELLOWSHIPS | TOTAL |
|-------------------------------------|----------------------------|--------------------------|------------------------------|--------------------------------|---------------------|
| Instruction | \$ 232,225,126 | \$ 23,821,286 | | | \$ 256,046,412 |
| Research | 158,835,071 | 85,187,000 | | | 244,022,071 |
| Public service | 56,566,590 | 27,450,568 | | | 84,017,158 |
| Academic support | 136,911,290 | 31,743,457 | | | 168,654,747 |
| Student services | 17,266,826 | 11,776,975 | | | 29,043,801 |
| Institutional support | 71,568,449 | 32,984,637 | | | 104,553,086 |
| Operations and maintenance of plant | 27,178,633 | 35,760,442 | | | 62,939,075 |
| Scholarships and fellowships | | | | \$ 20,999,390 | 20,999,390 |
| Hospital | 588,944,375 | 536,428,907 | | | 1,125,373,282 |
| Auxiliary | 38,421,311 | 442,181,428 | | | 480,602,739 |
| Depreciation | | | \$ 98,303,065 | | 98,303,065 |
| TOTAL OPERATING EXPENSES | \$ 1,327,917,671 | \$ 1,227,334,700 | \$ 98,303,065 | \$ 20,999,390 | \$ 2,674,554,826 |

| September 30, 2012 | RIES, WAGES, D BENEFITS | SUPPLIES AND SERVICES | D | EPRECIATION | CHOLARSHIPS D FELLOWSHIPS | TOTAL |
|-------------------------------------|----------------------------|--------------------------|----|-------------|------------------------------|---------------------|
| | (Restated) | (Restated) | | (Restated) | (Restated) | (Restated) |
| Instruction | \$ 224,190,242 | \$ 23,227,468 | | | | \$ 247,417,710 |
| Research | 159,292,354 | 88,420,940 | | | | 247,713,294 |
| Public service | 54,228,038 | 17,896,872 | | | | 72,124,910 |
| Academic support | 123,460,490 | 29,962,225 | | | | 153,422,715 |
| Student services | 17,241,447 | 8,489,860 | | | | 25,731,307 |
| Institutional support | 65,760,057 | 26,368,084 | | | | 92,128,141 |
| Operations and maintenance of plant | 26,359,477 | 32,605,308 | | | | 58,964,785 |
| Scholarships and fellowships | | | | | \$ 19,158,774 | 19,158,774 |
| Hospital | 536,212,418 | 498,350,263 | | | | 1,034,562,681 |
| Auxiliary | 37,542,944 | 428,560,390 | | | | 466,103,334 |
| Depreciation | | | \$ | 123,047,954 | | 123,047,954 |
| TOTAL OPERATING EXPENSES | \$ 1,244,287,467 | \$ 1,153,881,410 | \$ | 123,047,954 | \$ 19,158,774 | \$ 2,540,375,605 |
| | | | | | | |

(23) Segment Reporting

As discussed in Note 1, UAB's two significant identifiable activities that have bonds outstanding where revenue is pledged in support of the bonds are the University and the Hospital.

Condensed financial statement information related to the University and Hospital for the years ended September 30, 2013 and 2012 is as follows:

| UNIVERSITY | | 2013 | 201 | 2 (RESTATED |
|---|-----------|------------------------------------|-----------------|----------------------------------|
| CONDENSED STATEMENT OF NET POSITION | | | | |
| Current assets | \$ | 458,495,626 | \$ | 412,426,979 |
| Capital assets, net | | 903,768,432 | | 801,214,46 |
| Other assets | | 740,312,860 | | 643,045,923 |
| TOTAL ASSETS | \$ | 2,102,576,918 | \$ | 1,856,687,363 |
| DEFERRED OUTFLOW OF RESOURCES | \$ | 1,555,977 | \$ | 896,429 |
| Current liabilities | \$ | 228,914,407 | \$ | 192,666,510 |
| Long-term debt | | 436,572,538 | | 260,585,083 |
| Other noncurrent liabilities | | 14,727,477 | | 14,925,39 |
| TOTAL LIABILITIES | \$ | 680,214,422 | \$ | 468,176,990 |
| DEFERRED INFLOW OF RESOURCES | \$ | 273,518 | \$ | 209,880 |
| Invested in capital | \$ | 567,327,757 | \$ | 555,058,17 |
| Restricted nonexpendable | · | 273,422,983 | · | 252,616,872 |
| Restricted expendable | | 182,971, 009 | | 183,897,79 |
| Unrestricted | | 399,923,206 | | 397,624,082 |
| TOTAL NET POSITION | \$ | 1,423,644,955 | \$ | 1,389,196,91 |
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANGES IN NET POSITION | | <u> </u> | | |
| Tuition and fees, net | \$ | 146,183,606 | \$ | 130,569,650 |
| Grant and contract revenue | · | 373,172,028 | · | 367,310,01 |
| Sales and services, auxiliary | | 58,133,856 | | 21,281,90 |
| Other operating revenues | | 59,250,730 | | 95,349,08 |
| Salaries, wages, and benefits | | (716,942,278) | | (677,685,032 |
| Supplies and services | | (266,134,359) | | (253,634,899 |
| Depreciation expense | | (40,045,346) | | (66,839,816 |
| Scholarships and fellowships | | (20,999,390) | | (19,158,339 |
| OPERATING LOSS | \$ | (407,381,153) | \$ | (402,807,426 |
| State appropriations | \$ | 226,249,827 | \$ | 235,090,12 |
| Investment income | | 48,260,826 | | 71,929,20 |
| Interest expense | | (10,799,714) | | (6,838,327 |
| Gifts | | 31,956,966 | | 32,332,71 |
| Other nonoperating revenues | | 23,943,896 | | 31,653,88 |
| (LOSS) BEFORE OTHER CHANGES IN NET POSITION | \$ | (87,769,352) | \$ | (38,639,823 |
| Capital gifts | \$ | 4,419,032 | \$ | 418,16 |
| Endowment gifts | | 9,568,250 | | 11,009,61 |
| Other | | 8,740,788 | | 14,205,90 |
| Intergovernmental transfers | | 99,489,321 | | 83,994,03 |
| INCREASE IN NET POSITION Not position, beginning of year | \$ | 34,448,039 1,389,196,916 | <u>\$</u> \$ | 70,987,88 1,318,209,03 |
| Net position, beginning of year NET POSITION, END OF YEAR | \$ \$ | 1,423,644,955 | \$ | 1,389,196,91 |
| CONDENSED STATEMENT OF CASH FLOWS | • | 1,423,044,955 | <u> </u> | 1,309,190,91 |
| Net cash provided by (used in): | | | | |
| Operating activities | \$ | (343,769,182) | \$ | (327,562,787 |
| Noncapital financing activities | Ψ | 393,747,014 | Ψ | 398,036,42 |
| Capital and related financing activities | | 34,778,378 | | (110,079,784 |
| Investing activities | | (70,476,217) | | (9,968,914 |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | \$ | 14,279,993 | \$ | (49,575,063 |
| | Ÿ | 1-1,210,000 | ų. | (40,010,000 |
| Cash and cash equivalents, beginning of year | \$ | 111,100,469 | \$ | 160,675,532 |

| HOSPITAL | 2013 | 20 |)12 (RESTATED) |
|---|---------------------------------------|----|-----------------|
| CONDENSED STATEMENT OF NET POSITION | | | |
| Current assets | \$ 392,201,450 | \$ | 311,195,825 |
| Capital assets, net | 619,965,666 | | 631,099,384 |
| Other assets | 568,598,392 | | 542,758,190 |
| TOTAL ASSETS | \$ 1,580,765,508 | \$ | 1,485,053,399 |
| DEFERRED OUTFLOW OF RESOURCES | \$ 11,402,312 | \$ | 12,123,456 |
| Current liabilities | \$ 95,142,916 | \$ | 77,437,604 |
| Long-term debt | 493,374,412 | | 503,788,813 |
| Other noncurrent liabilities | 14,120,932 | | 14,349,359 |
| TOTAL LIABILITIES | \$ 602,638,260 | \$ | 595,575,776 |
| DEFERRED INFLOW OF RESOURCES | \$ | \$ | |
| Invested in capital | \$ 127,846,054 | \$ | 129,716,271 |
| Restricted nonexpendable | 128,099 | | 128,099 |
| Restricted expendable | 29,511,285 | | 27,975,954 |
| Unrestricted | 832,044,122 | | 743,780,755 |
| TOTAL NET POSITION | \$ 989,529,560 | \$ | 901,601,079 |
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANGES IN NET POSITION | | | |
| Operating revenues | \$ 1,278,463,833 | \$ | 1,194,902,008 |
| Operating expenses | (1,125,473,278) | | (1,034,562,682) |
| Depreciation expense | (57,843,816) | | (55,542,120) |
| OPERATING INCOME | \$ 95,146,739 | \$ | 104,797,206 |
| State appropriations | \$ 32,180,013 | \$ | 33,550,226 |
| Investment income | 38,659,513 | | 55,634,553 |
| Interest expense | (20,096,054) | | (21,140,183) |
| Gifts | 111,010 | | 348,648 |
| Other nonoperating revenues | 24,198,705 | | 281,797 |
| INCOME BEFORE OTHER CHANGES IN NET POSITION | \$ 170,199,926 | \$ | 173,472,247 |
| Capital gifts | \$ 28,329 | \$ | 34,212 |
| Other | | | 21,187 |
| Intergovernmental transfers | (82,299,774) | | (70,350,359) |
| INCREASE IN NET POSITION | \$ 87,928,481 | \$ | 103,177,287 |
| Net position, beginning of year | \$ 901,601,079 | \$ | 798,423,792 |
| NET POSITION, END OF YEAR | \$ 989,529,560 | \$ | 901,601,079 |
| CONDENSED STATEMENT OF CASH FLOWS | | | |
| Net cash provided by (used in): | | | |
| Operating activities | \$ 133,794,448 | \$ | 173,320,736 |
| Noncapital financing activities | (50,008,751) | | (36,217,223) |
| Capital and related financing activities | (50,126,792) | | (61,129,999) |
| Investing activities | (41,616,452) | | (90,229,119) |
| | \$ (7,957,547) | \$ | (14,255,605) |
| NET DECREASE IN CASH AND CASH EQUIVALENTS | | | 52,405,402 |
| Cash and cash equivalents, beginning of year | 38,149,797 | | |
| | \$ 38,149,797 30,192,250 | \$ | 38,149,797 |
| Cash and cash equivalents, beginning of year | \$ | \$ | |

(24) Major Component Unit Reporting

As discussed in Note 1, Triton is included in UAB's financial statements as a blended component unit. Triton financial information for the years ended December 31, 2012 and 2011 is included in UAB's financial statements and presented as follows:

| TRITON HEALTH SYSTEMS, LLC | | 2013 | | 2012 |
|---|----|---------------|----|---------------|
| CONDENSED STATEMENT OF NET ASSETS | | | | |
| Current assets | \$ | 196,647,562 | \$ | 182,166,351 |
| Capital assets, net | | 552,186 | | 769,892 |
| Other assets | | 14,833,106 | | 15,498,262 |
| TOTAL ASSETS | \$ | 212,032,854 | \$ | 198,434,505 |
| Current liabilities | \$ | 58,642,408 | \$ | 68,315,148 |
| Other noncurrent liabilities | | 2,301,066 | | |
| TOTAL LIABILITIES | \$ | 60,943,474 | \$ | 68,315,148 |
| Invested in capital net of related debt | \$ | 552,186 | \$ | 769,892 |
| Restricted nonexpendable | | 100,000 | | 100,000 |
| Unrestricted | | 150,437,194 | | 129,249,465 |
| TOTAL NET ASSETS | \$ | 151,089,380 | \$ | 130,119,357 |
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANGES IN NET ASSETS | | | | |
| Operating revenues | \$ | 571,244,193 | \$ | 579,322,188 |
| Operating expenses | Ψ | (526,806,239) | Ψ | (507,676,864) |
| Depreciation and amortization expense | | (413,902) | | (657,256) |
| OPERATING INCOME | \$ | | \$ | 70,988,068 |
| Investment income | | 603,110 | | 741,137 |
| Income tax expense | | (6,919,898) | | (18,124,588) |
| INCOME BEFORE OTHER CHANGES IN NET ASSETS | \$ | 37,707,264 | \$ | 53,604,617 |
| Distributions to members | \$ | (16,737,241) | \$ | (11,177,875) |
| INCREASE IN NET ASSETS | \$ | 20,970,023 | \$ | 42,426,742 |
| Net assets, beginning of year | | 130,119,357 | | 87,692,615 |
| NET ASSETS, END OF YEAR | \$ | 151,089,380 | \$ | 130,119,357 |
| CONDENSED STATEMENT OF CASH FLOWS | | | | |
| Net cash provided by (used in): | | | | |
| Operating activities | \$ | 26,453,289 | \$ | 45,608,243 |
| Noncapital financing activities | | (16,737,241) | | (11,177,875) |
| Capital and related financing activities | | (196,197) | | (228,725) |
| Investing activities | | 51,239,832 | | (27,979,227) |
| NET INCREASE IN CASH AND CASH EQUIVALENTS | \$ | 60,759,683 | \$ | 6,222,416 |
| Cash and cash equivalents, beginning of year | \$ | 114,874,451 | \$ | 108,652,035 |
| CASH AND CASH EQUIVALENTS, END OF YEAR | \$ | 175,634,134 | \$ | 114,874,451 |

Recently Issued Pronouncements

The GASB issued Statement No. 60, Accounting and Financial Reporting for Service Concession Arrangements (GASB 60), in November 2010. The objective of this Statement is to improve financial reporting by addressing issues related to service concession arrangements(SCAs), which are a type of public-private or public-public partnership. As used in this Statement, an SCA is an arrangement between a transferor (a government) and an operator (governmental or nongovernmental entity) in which (1) the transferor conveys to an operator the right and related obligation to provide services through the use of infrastructure or another public asset (a "facility") in exchange for significant consideration and (2) the operator collects and is compensated by fees from third parties. The requirements of this Statement are effective for financial statements for periods beginning after December 15, 2011. The adoption of this statement had no material impact on UAB's financial statements.

The GASB issued Statement No. 61, The Financial Reporting Entity: Omnibus-an amendment of GASB Statements No. 14 and No. 34, in November 2010. The objective of this Statement is to improve financial reporting for a governmental financial reporting entity. The requirements of Statement No. 14, The Financial Reporting Entity, and the related financial reporting requirements of Statement No. 34, Basic Financial Statements and Management's Discussion and Analysis-for State and Local Governments, were amended to better meet user needs and to address reporting entity issues that have arisen since the issuance of those Statements. This Statement modifies certain requirements for inclusion of component units in the financial reporting entity. This Statement also amends the criteria for reporting component units as if they were part of the primary government (that is, blending) in certain circumstances. Also, additional reporting guidance is provided for blending a component unit if the primary government is a business-type entity that uses a single column presentation for financial reporting. The provisions of this Statement are effective for financial statements for periods beginning after June 15, 2012. Refer to Note 3 for the discussion of the impact that the adoption of this statement had on UAB's financial statements.

The GASB issued Statement No. 62, Codification of Accounting and Financial Reporting Guidance Contained in Pre-November 30, 1989 FASB and AICPA Pronouncements, in December 2010. The objective of this Statement is to incorporate into the GASB's authoritative literature certain accounting and financial reporting guidance that is included in FASB Statements and Interpretations, Accounting Principles Board Opinions and AICPA Accounting Research Bulletins issued on or before November 30, 1989, which do not conflict with or contradict GASB pronouncements. This Statement also supersedes GASB Statement No. 20, Accounting and Financial Reporting for Proprietary Funds and Other Governmental Entities That Use Proprietary Fund Accounting, thereby eliminating the election provided in paragraph 7 of that Statement for enterprise funds and business-type activities to apply post-November 30, 1989 FASB Statements and Interpretations that do not conflict with or contradict GASB pronouncements. However, those entities can continue to apply, as other accounting literature, post-November 30, 1989 FASB pronouncements that do not conflict with or contradict GASB pronouncements, including this Statement. The provisions of this Statement are effective for financial statements for periods beginning after December 15, 2011. The adoption of this statement had no material impact on UAB's financial statements.

The GASB issued Statement No. 63, Financial Reporting of Deferred Outflows of Resources, Deferred Inflows of Resources, and Net Position(GASB 63), in June 2011. The objective of this Statement is to provide financial reporting guidance for deferred outflows of resources and deferred inflows of resources. Concept Statement No. 4, Elements of Financial Statements, introduced and defined those elements as a consumption of net assets by the government that is applicable to a future period, and an acquisition of net assets by the government that is applicable to a future reporting period, respectively. Previous financial reporting standards do not include guidance for reporting those financial statement elements, which are distinct from assets and liabilities. GASB 63 also renames the measure "net assets" to be "net position". The provisions of this Statement are effective for financial statements for periods beginning after December 15, 2011. Refer to Note 3 for the discussion of the impact that the adoption of this statement had on UAB's financial statements.

The GASB issued Statement No. 64, Derivative

Instruments: Application of Hedge Accounting Termination Provisions – an amendment of GASB Statement No. 53 (GASB 64), in June 2011. The objective of this Statement is to clarify whether an effective hedging relationship continues after the replacement of a swap counterparty or swap counterparty's credit support provider. This Statement sets forth criteria that establish when the effective hedging relationship continues and hedge accounting should continue to be applied. The provisions of this Statement are effective for financial statements for periods beginning after June 15, 2011. Since the University does not hold any derivative instruments, GASB 64 did not have an impact on the University's financial statements.

The GASB issued Statement No. 65, *Items Previously Reported as Assets and Liabilities* (GASB 65), in March 2012. This Statement establishes accounting and financial reporting standards that reclassify, as deferred outflows of resources or deferred inflows of resources, certain items that were previously reported as assets and liabilities and recognizes, as outflows of resources or inflows of resources, certain items that were previously reported as assets and liabilities. The provisions of this Statement are effective for financial statements for periods beginning after December 15, 2012. Refer to Note 3 for the discussion of the impact that the adoption of this statement had on UAB's financial statements.

The GASB issued Statement No. 66, Technical Corrections - 2012 - an amendment of GASB Statements No. 10 and No. 62 (GASB 66), in March 2012. The objective of this Statement is to improve accounting and financial reporting for a governmental financial reporting entity by resolving conflicting guidance that resulted from the issuance of two pronouncements, Statements No. 54, Fund Balance Reporting and Governmental Fund Type Definitions, and No. 62, Codification of Accounting and Financial Reporting Guidance Contained in Pre-November 30, 1989 and AICPA Pronouncements. The provisions of this Statement are effective for financial statements for periods beginning after December 15, 2012. The University is currently evaluating the impact, if any, that GASB 66 will have on its financial statements.

The GASB issued Statement No. 67, Financial Reporting for Pension Plans – an amendment of GASB Statement No. 25 (GASB 67), in June 2012. The objective of this Statement is to improve financial reporting by state and local governmental pen-

sion plans. This Statement is effective for financial statements for fiscal years beginning after June 15, 2013. The University is currently evaluating the impact, if any, that GASB 67 will have on its financial statements.

The GASB issued Statement No. 68, Financial Reporting for Pension Plans – an amendment of GASB Statement No. 27 (GASB 68), in June 2012. The objective of this Statement is to improve financial reporting by state and local governmental pension plans. This Statement is effective for financial statements for fiscal years beginning after June 15, 2014. The University is currently evaluating the impact, if any, that GASB 68 will have on its financial statements.

The GASB issued Statement No. 69, Government combinations and Disposals of Government Operations ("GASB 69"), in January 2013. The objective of this Statement is to establish accounting and financial reporting standards related to government combinations and disposals of government operations. This Statement is effective for fiscal years beginning after December 15, 2013. UAB is currently evaluating the impact, if any, that GASB 69 will have on its financial statements.

The GASB issued Statement No. 70, Accounting and Financial Reporting for Nonexchange Financial Guarantees ("GASB 70"), in April 2013. The objective of this Statement is to improve accounting and financial reporting by state and local governments that extend and receive nonexchange financial guarantees. This Statement is effective for fiscal years beginning after June 13, 2013. UAB is currently evaluating the impact, if any, that GASB 70 will have on its financial statements.

The GASB issued Statement No. 71, Pension Transition for Contributions Made Subsequent to the Measurement Date - an amendment of GASB Statement No. 68 ("GASB 71"), in November 2013. The objective of this Statement is to address an issue regarding application of the transition provisions of Statement No. 68. The issue relates to amounts associated with contributions, if any, made by a state or local government employer or nonemployer contributing entity to a defined benefit pension plan after the measurement date of the government's beginning net pension liability. The provisions of this Statement should be applied simultaneously with the provisions of Statement No. 68. UAB is currently evaluating the impact, if any, that GASB 71 will have on its financial statements.

The University of Alabama at Birmingham Required Supplementary Information September 30, 2013 and 2012

Required Supplementary Information

The following required supplementary information relates to UAB's single-employer other postemployment benefit plan (OPEB).

Actuarial Methods and Assumptions

Projections of benefits for financial reporting purposes are based up the plan as understood by UAB and plan members, and include types of benefits provided at the time of each valuation and the historical cost pattern of sharing of benefit costs between UAB and plan members to that point. The actuarial methods and assumptions used include techniques that are designed to reduce short-term volatility in actuarial accrued liabilities and the actuarial value of assets, consistent with the long-term perspective of the calculations.

Significant actuarial methods and assumptions used in the valuation were :

- actuarial valuation date, October 1, 2011
- · actuarial cost method-projected unit cost method;
- assumed return on investment of 7% per year, based on the estimated return on UAB's assets expected to be used to finance benefits;
- health care cost trend rate 9.5% and 7.8% for the years ended September 30, 2012 and 2011, respectively, reduced by increments to an ultimate rate of 5.0% over years through 2018;
- amortization of the initial unfunded actuarial liability over 30 years on a level percent of pay method with payroll growth rate of 3.25%;

Schedule of Funding Progress

| Actuarial Valuation Date | Actuarial Value of Assets | Act | uarial Accrued Liability | (Deficit) | Funded Ratio | Α | nnual Covered Payroll | (Deficit)/Covered Payroll |
|--------------------------|---------------------------|-----|-----------------------------|--------------------|-----------------|----|--------------------------|------------------------------|
| October 1, 2012 | None | \$ | 46,446,404 | \$ (46,446,404) | Zero | \$ | 967,667,454 | -4.8% |
| October 1, 2011 | None | \$ | 44,358,077 | \$ (44,358,077) | Zero | \$ | 921,253,387 | -4.8% |
| October 1, 2010 | None | \$ | 52,061,639 | \$ (52,061,639) | Zero | \$ | 887,356,263 | -5.9% |
| October 1, 2009 | None | \$ | 51,649,871 | \$ (51,649,871) | Zero | \$ | 838,331,004 | -6.2% |
| October 1, 2008 | None | \$ | 53,920,021 | \$ (53,920,021) | Zero | \$ | 838,658,508 | -6.4% |

The University of Alabama at Birmingham Administration

As of September 30, 2013



Ray L Watts, M.D.

President

Linda C. Lucas

Provost

Louis Dale

Vice President for Equity and Diversity

Will Ferniany

CEO, UAB Health System

Shirley Salloway Kahn

Vice President for Development, Alumni, and External Relations

Richard B. Marchase

Vice President for Research and Economic Development

Richard L. Margison

Vice President for Financial Affairs and Administration

E. Douglas Rigney, Jr.

Interim Vice President for Information Technology

Anupam Agarwal, M.D.

Interim Senior Vice President for Medicine and Dean, School of Medicine

Robert E. Palazzo

Dean, College of Arts and Sciences

Doreen C. Harper

Dean, School of Nursing

Eric P. Jack

Dean, Collat School of Business

Harold P. Jones

Dean, School of Health Professions

J. Iwan Alexander

Dean, School of Engineering

Max Michael III

Dean, School of Public Health

Bryan D. Noe

Dean, Graduate School

Rodney W. Nowakowski, O.D.

Dean, School of Optometry

Michael S. Reddy

Dean, School of Dentistry

Deborah L. Voltz

Dean, School of Education

The Board of Trustees of The University of Alabama

As of September 30, 2013

The Honorable Robert Bentley

Governor of Alabama President ex officio

Thomas R. Bice, Ed. D.

State Superintendent of Education Member ex officio

Paul W. Bryant, Jr.

President pro tempore Tuscaloosa

Karen Phifer Brooks

Tuscaloosa

John H. England, Jr.

Tuscaloosa

Joseph C. Espy III

Montgomery

Ronald W. Gray

Huntsville

Andria S. Hurst

Birmingham

John D. Johns

Birmingham

Vanessa Leonard

Rockford

W. Davis Malone III

Dothan

Harris V. Morrissette

Saraland

William "Britt" Sexton

Decatur

Finis E. St. John IV

Cullman

Marietta M. Urquhart

Mobile

Kenneth L. Vandervoort, M.D.

Anniston

James W. Wilson III

Montgomery

Trustees Emeriti

Frank H. Bromberg, Jr. Angus R. Cooper II Oliver H. Delchamps, Jr. Garry Neil Drummond Jack Edwards Joseph L. Fine Sandral Hullett Peter L. Lowe Sidney L. McDonald John J. McMahon, Jr. John T. Oliver, Jr. Joe H. Ritch Yetta G. Samford, Jr. Cleophus Thomas, Jr. John Russell Thomas

Robert E. Witt

Chancellor

Michael A. Bownes

Secretary of the Board